# Exploiting the sp<sup>2</sup> character of bicyclo[1.1.1]pentyl radicals in the transition-metal-free multi-component difunctionalization of [1.1.1]propellane

Weizhe Dong,<sup>1†</sup> Expédite Yen-Pon,<sup>1†</sup> Longbo Li,<sup>1†</sup> Ayan Bhattacharjee,<sup>1</sup> Anais Jolit,<sup>2</sup> and Gary A. Molander<sup>1\*</sup>

<sup>1</sup>Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 S. 34th Street, Philadelphia, Pennsylvania 19104-6323, United States.

<sup>2</sup>Medicinal Chemistry Department, Neuroscience Discovery Research, AbbVie Deutschland GmbH & Co. KG, 67061 Ludwigshafen, Germany.

\*Correspondence to: gmolandr@sas.upenn.edu

†These authors contributed equally to this work.

### SUPPLEMENTARY MATERIALS

#### **Table of Contents**

1. General Considerations	
1.1 Methods	S2
1.2 Chemicals	S2
2. Preparation of Starting Materials	
2.1 General Procedure for Preparing Redox Active Ester	S3

2.2 General Procedure for Propellane Synthesis	S25
3. Extended Optimizations and Control Studies	
3.1 Optimization and Control Studies with RAE	S27
3.2 Optimization and Control Studies with Organohalides	S29
4. Procedures for Reactions	S32
5. Procedure for Gram-Scale Synthesis of BCP Bpin	S75
6. Synthesis and Characterization of BCP Trifluoroborate 6	
6.1 Synthesis of Organotrifluoroborate 6 from 4k	S77
6.2 Telescoped Gram-Scale Synthesis of BCP $BF_3K$ (6)	S77
6.3 Cyclic Voltammogram of BCP BF <sub>3</sub> K (6)	S78
7. Post-functionalizations	S79
8. Mechanistic Investigations	
8.1 Studies of Radicals with Varied s Character	S84
8.2 TEMPO-trapping Experiments	S87
8.3 Radical Clock Experiments	S89
8.4 UV-vis Studies	S93
8.5 Influence of Through-space Interactions on Chemoselectivity	S99
8.6 Kinetic Studies	S100
8.7 <sup>11</sup> B NMR Studies	S102
8.8 Determinations of Quantum Yields	S104
9. X-ray Structure Determination of Compound 4ar	S107
10. References	S128
11. NMR Spectra of Synthesized Compounds	S130

#### 1. General Considerations

#### 1.1 Methods

All chemical transformations requiring inert atmospheric conditions or vacuum distillation utilized Schlenk line techniques with a 4- or 5-port dual-bank manifold. Purple light irradiation was accomplished via Kessil PR160L 390 nm lamp set to full intensity (~352 mW/cm<sup>2</sup>). The setup was described in a previous report.<sup>1</sup> Blue light irradiation was accomplished using Kessil H150-Blue LED lamps (456 nm, 34 W High Luminous DEX 2100 LEDs) that were each placed 1.5 inches away from reaction vessels with two fans to ensure the reactions remained at room temperature (rt). 10 W blue LED irradiation was accomplished via the LED reactor described in a previous report.<sup>2</sup> CFL irradiation is accomplished via a 26 W CFL (GE FLE26HT3/2/D). Unless otherwise noted, benchtop photo reactions were performed in 4 mL Chemglass vials (1-dram, 15 x 45 mm, 13-425 Green Open Top Cap, TFE Septa, part number: CG-4909-04) or 8 mL Chemglass vials (2-dram, 17 x 60 mm, 15-425 Green Open Top Cap, TFE Septa, part number: CG-4909-03). NMR Spectra (<sup>1</sup>H, <sup>13</sup>C{1H}, <sup>19</sup>F{1H}, <sup>11</sup>B{1H}) were performed at 300 K. <sup>1</sup>H NMR spectra were referenced to residual non-deuterated chloroform ( $\delta$  7.26) in CDCl<sub>3</sub>, residual DMSO-d<sub>5</sub> ( $\delta$  2.50 ppm) in DMSO-*d*<sub>6</sub>. <sup>13</sup>C NMR spectra were referenced to CDCl<sub>3</sub> (δ 77.2 ppm), DMSO-*d*<sub>6</sub> (δ 39.5 ppm), and acetone- $d_{\theta}$  ( $\delta$  206.2 ppm). Data is presented as follow: chemical shift (ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), coupling constant J (Hz), and integration. Reactions were monitored by LC-MS, GC-MS, <sup>1</sup>H NMR, and/or TLC using silica gel F254 plates (60 Å porosity, 250 µm thickness). TLC analysis was performed using EtOAc/hexanes or CH<sub>2</sub>Cl<sub>2</sub>/MeOH as the eluent and developed using permanganate stain, CAM (cerium ammonium molybdate) stain and/or UV light in 254 nm and/or 365 nm wavelengths. Flash chromatography was accomplished using an automated flash chromatography system [with a UV detector monitoring at 254 nm, 280 nm, and an evaporative light scattering detector (ELSD)] with RediSep<sup>®</sup> R<sub>f</sub> silica gel disposable flash columns (60 Å porosity, 40-60 µm) or RediSep R<sub>f</sub> Gold<sup>®</sup> silica gel disposable flash columns (60 Å porosity, 20-40 µm). Accurate mass measurement analyses were conducted using electron ionization (EI) or electrospray ionization (ESI). The signals were mass measured (TOF) against an internal lock mass reference of perfluorotributylamine (PFTBA) for EI-GCMS, and leucine enkephalin for ESI-LCMS. The utilized software calibrates the instruments and reports measurements by use of neutral atomic masses. The mass of the electron is not included. IR spectra were recorded on a Perkin Elmer Spectrum Two FT-IR using either neat oil or solid products. Melting points (°C) are uncorrected.

#### 1.2 Chemicals

All reagents were purchased and used as received from suppliers unless otherwise noted. Tetrahydrofuran (THF), CH<sub>2</sub>Cl<sub>2</sub>, and Et<sub>2</sub>O were dried by passing through alumina cartridges in a solvent purification system. Other dried solvents were purchased from commercial sources and used as received. Deuterated NMR solvents were purchased and stored over 4Å molecular sieves (MS). Carboxylic acids and organohalides were purchased from commercial sources unless otherwise noted. Me<sub>2</sub>PhSi-Bpin (CAS: 185990-03-8) is purchased from TCI or prepared following literature<sup>3</sup> and stored in glovebox.

#### 2. Preparation of Starting Materials

2.1 General Procedure for Preparing Redox Active Ester (General Procedure A – GP-A)



Redox active esters were prepared based on published procedures: to a round bottom flask were added *N*-hydroxyphthalimide (1.1 equiv), DMAP (0.05 equiv), carboxylic acid (1 equiv, if solid, otherwise added after the addition of the solvent  $CH_2Cl_2$ ).  $CH_2Cl_2$  (0.1 M) was added to the round bottom flask followed by DCC (1.1 equiv). The reaction mixture was stirred at rt. When judged complete by TLC, the reaction mixture was then filtered through a pad of Celite<sup>®</sup> and concentrated *in vacuo*. The product was purified by flash-column chromatography or recrystallization.





S-1h



S-1i





















он

0





S-1u



ο 0

ò

ó















′н НY





0

ò



ò

ó



S-1ab







Figure S1. Scope of RAEs used in this study

4

#### **Characterization Data of Redox-active Esters**



**1,3-Dioxoisoindolin-2-yl 1-Methylcyclohexane-1-carboxylate** (**1a**, 14.1 mmol scale, 3.7 g, 91%).

Prepared following **GP-A** and purified by column chromatography (5% EtOAc/hexanes). The product was obtained as a white solid.

 $^1\text{H}$  NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.89 – 7.85 (m, 2H), 7.80 – 7.75 (m, 2H), 2.29 – 2.18 (m, 2H), 1.72 – 1.61 (m, 3H), 1.61 – 1.52 (m, 2H), 1.42 (s, 3H), 1.41 – 1.34 (m, 2H), 1.34 – 1.21 (m, 1H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 173.8, 162.4, 134.8, 129.2, 124.0, 43.3, 35.8, 26.8, 25.6, 23.2.

The spectra are in accordance with the previous report.<sup>4</sup>



**1-(***tert***-Butyl) 4-(1,3-Dioxoisoindolin-2-yl) Piperidine-1,4-dicarboxylate** (**1b**, 5.0 mmol scale, 1.6 g, 87%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.87 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.78 (dd, *J* = 5.5, 3.1 Hz, 2H), 4.02 (s, 1H), 3.03 – 2.96 (m, 2H), 2.94 – 2.86 (m, 1H), 2.09 – 2.01 (m, 2H), 1.89 – 1.79 (m, 2H), 1.45 (s, 9H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  170.7, 162.0, 154.7, 134.9, 129.0, 124.1, 79.9, 77.4, 77.2, 77.0, 42.9, 38.7, 28.5, 27.9.

The spectra are in accordance with the previous report.<sup>5</sup>



1,3-Dioxoisoindolin-2-yl 4-Phenylbutanoate (1c, 5.0 mmol scale, 1.2 g, 58%).

Prepared following **GP-A** and purified by column chromatography (15% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.89 (dd, *J* = 5.4, 3.1 Hz, 2H), 7.79 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.33 (t, *J* = 7.5 Hz, 2H), 7.26 – 7.21 (m, 3H), 2.79 (t, *J* = 7.6 Hz, 2H), 2.69 (t, *J* = 7.3 Hz, 2H), 2.13 (p, *J* = 7.4 Hz, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 169.5, 162.1, 140.7, 134.8, 129.0, 128.6, 128.6, 126.3, 124.0, 34.7, 30.3, 26.4.

The spectra are in accordance with the previous report.<sup>6</sup>



1,3-Dioxoisoindolin-2-yl Cyclopropanecarboxylate (1d, 11.6 mmol scale, 2.5 g, 92%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.86 (dd, *J* = 5.4, 3.1 Hz, 2H), 7.77 (dd, *J* = 5.5, 3.1 Hz, 2H), 1.95 (tt, *J* = 8.3, 4.6 Hz, 1H), 1.28 – 1.23 (m, 2H), 1.21 – 1.14 (m, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 171.3, 162.1, 134.8, 129.0, 124.3, 10.7, 10.4.

The spectra are in accordance with the previous report.<sup>7</sup>



**1-(1,3-Dioxoisoindolin-2-yl) 4-Methyl-cubane-1,4-dicarboxylate** (**1e**, 1.0 mmol scale, 0.35 g, 58%).

Prepared following **GP-A** and purified by column chromatography (30% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.89 (dd, J = 5.4, 3.1 Hz, 2H), 7.79 (dd, J = 5.5, 3.1 Hz, 2H), 4.49 (dd, J = 5.6, 4.0 Hz, 3H), 4.36 (dd, J = 5.7, 4.0 Hz, 3H), 3.73 (s, 3H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  171.6, 167.1, 162.2, 134.9, 129.1, 124.1, 55.9, 53.1, 51.9, 47.8, 47.8, 47.7.

The spectra are in accordance with the previous report.<sup>8</sup>



**1-(1,3-Dioxoisoindolin-2-yl) 3-Methyl Bicyclo[1.1.1]pentane-1,3-dicarboxylate** (**1f**, 11.8 mmol scale, 2.5 g, 68%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.90 – 7.86 (m, 2H), 7.82 – 7.76 (m, 2H), 3.72 (s, 3H), 2.55 (s, 6H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 169.0, 164.8, 161.8, 135.0, 129.0, 124.2, 53.7, 52.1, 38.7, 35.5.

The spectra are in accordance with the previous report.<sup>8</sup>



1,3-Dioxoisoindolin-2-yl Adamantane-1-carboxylate (1g, 27.7 mmol scale, 8.5 g, 94%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.86 (dd, J = 5.4, 3.1 Hz, 2H), 7.77 (dd, J = 5.5, 3.1 Hz, 2H), 2.13 (d, J = 2.9 Hz, 6H), 2.11 – 2.08 (m, 3H), 1.77 (t, J = 2.8 Hz, 6H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 173.4, 162.3, 134.7, 129.2, 123.9, 40.6, 38.6, 36.3, 27.8.

The spectra are in accordance with the previous report.<sup>6</sup>



**1,3-Dioxoisoindolin-2-yl Bicyclo[1.1.1]pentane-1-carboxylate** (**1h**, 30.0 mmol scale, 7.7 g, >99%).

Prepared following **GP-A** and purified by filtering through a 60 g  $SiO_2$  plug using DCM as the eluent. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.87 (dd, *J* = 5.4, 3.1 Hz, 2H), 7.77 (dd, *J* = 5.5, 3.1 Hz, 2H), 2.55 (s, 1H), 2.32 (s, 6H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 164.7, 162.0, 134.8, 129.1, 124.0, 52.5, 40.0, 29.3. The spectra are in accordance with the previous report.<sup>9</sup>



1,3-Dioxoisoindolin-2-yl 2-Cyclopropylacetate (1i, 2.0 mmol scale, 0.35 g, 71%).

Prepared following **GP-A** and purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.88 (dd, J = 5.5, 3.1 Hz, 2H), 7.78 (dd, J = 5.5, 3.1 Hz, 2H), 2.58 (d, J = 7.1 Hz, 2H), 1.28 – 1.09 (m, 1H), 0.78 – 0.59 (m, 2H), 0.32 (dt, J = 6.1, 4.8 Hz, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 169.1, 162.1, 134.9, 129.1, 124.1, 36.2, 6.7, 4.8.

The spectra are in accordance with the previous report.<sup>10</sup>



1,3-Dioxoisoindolin-2-yl 3-(Pyridin-3-yl)propanoate (S-1a, 3.0 mmol scale, 0.42 g, 47%).

Prepared following **GP-A** and purified by quickly filtering through a 20 g SiO<sub>2</sub> plug using EtOAc (100 mL) as eluent. The product was obtained as a pale-yellow solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 8.57 – 8.54 (m, 1H), 8.52 (dd, J = 4.8, 1.6 Hz, 1H), 7.89 (dd, J = 5.4, 3.1 Hz, 2H), 7.83 – 7.77 (m, 2H), 7.62 (ddt, J = 7.8, 2.3, 1.1 Hz, 1H), 7.31 – 7.27 (m, 1H), 3.12 (t, J = 7.6 Hz, 2H), 3.01 (ddd, J = 8.0, 6.8, 0.8 Hz, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 168.7, 162.0, 150.0, 148.5, 136.1, 135.0, 134.7, 129.0, 124.2, 123.8, 32.5, 27.9.

The spectra are in accordance with the previous report.<sup>9</sup>



1,3-Dioxoisoindolin-2-yl 3-Phenylpropanoate (S-1b, 6.7 mmol scale, 1.7 g, 88%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.89 – 7.86 (m, 2H), 7.80 – 7.77 (m, 2H), 7.36 (t, *J* = 7.5 Hz, 2H), 7.31 – 7.24 (m, 3H), 3.13 (t, *J* = 7.8 Hz, 2H), 3.01 (t, *J* = 7.8 Hz, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 168.9, 161.9, 139.2, 134.8, 128.9, 128.7, 128.3, 126.7, 123.9, 32.7, 30.5.

The spectra are in accordance with the previous report.<sup>11</sup>



**4-(1,3-Dioxoisoindolin-2-yl) 1-Methyl ((Benzyloxy)carbonyl)**-*L*-aspartate (S-1c, 5.3 mmol scale, 1.2 g, 53%).

Prepared following **GP-A** and purified by column chromatography (60% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.88 (dd, J = 5.4, 3.1 Hz, 2H), 7.85 – 7.77 (m, 2H), 7.43 – 7.34 (m, 4H), 7.34 – 7.28 (m, 1H), 5.83 (d, J = 8.0 Hz, 1H), 5.37 – 4.89 (m, 2H), 4.80 (dt, J = 8.7, 4.8 Hz, 1H), 3.82 (s, 3H), 3.38 (dd, J = 16.9, 4.7 Hz, 1H), 3.28 (dd, J = 16.9, 5.1 Hz, 1H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 170.2, 167.4, 161.7, 156.0, 136.2, 135.1, 129.0, 128.7, 128.4, 128.3, 124.3, 67.5, 53.4, 50.4, 34.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 3374, 2954, 1818, 1789, 1744, 1524, 1467, 1346, 1218, 1187, 1083, 971, 878, 697, 519.

**HRMS** (ESI-TOF) calcd for (C<sub>21</sub>H<sub>18</sub>N<sub>2</sub>O<sub>8</sub>Na) [M+Na]<sup>+</sup> 449.0961, found 449.0967.

**Melting point:** 129 – 131 °C.



**1-Allyl 5-(1,3-Dioxoisoindolin-2-yl) (((9***H***-fluoren-9-yl)methoxy)carbonyl)-***L***-glutamate (S-1d, 4.7 mmol scale, 2.40 g, 91%).** 

Prepared following **GP-A** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.88 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.82 – 7.75 (m, 4H), 7.62 (t, *J* = 8.1 Hz, 2H), 7.40 (t, *J* = 8.2 Hz, 2H), 7.31 (td, *J* = 7.5, 1.2 Hz, 2H), 5.93 (ddt, *J* = 16.6, 11.2, 5.8 Hz, 1H), 5.52 (d, *J* = 8.3 Hz, 1H), 5.36 (d, *J* = 17.1 Hz, 1H), 5.29 (dd, *J* = 10.0, 0.8 Hz, 1H), 4.68 (d, *J* = 5.9 Hz, 2H), 4.57 – 4.47 (m, 2H), 4.43 – 4.36 (m, 1H), 4.23 (t, *J* = 6.7 Hz, 1H), 2.86 – 2.66 (m, 2H), 2.49 – 2.36 (m, 1H), 2.24 – 2.13 (m, 1H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 171.2, 169.0, 161.9, 156.1, 143.9, 141.5, 134.9, 131.3, 129.0, 127.9, 127.2, 125.3, 125.2, 124.2, 120.1, 119.6, 67.3, 66.6, 53.3, 47.3, 27.7.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 1782, 1744, 1694, 1526, 1357, 1292, 1193, 1119, 1103, 1083, 1001, 963, 935, 906, 876, 759, 738, 693.

**HRMS** (ESI-TOF) calcd for (C<sub>31</sub>H<sub>26</sub>N<sub>2</sub>NaO<sub>8</sub>) [M+Na]<sup>+</sup> 577.1587, found 577.1592.

**Melting point:** 139 – 142 °C.



1,3-Dioxoisoindolin-2-yl 6-Bromohexanoate (S-1e, 5.1 mmol scale, 1.1 g, 65%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.91 – 7.85 (m, 2H), 7.82 – 7.75 (m, 2H), 3.43 (t, *J* = 6.7 Hz, 2H), 2.69 (t, *J* = 7.4 Hz, 2H), 1.99 – 1.87 (m, 2H), 1.87 – 1.76 (m, 2H), 1.67 – 1.50 (m, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 169.5, 162.1, 134.9, 129.1, 124.1, 33.3, 32.4, 31.0, 27.5, 24.0.

The spectra are in accordance with the previous report.<sup>12</sup>



#### 1,3-Dioxoisoindolin-2-yl 2-(Phenylthio)acetate (S-1f, 29.7 mmol scale, 7.8 g, 84%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.88 (dd, *J* = 5.4, 3.1 Hz, 2H), 7.78 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.59 – 7.55 (m, 2H), 7.38 – 7.34 (m, 2H), 7.33 – 7.29 (m, 1H), 3.89 (s, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 166.4 , 161.7, 134.9, 133.4, 132.0, 129.4, 128.9, 128.3, 124.1, 34.6.

The spectra are in accordance with the previous report.9



1,3-Dioxoisoindolin-2-yl 2-(4-Fluorophenyl)acetate (S-1g, 6.5 mmol scale, 1.5 g, 77%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.88 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.82 – 7.76 (m, 2H), 7.39 – 7.33 (m, 2H), 7.11 – 7.03 (m, 2H), 3.97 (s, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 167.7, 162.5 (d, *J* = 246.7 Hz), 161.9, 134.9, 131.1 (d, *J* = 8.2 Hz), 129.0, 127.4, 124.2, 115.9 (d, *J* = 21.7 Hz), 37.1.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -114.5.

The spectra are in accordance with the previous report.<sup>13</sup>



1,3-Dioxoisoindolin-2-yl 2-Phenylacetate (S-1h, 7.3 mmol scale, 1.8 g, 88%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

 $^{1}\text{H}$  NMR (600 MHz, CDCl\_3)  $\delta$  7.89 – 7.82 (m, 2H), 7.79 – 7.74 (m, 2H), 7.42 – 7.36 (m, 4H), 7.36 – 7.30 (m, 1H), 4.00 (s, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 167.8, 161.9, 134.9, 131.6, 129.4, 129.0, 127.9, 124.1, 37.8.

The spectra are in accordance with the previous report.9



**1,3-Dioxoisoindolin-2-yl 4,4-Difluorocyclohexane-1-carboxylate** (**S-1i**, 6.1 mmol scale, 1.7 g, 92%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.88 (dd, J = 5.5, 3.1 Hz, 2H), 7.79 (dd, J = 5.5, 3.1 Hz, 2H), 2.88 (ddt, J = 13.0, 9.0, 3.8 Hz, 1H), 2.23 – 2.13 (m, 4H), 2.08 (tdd, J = 13.6, 9.2, 5.2 Hz, 2H), 1.96 – 1.84 (m, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 170.5, 162.0, 134.9, 129.0, 124.1, 122.3 (t, J = 241.3 Hz), 37.9, 32.1 (t, *J* = 24.8 Hz), 25.1 (t, *J* = 5.3 Hz).

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>)  $\delta$  -95.76 (d, J = 238.1 Hz), -98.48 (d, J = 238.5 Hz).

The spectra are in accordance with the previous report.<sup>9</sup>



**1,3-Dioxoisoindolin-2-yl 3-Oxocyclobutane-1-carboxylate (S-1j**, 3.0 mmol scale, 0.65 g, 84%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.87 (dd, *J* = 5.5, 3.2 Hz, 2H), 7.78 (dd, *J* = 5.5, 3.1 Hz, 2H), 3.65 – 3.59 (m, 3H), 3.51 (ddt, *J* = 14.5, 8.9, 3.5 Hz, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 201.3, 170.6, 161.6, 134.9, 128.7, 124.0, 52.1, 24.9.

The spectra are in accordance with the previous report.<sup>5</sup>



**1,3-Dioxoisoindolin-2-yl 2,3-Dihydrobenzo**[*b*][**1,4**]dioxine-2-carboxylate (S-1k, 8.3 mmol scale, 2.5 g, 91%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.89 (dd, J = 5.5, 3.1 Hz, 2H), 7.80 (dd, J = 5.5, 3.1 Hz, 2H), 7.06 – 6.99 (m, 1H), 6.98 – 6.93 (m, 1H), 6.94 – 6.82 (m, 2H), 5.27 (dd, J = 4.8, 2.8 Hz, 1H), 4.61 (dd, J = 11.6, 4.7 Hz, 1H), 4.56 (dd, J = 11.6, 2.8 Hz, 1H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 164.9, 161.5, 142.9, 141.8, 135.2, 128.9, 124.4, 122.6, 117.8, 117.6, 70.8, 64.9.

The spectra are in accordance with the previous report.<sup>14</sup>



**1,3-Dioxoisoindolin-2-yl** (3aR,6S,6aS)-6-Methoxy-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3] dioxole-4-carboxylate (S-1I, 1.8 mmol scale, 0.41 g, 62%).

Prepared following **GP-A** and purified by column chromatography (30% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.89 (dd, J = 5.5, 3.1 Hz, 2H), 7.83 – 7.77 (m, 2H), 5.36 (dd, J = 5.8, 1.2 Hz, 1H), 5.14 (s, 1H), 5.01 (t, J = 0.9 Hz, 1H), 4.67 (dd, J = 5.8, 0.7 Hz, 1H), 3.50 (s, 3H), 1.53 – 1.49 (m, 3H), 1.38 – 1.32 (m, 3H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 166.9, 161.5, 135.0, 129.0, 124.2, 113.4, 109.9, 84.3, 82.4, 82.2, 56.2, 26.6, 25.2.

The spectra are in accordance with the previous report.<sup>15</sup>



**1-(***tert***-butyl) 2-(1,3-dioxoisoindolin-2-yl) (***S***)-pyrrolidine-1,2-dicarboxylate (S-1m, 23 mmol scale, 6.9 g, 82%).** 

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.95 – 7.83 (m, 2H), 7.83 – 7.72 (m, 2H), 4.73 – 4.55 (m, 1H), 3.69 – 3.54 (m, 1H), 3.54 - 3.39 (m, 1H), 2.53 - 2.39 (m, 1H), 2.39 - 2.32 (m, 1H), 2.16 - 2.04 (m, 1H), 2.04 - 1.92 (m, 1H), 1.56 - 1.43 (m, 9H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 169.8, 169.5, 161.8, 161.7, 154.2, 153.6, 134.9, 134.8, 129.1, 124.1, 124.0, 81.3, 80.5, 57.3, 57.2, 46.6, 46.4, 31.6, 30.4, 28.5, 28.2, 24.6, 23.7.

The spectra are in accordance with the previous report.8



**1,3-Dioxoisoindolin-2-yl** (S)-3-(4-Acetoxyphenyl)-2-((*tert*-butoxycarbonyl)amino)propano ate (S-1n, 2.0 mmol scale, 651 mg, 71%).

Prepared following **GP-A** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.90 (dd, J = 5.5, 3.2 Hz, 2H), 7.80 (dd, J = 5.5, 3.1 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 7.08 (d, J = 8.1 Hz, 2H), 5.05 – 4.94 (m, 1H), 4.78 (br, 1H), 3.41 – 3.13 (m, 2H), 2.29 (s, 3H), 1.44 (s, 9H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 169.5, 168.6, 161.6, 154.8, 150.1, 135.0, 132.4, 130.9, 128.9, 124.2, 121.9, 80.8, 52.7, 37.7, 28.4, 21.4.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 1785, 1746, 1702, 1493, 1367, 1250, 1213, 1203, 1170, 1130, 1056, 1016, 973, 920, 876, 843, 746.

**HRMS** (ESI-TOF) calcd for (C<sub>24</sub>H<sub>24</sub>N<sub>2</sub>NaO<sub>8</sub>) [M+Na]<sup>+</sup> 491.1430, found 491.1417.

**Melting point:** 155 – 156 °C.



**1,3-Dioxoisoindolin-2-yl (***tert***-Butoxycarbonyl)-***L***-tryptophanate (S-10, 3.3 mmol scale, 876 mg, 59%).** 

Prepared following **GP-A** and purified by recrystallization (CHCl<sub>3</sub>-MeOH). The product was obtained as a yellow solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 8.20 (s, 1H), 7.91 – 7.88 (m, 2H), 7.82 – 7.78 (m, 2H), 7.63 (d, J = 8.1 Hz, 1H), 7.42 (s, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 7.15 (t, J = 7.6 Hz, 1H), 5.15 – 5.12 (m, 1H), 5.04 (d, J = 8.8 Hz, 1H), 3.58 (dd, J = 15.0, 5.8 Hz, 1H), 3.47 (dd, J = 15.0, 4.5 Hz, 1H), 1.44 (s, 9H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) 169.0, 161.8, 155.0, 136.2, 135.0, 129.0, 128.3, 124.3, 124.2, 122.4, 120.0, 118.9, 111.4, 108.9, 80.6, 53.4, 28.5, 28.2.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 3413, 2979, 1817, 1788, 1742, 1707, 1502, 1458, 1368, 1252, 1186, 1164, 1052, 975, 911, 878, 783, 739, 697, 518.

**HRMS** (ESI-TOF) calcd for (C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>6</sub>Na) [M+Na]<sup>+</sup> 472.1485, found 472.1489.

**Melting point:** 180 – 182 °C.



**1,3-Dioxoisoindolin-2-yl 3-Chloro-2,2-dimethylpropanoate** (S-1p, 7.3 mmol scale, 1.31 g, 65%).

Prepared following **GP-A** and purified by filtering through a 30 g SiO<sub>2</sub> plug using DCM as eluent (125 mL). The product was obtained as a colorless liquid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.88 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.79 (dd, *J* = 5.5, 3.1 Hz, 2H), 3.76 (s, 2H), 1.53 (s, 6H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 171.6, 161.9, 135.0, 129.1, 124.1, 50.9, 44.6, 23.4.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 1810, 1785, 1739, 1468, 1370, 1290, 1186. 1160, 1130, 1055, 1019, 977, 964, 878, 859, 816, 786, 759, 659, 518.

**HRMS** (ESI-TOF) calcd for (C<sub>13</sub>H<sub>12</sub>CINO<sub>4</sub>Na) [M+Na]<sup>+</sup> 304.0353, found 304.0349.



**1-(1,3-Dioxoisoindolin-2-yl) 4-Methyl Bicyclo[2.2.2]octane-1,4-dicarboxylate** (S-1q, 3.0 mmol scale, 0.99 g, 92%).

Prepared following **GP-A** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid.

 $^1\text{H}$  NMR (600 MHz, CDCl\_3)  $\delta$  7.89 – 7.84 (m, 2H), 7.80 – 7.75 (m, 2H), 3.67 (s, 3H), 2.11 – 2.00 (m, 6H), 1.95 – 1.83 (m, 6H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl\_3)  $\delta$  177.5, 173.4, 162.1, 134.8, 129.1, 124.0, 52.0, 38.6, 38.5, 27.8, 27.6.

The spectra are in accordance with the previous report.<sup>16</sup>



**1-(1,3-Dioxoisoindolin-2-yl) 1-Methyl Cyclopropane-1,1-dicarboxylate (S-1r**, 2.0 mmol scale, 460 mg, 79%).

Prepared following **GP-A** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ7.88 (dd, J = 5.4, 3.1 Hz, 2H), 7.79 (dd, J = 5.5, 3.1 Hz, 2H), 3.83 (s, 3H), 1.83 (td, J = 6.2, 2.5 Hz, 2H), 1.77 (td, J = 6.3, 2.5 Hz, 2H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 168.8, 166.2, 161.8, 134.9, 129.0, 124.1, 53.2, 26.1, 19.0.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 1785, 1738, 1347, 1188, 1021, 936, 875, 698, 517.

**HRMS** (ESI-TOF) calcd for (C<sub>14</sub>H<sub>11</sub>NNaO<sub>6</sub>) [M+Na]<sup>+</sup> 312.0484, found 312.0475.

**Melting point:** 102 – 103 °C.



1,3-Dioxoisoindolin-2-yl 1-Phenylcyclopropane-1-carboxylate (S-1s, 6.2 mmol scale, 1.3 g, 70%).

Prepared following **GP-A** and purified by column chromatography (5% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.84 (dd, J = 5.5, 3.1 Hz, 2H), 7.74 (dd, J = 5.5, 3.1 Hz, 2H), 7.55 – 7.48 (m, 2H), 7.36 (t, J = 7.4 Hz, 2H), 7.33 – 7.22 (m, 1H), 1.91 (q, J = 4.3 Hz, 2H), 1.49 (q, J = 4.3 Hz, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 171.2, 162.0, 137.1, 134.8, 130.7, 129.0, 128.6, 128.1, 124.0, 27.4, 18.8.

The spectra are in accordance with the previous report.<sup>8</sup>



**1,3-Dioxoisoindolin-2-yl 3,3,3-Trifluoro-2-methoxy-2-phenylpropanoate** (S-1t, 1.5 mmol scale, 0.29 g, 51%).

The praparation of compound **S-1aa** is adapted from the report of Doyle *et al.*<sup>9</sup> To a 25 mL flask with a stir bar was charged  $\alpha$ -methoxy- $\alpha$ -trifluoromethylphenylacetic acid (351 mg, 1.5 mmol, 1 equiv), DMF (11.0 mg, 0.15 mmol, 0.1 equiv) and oxalyl chloride (222 mg, 2.6 mmol, 1.75 equiv). Then 8 mL of DCM was added, followed by *N*-hydroxyphthalimide (269 mg, 1.7 mmol, 1.1 equiv) and NEt<sub>3</sub> (167 mg, 1.7 mmol, 1.1 equiv). The reaction was allowed to run overnight and then concentrated under reduced pressure. The crude was purifies by SiO<sub>2</sub> column chromatophrapgy (10% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.92 (dd, J = 5.4, 3.1 Hz, 2H), 7.82 (dd, J = 5.5, 3.1 Hz, 2H), 7.74 – 7.71 (m, 2H), 7.52 – 7.47 (m, 3H), 3.82 (d, J = 1.4 Hz, 3H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 163.9, 161.4, 135.2, 131.0, 130.4, 128.9, 128.7, 127.6, 124.3, 122.8 (q, *J* = 289.0 Hz), 85.0(q, *J* = 29.5 Hz), 56.6.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -72.3.

The spectra are in accordance with the previous report.<sup>17</sup>



1,3-Dioxoisoindolin-2-yl Picolinate (S-1u, 20 mmol scale, 4.8 g, 90%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 8.88 – 8.83 (m, 1H), 8.27 – 8.22 (m, 1H), 7.96 – 7.89 (m, 3H), 7.84 – 7.78 (m, 2H), 7.64 – 7.59 (m, 1H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 161.8, 161.5, 150.6, 144.4, 137.5, 135.0, 129.1, 128.6, 126.8, 124.2.

The spectra are in accordance with the previous report.<sup>18</sup>



1,3-Dioxoisoindolin-2-yl 3,7-Dimethyloct-6-enoate (S-1v, 3.0 mmol scale, 0.7 g, 74%).

Prepared following **GP-A** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.90 – 7.82 (m, 2H), 7.80 – 7.74 (m, 2H), 5.14 – 5.04 (m, 1H), 2.66 (dd, J = 15.0, 5.7 Hz, 1H), 2.45 (dd, J = 15.0, 8.3 Hz, 1H), 2.14 – 1.95 (m, 3H), 1.67 (s, 3H), 1.60 (s, 3H), 1.52 – 1.42 (m, 1H), 1.40 – 1.28 (m, 1H), 1.08 (d, J = 6.7 Hz, 3H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 169.1, 162.1, 134.8, 132.0, 129.0, 124.0, 124.0, 38.3, 36.6, 30.3, 25.8, 25.4, 19.5, 17.8.

The spectra are in accordance with the previous report.<sup>12</sup>



**1,3-Dioxoisoindolin-2-yl** (*E*)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzo furan-5-yl)-4-methylhex-4-enoate (S-1w, 3.1 mmol scale, 0.58 g, 40%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.87 (dd, J = 5.4, 3.1 Hz, 2H), 7.78 (dd, J = 5.5, 3.1 Hz, 2H), 5.34 (t, J = 7.0 Hz, 1H), 5.19 (s, 2H), 4.36 (br, 1H), 3.77 (s, 3H), 3.42 (d, J = 7.1 Hz, 2H), 2.76 (t, J = 7.8 Hz, 2H), 2.45 (t, J = 7.9 Hz, 2H), 2.15 (s, 3H), 1.85 (s, 3H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 173.1, 169.4, 163.9, 162.1, 153.9, 144.2, 134.9, 133.2, 129.1, 124.1, 124.0, 122.1, 116.9, 106.6, 70.2, 61.2, 34.2, 34.0, 22.8, 16.3, 11.8.

The spectra are in accordance with the previous report.<sup>19</sup>



**1,3-Dioxoisoindolin-2-yl 4-([1,1'-Biphenyl]-4-yl)-4-oxobutanoate** (**S-1x**, 3.0 mmol scale, 1.4 g, 85%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a purple solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 8.11 – 8.04 (m, 2H), 7.89 (dd, J = 5.5, 3.1 Hz, 2H), 7.79 (dd, J = 5.5, 3.1 Hz, 2H), 7.70 (d, J = 8.4 Hz, 2H), 7.67 – 7.60 (m, 2H), 7.53 – 7.45 (m, 2H), 7.43 – 7.38 (m, 1H), 3.50 (t, J = 6.9 Hz, 2H), 3.18 (t, J = 6.9 Hz, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 196.2, 169.5, 162.0, 146.3, 139.9, 135.0, 134.9, 129.1, 129.1, 128.9, 128.5, 127.5, 127.5, 124.2, 33.4, 25.7.

The spectra are in accordance with the previous report.<sup>9</sup>



**1,3-Dioxoisoindolin-2-yl 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1***H***-indol-3-yl)acetate** (**S-1y**, 5.0 mmol scale, 2.1 g, 53%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.88 (dt, J = 7.6, 3.8 Hz, 2H), 7.79 (dd, J = 5.6, 3.1 Hz, 2H), 7.69 (d, J = 8.2 Hz, 2H), 7.50 – 7.46 (m, 2H), 7.03 (d, J = 2.5 Hz, 1H), 6.93 (d, J = 9.0 Hz, 1H), 6.71 (dd, J = 9.0, 2.5 Hz, 1H), 4.04 (s, 2H), 3.89 (s, 3H), 2.42 (s, 3H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 168.5, 167.2, 162.0, 156.4, 139.6, 136.6, 135.0, 133.9, 131.5, 130.9, 130.1, 129.4, 129.1, 124.2, 115.2, 112.7, 110.4, 100.8, 55.9, 27.3, 13.6.

The spectra are in accordance with the previous report.<sup>10</sup>



1,3-Dioxoisoindolin-2-yl 2-(2,4-Dichlorophenoxy)acetate (S-1z, 2.0 mmol scale, 0.47 g, 64%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.94 – 7.85 (m, 2H), 7.84 – 7.74 (m, 2H), 7.41 (d, J = 2.5 Hz, 1H), 7.24 (dd, J = 8.8, 2.5 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H), 5.10 (s, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 165.1, 161.6, 152.0, 135.2, 130.7, 128.9, 128.3, 128.0, 124.8, 124.3, 115.7, 64.8.

The spectra are in accordance with the previous report.<sup>20</sup>



(1*S*,2*S*,4*aR*,4*bR*,7*S*,9*aS*,10*S*,10*aR*)-10-(((1,3-Dioxoisoindolin-2-yl)oxy)carbonyl)-1-methyl-8-methylene-13-oxo-1,2,5,6,8,9,10,10*a*-octahydro-4*a*,1-(epoxymethano)-7,9*a*-methanoben zo[*a*]azulene-2,7(4*bH*)-diyl Diacetate (S-1aa, 5.8 mmol scale, 1.7 g, 52% over two steps).

The praparation of compound **S-1aa** is adapted from the report of Aggarwal *et al.*<sup>9</sup> To a solution of Gibberellic acid (2.0 g, 5.8 mmol, 1.0 equiv), acetic anhydride (7.1 g, 69.3 mmol, 12 equiv) and DMAP (70.5 mg, 0.58 mmol, 0.1 equiv) in anhydrous DCM (100 mL) at room temperature was slowly added pyridine (9.1 g, 115.5 mmol, 20 equiv) over 5 min. The reaction mixture was monitored by LC-MS and was found completed after 24 h. The reaction mixture was quench with water (100 mL) and extracted with DCM (50mL×2). The combined organic layers was washed with satd NaHCO<sub>3</sub> (50mL×2) and brine (50mL). The organic phas was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure to give a foam-like powder. (**Note**: it is very important to make sure the mixture is completely dry as the remaining acetic acid could interfere with the phthalimide ester formation). The crude material was directly used in the preparation of the phthalimide ester following **GP-A** and purified by recrystallization using EtOH.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.91 (dd, J = 5.5, 3.1 Hz, 2H), 7.82 (dd, J = 5.5, 3.1 Hz, 2H), 6.41 (d, J = 9.3 Hz, 1H), 5.92 (dd, J = 9.3, 3.8 Hz, 1H), 5.39 (d, J = 3.8 Hz, 1H), 5.29 – 5.26 (m, 1H), 5.12 – 5.09 (m, 1H), 3.40 (d, J = 11.1 Hz, 1H), 3.16 (d, J = 11.1 Hz, 1H), 2.92 (dt, J = 15.1, 3.1

Hz, 1H), 2.53 - 2.44 (m, 3H), 2.28 - 2.23 (m, 1H), 2.12 (d, J = 3.7 Hz, 1H), 2.11 (s, 3H), 2.07 (s, 3H), 2.04 (d, J = 4.7 Hz, 1H), 1.85 (td, J = 11.7, 7.5 Hz, 1H), 1.79 - 1.73 (m, 1H), 1.33 (s, 3H). <sup>13</sup>**C** NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  176.6, 170.1, 168.8, 161.8, 153.2, 135.1, 134.1, 129.6, 129.0, 124.3,

108.9, 89.9, 84.0, 70.2, 54.2, 52.3, 51.6, 51.5, 48.2, 42.4, 39.9, 36.3, 22.2, 20.9, 17.1, 14.5.

The spectra are in accordance with the previous report.9



**1,3-Dioxoisoindolin-2-yl 4-((**5*S*,8*R*,9*S*,10*S*,13*R*,14*S*,17*R*)-10,13-Dimethyl-3,7,12-trioxohexa decahydro-1*H*-cyclopenta[*a*]phenanthren-17-yl)pentanoate (S-1ab, 4.0 mmol scale, 1.6 g, 72%).

Prepared following **GP-A** and purified by column chromatography (60% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.81 (dd, J = 5.5, 3.1 Hz, 2H), 7.72 (dd, J = 5.5, 3.0 Hz, 2H), 2.88 – 2.76 (m, 3H), 2.69 (ddd, J = 16.0, 8.6, 5.1 Hz, 1H), 2.57 (dt, J = 16.2, 8.2 Hz, 1H), 2.32 – 2.19 (m, 4H), 2.19 – 2.12 (m, 2H), 2.11 – 2.06 (m, 2H), 2.02 – 1.93 (m, 4H), 1.93 – 1.86 (m, 1H), 1.80 (td, J = 11.5, 7.1 Hz, 1H), 1.55 (td, J = 14.5, 4.6 Hz, 1H), 1.50 – 1.43 (m, 1H), 1.42 – 1.35 (m, 1H), 1.34 (s, 3H), 1.27 – 1.16 (m, 2H), 1.05 (s, 3H), 0.85 (d, J = 6.6 Hz, 3H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 212.1, 209.2, 208.8, 170.0, 162.1, 134.9, 129.1, 124.1, 57.1, 51.9, 49.2, 47.0, 45.8, 45.7, 45.1, 43.0, 38.8, 36.7, 36.2, 35.4, 34.1, 30.5, 28.6, 27.8, 25.3, 22.1, 18.7, 12.0.

The spectra are in accordance with the previous report.<sup>10</sup>



**1,3-Dioxoisoindolin-2-yl** (4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-Hydroxy-2,4a,6a,6b,9 ,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydr opicene-2-carboxylate (S-1ac, 3.2 mmol scale, 1.0 g, 52%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.88 (dd, *J* = 5.4, 3.1 Hz, 2H), 7.79 (dd, *J* = 5.5, 3.1 Hz, 2H), 5.76 (s, 1H), 3.22 (dd, *J* = 11.3, 5.0 Hz, 1H), 2.78 (dt, *J* = 13.6, 3.6 Hz, 1H), 2.46 (ddd, *J* = 13.7, 4.3,

1.7 Hz, 1H), 2.33 (s, 1H), 2.14 (dq, *J* = 13.0, 2.9 Hz, 1H), 2.10 – 2.01 (m, 2H), 1.87 (td, *J* = 13.7, 4.9 Hz, 1H), 1.79 (t, *J* = 13.7 Hz, 1H), 1.69 – 1.57 (m, 6H), 1.55 – 1.47 (m, 1H), 1.47 – 1.44 (m, 1H), 1.43 (s, 3H), 1.42 – 1.39 (m, 1H), 1.38 (s, 3H), 1.31 (s, 1H), 1.24 – 1.18 (m, 1H), 1.14 (s, 3H), 1.12 (s, 3H), 1.07 (ddt, *J* = 13.8, 4.7, 2.2 Hz, 1H), 1.00 (s, 3H), 0.99 – 0.94 (m, 1H), 0.91 (s, 3H), 0.80 (s, 3H), 0.70 (dd, *J* = 11.8, 1.9 Hz, 1H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 200.2, 172.8, 168.5, 162.3, 134.9, 129.2, 129.1, 124.1, 78.9, 62.0, 55.1, 47.9, 45.5, 44.1, 43.3, 41.4, 39.3, 37.4, 37.3, 33.0, 32.0, 31.6, 28.5, 28.3, 28.1, 27.5, 26.7, 26.6, 23.7, 18.9, 17.7, 16.5, 15.8.

The spectra are in accordance with the previous report.<sup>21</sup>



**1,3-Dioxoisoindolin-2-yl 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoate (S-1ad**, 4.0 mmol scale, 0.9 g, 57%).

Prepared following **GP-A** and purified by recrystallization with EtOH. The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.88 (dd, J = 5.4, 3.1 Hz, 2H), 7.79 (dd, J = 5.5, 3.1 Hz, 2H), 7.01 (d, J = 7.4 Hz, 1H), 6.69 – 6.64 (m, 2H), 4.02 (t, J = 5.2 Hz, 2H), 2.32 (s, 3H), 2.20 (s, 3H), 2.03 – 1.85 (m, 4H), 1.46 (s, 6H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 173.9, 162.2, 157.1, 136.6, 134.8, 130.4, 129.2, 124.0, 123.8, 120.9, 112.1, 67.9, 42.1, 37.5, 25.3, 25.2, 21.6, 15.9.

The spectra are in accordance with the previous report.<sup>21</sup>



**1,3-Dioxoisoindolin-2-yl** (1S,4R)-4,7,7-Trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carb oxylate (S-1ae, 2.6 mmol scale, 0.39 g, 43%).

Prepared following **GP-A** and purified by column chromatography (50% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.91 (dd, J = 5.4, 3.1 Hz, 2H), 7.82 (dd, J = 5.5, 3.1 Hz, 2H), 2.61 (ddd, J = 13.5, 10.8, 4.2 Hz, 1H), 2.29 (ddd, J = 13.7, 9.3, 4.6 Hz, 1H), 2.02 (ddd, J = 13.1, 10.8, 4.6 Hz, 1H), 1.79 (ddd, J = 13.4, 9.3, 4.2 Hz, 1H), 1.19 (s, 3H), 1.18 (s, 3H), 1.17 (s, 3H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  177.3, 164.4, 161.5, 135.2, 129.0, 124.3, 90.0, 55.7, 54.9, 31.0, 29.0, 16.7, 16.6, 10.0.

The spectra are in accordance with the previous report.<sup>21</sup>



**1,3-Dioxoisoindolin-2-yl 2-(2-Fluoro-[1,1'-biphenyl]-4-yl)propanoate** (S-1af, 1.5 mmol scale, 0.43 g, 73%).

Prepared following **GP-A** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.88 (dt, J = 7.7, 3.8 Hz, 2H), 7.78 (dd, J = 5.5, 3.1 Hz, 2H), 7.57 (dt, J = 8.1, 1.5 Hz, 2H), 7.47 (dt, J = 15.6, 7.9 Hz, 3H), 7.40 – 7.36 (m, 1H), 7.28 (dd, J = 7.9, 1.8 Hz, 1H), 7.26 – 7.23 (m, 1H), 4.17 (q, J = 7.2 Hz, 1H), 1.73 (d, J = 7.2 Hz, 3H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 170.4, 161.9, 159.9 (d, J = 248.9 Hz), 139.6 (d, J = 7.8 Hz), 135.4, 134.9, 131.3 (d, J = 3.3 Hz), 129.1 (d, J = 2.9 Hz), 129.0, 128.7, 128.6, 127.9, 124.1, 123.7 (d, J = 3.4 Hz), 115.6 (d, J = 24.3 Hz), 42.5, 19.0.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -116.9.

The spectra are in accordance with the previous report.<sup>22</sup>



1,3-Dioxoisoindolin-2-yl 2-(2-Allylphenyl)acetate (S-1ag, 0.8 mmol scale, 224 mg, 88%).

The 2-allylphenyl acetic acid was prepared in 3 steps starting from the commercially available 2bromophenyl acetic acid following a procedure from the literature.<sup>23</sup> The corresponding redox active ester was prepared following **GP-A** and purified by column chromatography (20% EtOAc/hexanes). The desired product was obtained as a white solid.

<sup>1</sup>**H NMR** (500 MHz, CDCl<sub>3</sub>) δ 7.88 (dd, J = 5.5, 3.1 Hz, 2H), 7.79 (dd, J = 5.5, 3.1 Hz, 2H), 7.35 (dd, J = 7.6, 1.7 Hz, 1H), 7.31 – 7.23 (m, 3H), 5.99 (ddt, J = 16.5, 10.1, 6.2 Hz, 1H), 5.14 (dd, J = 10.1, 1.7 Hz, 1H), 5.07 (dd, J = 17.2, 1.8 Hz, 1H), 4.02 (s, 2H), 3.49 (d, J = 6.0 Hz, 2H).

 $^{13}\textbf{C}$  NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  167.9, 162.0, 138.7, 136.2, 134.9, 130.8, 130.5, 130.3, 129.1, 128.5, 127.1, 124.1, 116.7, 37.6, 35.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 1815, 1785, 1745, 1359, 1345, 1184, 1137, 1080, 1058, 968, 932, 875, 843, 790, 768, 739, 693.

**HRMS** (ESI-TOF) calcd for (C<sub>19</sub>H<sub>15</sub>NNaO<sub>4</sub>) [M+Na]<sup>+</sup> 344.0899, found 344.0896.

Melting point: 82 – 83 °C.

#### 2.2 General Procedure for Propellane Synthesis



The procedure was adapted from the report of the Baran group.<sup>24</sup> To an appropriately-sized round bottom flask was added 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane (5.0 g, 16.8 mmol) and Et<sub>2</sub>O (10-12 mL) under inert atmosphere. Once dissolved, the reaction was cooled to -78 °C in a dry ice-acetone bath. The reaction turned into a slurry at -78 °C. To the light brown slurry was added PhLi (20 mL, 38.0 mmol, 2.3 equiv, 1.9 M soln in *n*-Bu<sub>2</sub>O) dropwise over 10 to 15 min. The reaction was then stirred at -78 °C for another 30 min and then was allowed to warm to 0 °C using an ice-water bath. After 2 h, the reaction turned into a dark-brown slurry, which indicates the reaction is finished. The product propellane is co-distilled with Et<sub>2</sub>O by house vacuum (*ca.* 4 Torr) as a clear, colorless solution. The receiving flask was submerged in a -78 °C bath or liquid nitrogen bath.



Figure S2. Distillation set-up



Figure S3. Solution of propellane in Et<sub>2</sub>O

#### Determination of the Concentration of Propellane:

In an NMR tube was added 0.100 mmol of 1,3,5-trimethoxybenzene and an appropriate amount of CDCl<sub>3</sub>. Then 100  $\mu$ L of the [1.1.1]propellane solution was added into the NMR tube, and the ratio of 1,3,5-trimethoxybenzene:propellane was used to calculate the concentration of [1.1.1]propellane.

\*Integration of 3 aromatic protons on 1,3,5-trimethoxybenzene (~6.1 ppm) is set to 1 and the 6 [1.1.1]propellane protons are integrated at ~2.0 ppm.

$$c(propellane) = \frac{lnt (propellane) \times 0.1mmol \times 3}{6 \times 0.1mL} = lnt (propellane) \times 0.5 M$$

Sample calculation:



$$c(propellane) = Int(propellane) \times 0.5 M = 1.84 \times 0.5 M = 0.9 M$$

#### Note

1. The quality of starting materials are important to achieve a high concentration of [1.1.1]propellane. We observed lower concentrations (0.5 - 0.7 M) when we used a poor quality of tetrahalide and PhLi. The tetrahalide should be a white or light-yellow powder instead of a yellow, chunky solid. Typically, we purchased tetrahalide from Chemscene and PhLi from Sigma-Aldrich.

2. The use of ether solvent (Et<sub>2</sub>O and *n*-Bu<sub>2</sub>O) proved to be crucial for the formation of propellane.

3. The vacuum for distillation is also important: the vacuum should not be too strong because it will lead to loss of product. Careful control while opening the vacuum valve and use of a larger reaction flask are helpful because the reaction mixture tends to bump a lot because of the presence of solids. In the picture, we set up a 20 g scale reaction with a 500 mL round-bottom flask. During co-distillation, the reaction mixture was stirred in a room temperature water bath.

4. Propellane is stable at least for months when stored in  $Et_2O$  at < -20 °C. It is semi-stable at room temperature only for a short amount of time (10 - 20 min), as we observed significant polymerization after 2 h at rt.

#### 3. Extended Optimizations and Control Studies

#### 3.1 Optimization and Control Studies with RAE

The optimization of the multicomponent reaction was achieved using RAE **1b** as the model substrate.



#### **Optimization procedure:**

The proper amount of radical precursor (0.3 mmol, 1 equiv) was added to an 8 mL sealable vial. Dry B<sub>2</sub>pin<sub>2</sub> (or another borylation reagent) was added along with any other additives. Degassed solvent was then added followed by [1.1.1]propellane. The tube was sealed with Parafilm<sup>®</sup> and irradiated for 16 h under the indicated wavelength at 1 inch distance. The reaction temperature was maintained at rt by two fans. The mixture was then partitioned between Et<sub>2</sub>O (50 mL) and brine (25 mL). The organic layer was washed two more times with brine (25 mL each), dried (MgSO<sub>4</sub>), filtered, and dried under vacuum. LC-MS analysis was performed at this stage by adding 20  $\mu$ L of the reaction mixture in 1 mL of MeCN. If product was detected, the crude was then purified by flash column chromatography (30% EtOAc in hexanes).

Table S1: Reaction scheme and deviations from the standard conditions.

Deviation from standard conditions	% Yield (NMR yield)
None	89
Katritzky salt (1 equiv) instead of <b>1b</b>	traces
<i>N</i> -Boc-4-bromopiperidine <b>2a</b> (1 equiv) instead of <b>1b</b>	0
$B_2(OH)_4$ (1.2 equiv) instead of $B_2pin_2^*$	64 (84)
$B_2(OH)_4$ (3 equiv) instead of $B_2pin_2^*$	(81)
$B_2 cat_2$ (3 equiv) instead of $B_2 pin_2^{**}$	10
$Me_2PhSi-Bpin $ <b>3b</b> (3 equiv) instead of $B_2pin_2$	40
456 nm instead of 390 nm	30
1.2 equiv of B <sub>2</sub> pin <sub>2</sub> instead of 3 equiv	60
No precautions (adding 4 equiv of $H_2^{0}$ , under air)	62
with 4-CzIPN (2 mol %) at 456 nm	42

DMF instead of DMA	(58)
MeCN instead of DMA	(59)
THF instead of DMA	(26)
MeOH instead of DMA	(26)
Freeze-pump-thaw (3 cycles)	(82)
No light	0
No light, 60 °C	0

Yields indicated between parentheses were measured by <sup>1</sup>H NMR using 1,3,5-trimethoxybenzene as a standard.

\*After completion, pinacol (4 equiv) and MgSO<sub>4</sub> (10 equiv) were added, and the reaction was vigorously stirred for another 16 h. The product was isolated as the pinacol boronate. The yield indicated is over these two steps.

\*\*After completion, pinacol (10 equiv) and NEt<sub>3</sub> (3 mL) were added, and the reaction was stirred vigorously for another 1 h. The product was isolated as the pinacol boronate. The yield indicated is over these two steps.



Katritzky salt

#### Notes

- Completion of this specific reaction is reached after 6 h but all reactions were left for 16 h as the reaction time for other substrates varies.
- Anhydrous solvent and air-free condition are not mandatory and will result in only a slight decrease of the yield.

#### 3.2 Optimization and Control Studies with Organohalides

The optimization of the multicomponent reaction was achieved using 4-bromo-*N*-Boc-piperidine **2a** as the model substrate.



#### **Optimization general procedure:**

The proper amount of radical precursor (0.1 mmol, 1 equiv) was added to a 4 mL sealable vial followed by the base (0.05 – 0.1 mmol, 0.5 – 1 equiv), if required. The borylation reagent was added, followed by solvent (0.1 M) and [1.1.1]propellane (0.15 mmol, 1.5 equiv). The tube was sealed with Parafilm<sup>®</sup> and irradiated for 16 h under the indicated wavelength at 1 inch distance. The reaction temperature was maintained at rt by two fans. LCMS analysis was performed at this stage by adding 20  $\mu$ L of the reaction mixture in 1 mL of MeCN. The yield was determined by <sup>1</sup>H NMR using 1,3,5-trimethoxybenzene as an internal standard.

#### Table S2: Solvent screen

Deviations from standard conditions	
Solvent	% NMR Yield
THF	30
Et <sub>2</sub> O	35
MeOH	0
MeOH *	60
EtOH *	45
<i>i</i> -PrOH *	40
<i>n</i> -BuOH *	30
<i>t</i> -BuOH *	42
acetone	trace
MeCN	trace
toluene	trace
DMA	trace
DMSO	trace
DMF	trace
$CH_2CI_2$	20
1,4-dioxane	20
CPME	18
MTBE	35
DME	15

cyclohexane	23
EtOAc	23
TFT	trace
xylenes	9
CHCl <sub>3</sub>	0
DCE	20

\* 1 equiv of  $K_2CO_3$  was added.

Table S3



Deviation from standard conditions	% NMR yield
None	66
N-Boc-4-iodopiperidine 2b instead of 2a	72
Katritzky salt (1 equiv) instead of <b>2a</b>	27
1b instead of 2a	<20
3 equiv of [1.1.1]propellane instead of 2 equiv	35
1.5 equiv of [1.1.1]propellane instead of 2 equiv	50
3 equiv of Me <sub>2</sub> PhSi-Bpin instead of 2 equiv	17
1 equiv of $K_{3}PO_{4}$ instead of 0.5 equiv	56
$Cs_2CO_3$ (0.5 equiv) instead of $K_3PO_4$	37
$K_2CO_3$ (0.5 equiv) instead of $K_3PO_4$	58
DIPEA (0.5 equiv) instead of $K_3PO_4$	42
TMEDA (0.5 equiv) instead of $K_3PO_4$	35
Ph <sub>3</sub> Si-Bpin (2 equiv) instead of Me <sub>2</sub> PhSi-Bpin	12
B <sub>2</sub> pin <sub>2</sub> (3 equiv) instead of Me <sub>2</sub> PhSi-Bpin	8
<i>i</i> -PrOH (0.1 M) instead of MeOH	56
Et <sub>2</sub> O (0.1 M) instead of MeOH (w/o base)	32
10 W blue LED	0
34 W Kessil blue LED	27
Freeze-pump-thaw (4 cycles)	58

No base	0
No light	8
No light at 60 °C	trace



Katritzky salt

Notes

- Increasing or decreasing the amount of base, [1.1.1]propellane, or borylation reagent led to a lower yield
- Anhydrous solvent and air-free condition are not mandatory.

#### 4. Procedures for Reactions

### General Procedure for Three-component Borylation with RAE (General Procedure B – GP-B)



To an 8 mL reaction vial equipped with a stirrer bar was added RAE (0.3 mmol, 1 equiv) followed by dry B<sub>2</sub>pin<sub>2</sub> (228.5 mg, 0.9 mmol, 3 equiv). The reaction vessel was sealed with a cap containing a TFE-lined silicone septum and then was evacuated and backfilled with argon three times. When done, degassed DMA (3 mL, 0.1 M) was added. Next, freshly prepared and titrated [1.1.1]propellane (0.45 mmol, 1.5 equiv, 0.8 - 1.3 M solution in Et<sub>2</sub>O) was then added, and the vial was quickly sealed with Parafilm<sup>®</sup>. The reaction mixture was then irradiated under vigorous stirring at 52 W 390 nm using a Kessil lamp at 1 inch distance for 16 h. Room temperature was maintained by the use of two fans. When judged complete (*Note:* after completion, the reaction mixture is generally orange), the mixture was then partitioned between Et<sub>2</sub>O (10 mL) and satd aq NH<sub>4</sub>Cl (10 mL). The organic layer was washed two more times with brine (10 mL × 2), dried (MgSO<sub>4</sub>), filtered, and further dried under vacuum. The crude mixture was then purified by SiO<sub>2</sub> flash column chromatography.

### General Procedure for BCP Boronic Acid Preparation with RAE (General Procedure C – GP-C)



To an 8 mL reaction vial equipped with a stirrer bar was added RAE (0.3 mmol, 1 equiv) followed by dry  $B_2(OH)_4$  (32.3 mg, 0.36 mmol, 1.2 equiv). The reaction vessel was sealed with a cap containing a TFE-lined silicone septum and then was evacuated and backfilled with argon three times. When done, degassed DMA (3 mL, 0.1 M) was added. Next, freshly prepared and titrated [1.1.1]propellane (0.45 mmol, 1.5 equiv, 0.8 - 1.3 M solution in Et<sub>2</sub>O) was then added, and the vial was quickly sealed with Parafilm<sup>®</sup>. The reaction mixture was then irradiated under vigorous stirring at 52 W 390 nm using a Kessil lamp at 1 inch distance for 16 h. Room temperature was maintained by the use of two fans. When judged complete after 16 h (*Note:* after completion, the reaction mixture remains transparent in most cases, which is different from using  $B_2pin_2$ ), pinacol (141.8 mg, 1.2 mmol, 4 equiv) and MgSO<sub>4</sub> (361.2 mg, 3 mmol, 10 equiv) were added to the reaction mixture, and the reaction mixture was allowed to stirred at rt for 4 h. The mixture was

then partitioned between  $Et_2O$  (10 mL) and satd aq NH<sub>4</sub>Cl (10 mL). The organic layer was washed two more times with brine (10 mL × 2), dried (MgSO<sub>4</sub>), filtered, and further dried under vacuum. The crude mixture was then purified by SiO<sub>2</sub> flash column chromatography.

# General Procedure for the Preparation of 1,2,3-Substituted BCPs (General Procedure D – GP-D)



The C<sub>2</sub>-substituted [1.1.1]propellane is prepared according to report from the Baran group.<sup>25</sup> The [1.1.1]propellane was dissolved in DMA to a 0.3 M solution. To a 4 mL reaction vial equipped with a stirrer bar was added RAE (0.2 mmol, 1 equiv) followed by dry B<sub>2</sub>(OH)<sub>4</sub> (35.9 mg, 0.4 mmol, 2.0 equiv). The reaction vessel was sealed with a cap containing a TFE-lined silicone septum and then was evacuated and backfilled with argon three times. When done, C<sub>2</sub>-substituted [1.1.1]propellane stock solution (1 mL) was added and then degassed DMA (1 mL) was added. The vial was quickly sealed with Parafilm<sup>®</sup>. The reaction mixture was then irradiated under vigorous stirring at 52 W 390 nm using a Kessil lamp at 1 inch distance for 16 h. Room temperature was maintained by the use of two fans. When judged complete after 16 h, pinacol (236.4 mg, 2 mmol, 10 equiv) and NEt<sub>3</sub>(1 mL) were added to the reaction mixture, and the reaction mixture was allowed to stirred at rt for 1 h. The mixture was then partitioned between Et<sub>2</sub>O (10 mL) and satd aq NH<sub>4</sub>Cl (10 mL). The organic layer was washed two more times with brine (10 mL × 2), dried (MgSO<sub>4</sub>), filtered, and further dried under vacuum. The crude mixture was then purified by SiO<sub>2</sub> flash column chromatography.

## General Procedure for Three-component Borylation with RAE generated *in situ* (General Procedure E – GP-E)



To an 8 mL reaction vial equipped with a stirrer bar was added the carboxylic acid (0.3 mmol, 1 equiv), *N*-hydroxyphthalimide (53.8 mg, 0.33 mol, 1.1 equiv), DMAP (1.8 mg, 0.015 mmol, 5 mol %)

and DMA (3 mL, 0.1 M). The reaction vessel was sealed with a cap containing a TFE-lined silicone septum and was allowed to stir at rt for 3 h. When judged complete by TLC, dry B<sub>2</sub>pin<sub>2</sub> (228.5 mg, 0.9 mmol, 3 equiv) and [1.1.1]propellane (0.45 mmol, 1.5 equiv, 0.8 - 1.3 M soln in Et<sub>2</sub>O) was then added. The headspace of the reaction vessel was sparged with argon for 10 s and sealed again with the cap and Parafilm<sup>®</sup>. The reaction mixture was then irradiated under vigorous stirring at 52 W 390 nm using a Kessil lamp at 1 inch distance for 16 h. Room temperature was maintained by the use of two fans. When judged complete (*Note:* after completion, the reaction mixture is generally orange), the mixture was then partitioned between Et<sub>2</sub>O (10 mL) and satd aq NH<sub>4</sub>Cl (10 mL). The organic layer was washed two more times with brine (10 mL × 2), dried (MgSO<sub>4</sub>), filtered, and further dried under vacuum. The crude mixture was then purified by SiO<sub>2</sub> flash column chromatography.

# General Procedure for Three-component Borylation with Alkyl Halides (General Procedure F – GP-F)



To an 8 mL reaction vial equipped with a stirrer bar was added alkyl halide (0.3 mmol, 1 equiv) and  $K_3PO_4$  (31.8 mg, 0.15 mmol, 0.5 equiv). The vial was then transferred to a nitrogen-filled glovebox. Me<sub>2</sub>PhSi-Bpin (157.3 mg, 0.6 mmol, 2 equiv) was added, and then the vial was sealed with a cap containing a TFE-lined silicone septum and transferred out of the glovebox. MeOH (3 mL, 0.1 M) was added. Next, [1.1.1]propellane (0.6 mmol, 2.0 equiv, 0.8 – 1.3 M solution in Et<sub>2</sub>O) was added, and the vial was quickly sealed with Parafilm<sup>®</sup>. The reaction mixture was then irradiated under vigorous stirring at 52 W 390 nm using a Kessil lamp at 1 inch distance for 16 h. Room temperature was maintained by the use of two fans. When judged complete, the crude material was passed through a pad of Celite<sup>®</sup> and eluted with another 10 mL of acetone. The filtrate was concentrated under reduced pressure and purified by SiO<sub>2</sub> column chromatography.

# General Procedure for Three-component Borylation with Aryl/alkenyl lodides (General Procedure G – GP-G)



To an 8 mL reaction vial equipped with a stirrer bar was added aryl/alkenyl halide (0.3 mmol, 1 equiv) and  $K_3PO_4$  (31.8 mg, 0.15 mmol, 0.5 equiv). The vial was then transferred to a nitrogen-filled glovebox. Me<sub>2</sub>PhSi-Bpin (157.3 mg, 0.6 mmol, 2 equiv) was added, and then the vial was sealed with a cap containing a TFE-lined silicone septum and transferred out of the glovebox. MeOH (3 mL, 0.1 M) was added. Next, [1.1.1]propellane (0.9 mmol, 3.0 equiv, 0.8 – 1.3 M soln in Et<sub>2</sub>O) was added, and the vial was quickly sealed with Parafilm<sup>®</sup>. The reaction mixture was then irradiated under vigorous stirring at 52 W 390 nm using a Kessil lamp at 1 inch distance for 16 h.

Room temperature was maintained by the use of two fans. When judged complete, the crude material was passed through a pad of Celite<sup>®</sup> and eluted with another 10 mL of acetone. The filtrate was concentrated under reduced pressure and purified by C18 column chromatography.

#### Note:

- 1. In <sup>13</sup>C NMR, the carbon directly attached to the boron atom was not detected because of quadrupolar broadening.
- 2. The purification of the boronate material is generally done by solid-loading the crude material with Celite<sup>®</sup> and then purify using an automated instrument for column chromatopraphy. The silica-gel chromatography is generally done within 15 minutes, and we observed no or slightly decreased yields (<10%) comparing with NMR yields. However, we noticed significant decrease in yields after running the column for >30 min and complete protodeborylation of products on column after 1 h. In some cases of aryl- and vinyl-substituted BCPs, reverse-phase (C18) chromatography provides quick and simple separations of products but resulted in more product loss (10-20%), probably because of limited solubility of some products in water-MeCN eluent.
- 3. BCP boronates are stable under proper storage (4 °C, sealed in Ar environment). No decomposition is observed for products that are under proper storage for over 6 months. The boronate is not sensitive to light but could be sensitive to air. We noticed that slow oxidation of boronate to alcohol is possible when the boronate was in solution without Parafilm<sup>®</sup>. In those cases, significant oxidation was observed (30-50% of product) over the timescale of months.


**3-(2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)ethyl)pyridi ne (4a**, 36.1 mg, 40%).

Prepared following **GP-B** and purified by column chromatography (45% EtOAc/hexanes). The product was obtained as a pale-yellow solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 8.46 – 8.37 (m, 2H), 7.49 (dt, *J* = 7.9, 2.0 Hz, 1H), 7.18 (dd, *J* = 7.9, 4.8 Hz, 1H), 2.59 – 2.52 (m, 2H), 1.74 (s, 6H), 1.71 – 1.64 (m, 2H), 1.22 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 149.7, 147.0, 138.0, 136.0, 123.4, 83.4, 75.1, 51.5, 45.7, 34.4, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2959, 2905, 2865, 1727, 1575, 1510, 1478, 1435, 1405, 1371, 1347, 1309, 1197, 1144, 1033, 1006, 855, 805, 714.

**HRMS** (ESI-TOF) calcd for (C<sub>18</sub>H<sub>27</sub>BNO<sub>2</sub>) [M+H]<sup>+</sup> 300.2135, found 300.2133.

**Melting point:** 69.2 – 70.6 °C.



**4,4,5,5-Tetramethyl-2-(3-phenethylbicyclo[1.1.1]pentan-1-yl)-1,3,2-dioxaborolane** (**4b**, 41.0 mg, 46%).

Prepared following **GP-B** and purified by column chromatography (25% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.28 – 7.22 (m, 2H), 7.20 – 7.13 (m, 3H), 2.59 – 2.52 (m, 2H), 1.76 (s, 6H), 1.72 - 1.66 (m, 2H), 1.24 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 142.7, 128.4, 128.3, 125.6, 83.3, 51.5, 50.2, 48.8, 46.1, 34.9, 32.6, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.6.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2969, 1454, 1257, 699.

**HRMS** (EI-TOF) calcd for  $(C_{18}H_{24}BNO_2)$  [M-CH<sub>3</sub>]<sup>+</sup> 283.1869, found 283.1884.

Melting point: 90 - 91 °C.



Methyl (S)-2-(((Benzyloxy)carbonyl)amino)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)propanoate (4c, 92.9 mg, 72%).

Prepared following **GP-B** and purified by column chromatography (35% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.41 – 7.29 (m, 5H), 5.20 (d, J = 8.3 Hz, 1H), 5.10 (s, 2H), 4.36 (td, J = 7.8, 4.6 Hz, 1H), 3.72 (s, 3H), 1.94 (dd, J = 14.7, 4.6 Hz, 1H), 1.80 (s, 6H), 1.80 – 1.73 (m, 1H), 1.22 (s, 12H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  173.1, 155.8, 136.5, 128.7, 128.3, 128.2, 83.5, 67.1, 52.6, 52.5, 52.4, 43.2, 35.4, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.0.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 3342, 2961, 2925, 2869, 1725, 1511, 1436, 1405, 1372, 1346, 1310, 1261, 1201, 1168, 1144, 1045, 855, 739, 698, 666.

**HRMS** (ESI-TOF) calcd for (C<sub>23</sub>H<sub>32</sub>BNO<sub>6</sub>Na) [M+Na]<sup>+</sup> 452.2220, found 452.2225.



Allyl (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-(3-(4,4,5,5-tetramethyl-1,3,2-dio xaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)butanoate(4d, 82.0 mg, 48%).

Prepared following **GP-B** and purified by column chromatography (40% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.76 (d, J = 7.6 Hz, 2H), 7.63 – 7.55 (m, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 5.90 (ddt, J = 16.6, 11.0, 5.8 Hz, 1H), 5.33 (d, J = 17.1 Hz, 1H), 5.26 (d, J = 10.8 Hz, 2H), 4.63 (dt, J = 13.5, 6.4 Hz, 2H), 4.40 (d, J = 7.2 Hz, 3H), 4.22 (t, J = 7.0 Hz, 1H), 1.75 (s, 6H), 1.60 (tt, J = 13.0, 6.2 Hz, 1H), 1.39 (tt, J = 13.4, 8.7 Hz, 2H), 1.23 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 172.4, 156.0, 144.0, 143.8, 141.4, 131.6, 127.8, 127.2, 125.2, 120.1, 120.08, 118.9, 83.4, 67.0, 66.0, 54.0, 51.3, 47.3, 45.2, 29.5, 28.8, 24.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 31.2.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2956, 1708, 1511, 1449, 1391, 1380, 1371, 1341, 1307, 1249, 1196, 1166, 1142, 1050, 1032, 987, 854, 758, 738.

**HRMS** (ESI-TOF) calcd for (C<sub>33</sub>H<sub>40</sub>BNaNO<sub>6</sub>) [M+Na]<sup>+</sup> 580.2846, found 580.2859.



**2-(3-(5-Bromopentyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (4e, 78.1 mg, 76%).

Prepared following **GP-B** and purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 3.37 (t, *J* = 6.9 Hz, 2H), 1.86 – 1.78 (m, 2H), 1.71 (s, 6H), 1.43 – 1.35 (m, 2H), 1.34 – 1.27 (m, 2H), 1.23 – 1.19 (m, 2H), 1.22 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 83.3, 51.6, 46.2, 34.1, 33.1, 33.0, 28.5, 25.4, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.2.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2958, 2929, 2905, 2865, 1435, 1404, 1390, 1379, 1371, 1345, 1307, 1275, 1213, 1196, 1166, 1144, 1111, 1035, 855, 666.

**HRMS** (EI-TOF) calcd for (C<sub>15</sub>H<sub>25</sub>BBrO<sub>2</sub>) [M-CH<sub>3</sub>]<sup>+</sup> 327.1131, found 327.1107.

Melting point: 41 - 42 °C.



**4,4,5,5-Tetramethyl-2-(3-((phenylthio)methyl)bicyclo[1.1.1]pentan-1-yl)-1,3,2-dioxaboro Iane** (**4**f, 57.0 mg, 60%).

Prepared following **GP-B** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a yellow solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.32 – 7.28 (m, 2H), 7.26 – 7.20 (m, 2H), 7.14 – 7.09 (m, 1H), 2.97 (s, 2H), 1.82 (s, 6H), 1.21 (s, 12H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 137.2, 128.8, 128.6, 125.5, 83.4, 51.9, 44.4, 36.3, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2973, 2906, 2869, 1480, 1437, 1403, 1390, 1379, 1371, 1310, 1242, 1197, 1166, 1143, 1032, 855, 738, 690.

**HRMS** (EI-TOF) calcd for (C<sub>18</sub>H<sub>25</sub>BNO<sub>2</sub>S) [M]<sup>+</sup> 316.1668, found 316.1661.

Melting point: 63 - 64 °C.



**2-(3-(4-Fluorobenzyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (4g, 41.0 mg, 45%).

Prepared following **GP-B** with the following modification: 3 equiv of [1.1.1.]propellane was used. The compound was purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.04 – 6.97 (m, 2H), 6.96 – 6.90 (m, 2H), 2.62 (s, 2H), 1.69 (s, 6H), 1.20 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 161.4 (d, *J* = 242.9 Hz), 135.1 (d, *J* = 3.2 Hz), 130.3 (d, *J* = 7.9 Hz), 114.9 (d, *J* = 21.1 Hz), 83.3, 51.3, 45.8, 39.3, 24.8.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -118.30.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.1.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 1509, 1474, 1372, 1329, 1274, 1251, 1144, 1086, 1009, 981, 850, 839, 793, 750, 697, 673.

**HRMS** (EI-TOF) calcd for (C<sub>18</sub>H<sub>24</sub>BFO<sub>2</sub>) [M]<sup>+</sup> 302.1853, found 302.1848.

Melting point: 90 °C.



2-(3-Benzylbicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4h)

Prepared following **GP-B** and purified by column chromatography (5% EtOAc/hexanes). The product was obtained as a white solid. (18.0 mg, 21%)

Prepared following **GP-B** with the following modification: 3 equiv of [1.1.1.]propellane was used. The compound was purified by column chromatography (5% EtOAc/hexanes). The product was obtained as a white solid. (30.4 mg, 36%).

 $^{1}\text{H}$  NMR (400 MHz, CDCl\_3)  $\delta$  7.26-7.22 (m, 2H), 7.18 – 7.13 (m, 1H), 7.08 – 7.03 (m, 2H), 2.65 (s, 2H), 1.70 (s, 6H), 1.20 (s, 12H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 139.5, 129.1, 128.2, 125.7, 83.3, 51.4, 45.9, 40.8, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.4.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2970, 2906, 2867, 1494, 1434, 1402, 1371, 1350, 1311, 1195, 1168, 1141, 1030, 961, 855, 761, 705, 687, 667, 480.

HRMS (EI-TOF) calcd for (C<sub>18</sub>H<sub>25</sub>BO<sub>2</sub>) [M]<sup>+</sup> 284.1948, found 283.1968. Melting point: 105 - 108 °C.



## **2-(3-(4,4-Difluorocyclohexyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (**4i**, 54.0 mg, 58%).

Prepared following **GP-B** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid.

 $^1\text{H}$  NMR (400 MHz, CDCl\_3)  $\delta$  2.15 – 1.99 (m, 2H), 1.70 (s, 6H), 1.68 – 1.53 (m, 4H), 1.41 – 1.13 (m, 15H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>)  $\delta$  123.7 (dd, *J* = 241.8, 239.5 Hz), 83.2, 49.3, 48.4 (d, *J* = 2.9 Hz), 37.4 (d, *J* = 1.5 Hz), 33.3 (dd, *J* = 25.5, 22.2 Hz), 25.1 (d, *J* = 9.8 Hz), 24.7.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.9.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>)  $\delta$  -91.18 (d, *J* = 234.6 Hz), -102.04 (d, *J* = 234.6 Hz).

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2957, 2866, 1433, 1401, 1392, 1373, 1355, 1314, 1272, 1196, 1168, 1143, 1107, 1088, 1042, 1018, 950, 929, 854, 665.

**HRMS** (EI-TOF) calcd for (C<sub>17</sub>H<sub>26</sub>BFO<sub>2</sub>) [M-HF]<sup>+</sup> 292.2010, found 292.1990.

Melting point: 134 – 136 °C.



**3-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)cyclo butan-1-one (4***j*, 41.0 mg, 52%).

Prepared following **GP-B** and purified by column chromatography (30% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 3.03 – 2.92 (m, 2H), 2.83 – 2.73 (m, 2H), 2.40 (tt, *J* = 9.0, 6.3 Hz, 1H), 1.78 (s, 6H), 1.23 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 207.9, 83.5, 49.24, 49.21, 47.6, 25.2, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.1.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2978, 2959, 2865, 1773, 1505, 1438, 1408, 1372, 1351, 1318, 1279, 1203, 1168, 1144, 1125, 1107, 1050, 964, 857.

HRMS (EI-TOF) calcd for  $(C_{15}H_{23}BO_3)$  [M]<sup>+</sup> 262.1740, found 262.1757. Melting point: 129 – 131 °C.



*tert*-Butyl 4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)piperi dine-1-carboxylate (4k)

Prepared following **GP-B** and purified by column chromatography (30% EtOAc/hexanes). The product was obtained as a white solid. (100.1 mg, 89%).

Prepared following **GP-C** and purified by column chromatography (30% EtOAc/hexanes). The product was obtained as a white solid (73 mg, 64%).

Prepared following **GP-E** and purified by column chromatography (30% EtOAc/hexanes). The product was obtained as a white solid (76 mg, 67%).

Prepared following **GP-F** and purified by column chromatography (30% EtOAc/hexanes). The product was obtained as a white solid (58.4 mg, 52%).

Prepared following **GP-F** with the following modification: the corresponding organoiodide was used. The compound was purified by column chromatography (30% EtOAc/hexanes). The product was obtained as a white solid (73 mg, 65%).

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 4.10 (br, 2H), 2.60 (br, 2H), 1.69 (s, 6H), 1.53 – 1.48 (m, 2H), 1.44 (s, 9H), 1.32 (tt, *J* = 11.9, 3.5 Hz, 1H), 1.22 (s, 12H), 1.06 – 0.98 (m, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 155.1, 83.4, 79.3, 49.2, 48.9, 44.0, 37.8, 28.7, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2974, 2929, 1692, 1404, 1390, 1379, 1308, 1274, 1234, 1197, 1169, 1143, 1096, 1008, 995, 978, 855.

**HRMS** (ESI-TOF) calcd for (C<sub>21</sub>H<sub>37</sub>BNO<sub>4</sub>) [M+H]<sup>+</sup> 378.2816, found 378.2802.

Melting point: 93 - 94 °C.



#### **2-(3-(2,3-Dihydrobenzo[***b***][1,4]dioxin-2-yl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (**4**I, 61.7 mg, 63%)

Prepared following **GP-B** and purified by column chromatography (30% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 6.89 – 6.85 (m, 1H), 6.85 – 6.69 (m, 3H), 4.18 (dd, *J* = 11.2, 2.3 Hz, 1H), 3.94 (dd, *J* = 7.5, 2.3 Hz, 1H), 3.88 (dd, *J* = 11.1, 7.5 Hz, 1H), 2.00 – 1.80 (m, 6H), 1.23 (s, 12H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  143.8, 143.4, 121.5, 121.2, 117.4, 117.0, 83.6, 71.8, 65.8, 50.2, 44.0, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.1.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 2874, 1495, 1467, 1438, 1408, 1391, 1380, 1372, 1348, 1312, 1271, 1259, 1203, 1167, 1144, 1087, 1044, 855, 748.

**HRMS** (EI-TOF) calcd for  $(C_{19}H_{25}BO_4)$  [M]<sup>+</sup> 328.1846, found 328.1862.



**2-(3-((3aS,4S,6S,6aS)-6-Methoxy-2,2-dimethyltetrahydrofuro[3,4-***d*][1,3]dioxol-4yl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4m, 64.0 mg, 58%).

Prepared following **GP-B** and purified by column chromatography (25% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>)  $\delta$  4.90 (s, 1H), 4.59 (dd, *J* = 6.0, 1.4 Hz, 1H), 4.48 (d, *J* = 6.0 Hz, 1H), 4.05 (d, *J* = 1.3 Hz, 1H), 3.34 (s, 3H), 1.80 (s, 6H), 1.45 (s, 3H), 1.30 (s, 3H), 1.22 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 112.3, 109.5, 87.5, 86.1, 83.5, 81.4, 55.0, 50.1, 45.8, 26.8, 25.4, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.4.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2977, 2913, 1518, 1473, 1454, 1373, 1332, 1254, 1203, 1145, 1105, 1090, 1063, 1030, 1009, 982, 928, 868, 851, 673.

**HRMS** (EI-TOF) calcd for (C<sub>18</sub>H<sub>28</sub>BO<sub>6</sub>) [M-CH<sub>3</sub>]<sup>+</sup> 351.1979, found 351.1982.

Melting point: 68 – 70 °C.



*tert*-Butyl 2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)pyrr olidine-1-carboxylate (4n, 73.0 mg, 67%).

Prepared following **GP-B** and purified by column chromatography (35% EtOAc/hexanes). The product was obtained as a white waxy solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ (mixture of rotamers) δ 3.79 - 3.62 (m, 1H), 3.35 - 3.31 (m, 2H), 1.86 - 1.76 (m, 4H), 1.76 (s, 6H), 1.45 (s, 9H), 1.22 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ (mixture of rotamers) δ 155.2, 83.5, 79.1, 57.7, 50.4, 47.9, 46.3, 28.7, 28.1, 24.9, 23.3.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.4

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 2874, 1693, 1517, 1475, 1454, 1390, 1367, 1331, 1254, 1163, 1009, 982, 951, 926, 851, 773, 674.

**HRMS** (EI-TOF) calcd for (C<sub>16</sub>H<sub>25</sub>BNO<sub>4</sub>) [M-*t*-Bu]<sup>+</sup> 306.1877, found 306.1863.



**4-(2-((***tert***-Butoxycarbonyl)amino)-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)ethyl)phenylacetate** (**4o**, 86 mg, 61%).

Prepared following **GP-B** and purified by column chromatography (40% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.18 (d, J = 8.0 Hz, 2H), 6.97 (d, J = 8.4 Hz, 2H), 4.27 (d, J = 9.3 Hz, 1H), 3.86 – 3.77 (m, 1H), 2.73 (dd, J = 14.4, 6.1 Hz, 1H), 2.54 (dd, J = 14.4, 8.6 Hz, 1H), 2.26 (s, 3H), 1.79 – 1.68 (m, 6H), 1.35 (s, 9H), 1.21 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 169.6, 155.6, 149.1, 136.2, 130.1, 121.3, 83.5, 79.1, 52.0, 49.6, 47.7, 37.6, 28.4, 24.8, 21.2.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 31.6.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2976, 2871, 1762, 1698, 1507, 1435, 1403, 1391, 1367, 1308, 1196, 1165, 1143, 1044, 1019, 911, 854, 729.

**HRMS** (ESI-TOF) calcd for (C<sub>26</sub>H<sub>38</sub>BNaNO<sub>6</sub>) [M+Na]<sup>+</sup> 494.2690, found 494.2668.



*tert*-Butyl (2-(1*H*-Indol-3-yl)-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1] pentan-1-yl)ethyl)carbamate (4p, 113.4 mg, 84%).

Prepared following **GP-B** and purified by column chromatography (45% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) (mixture of rotamers) δ 8.32 (s, 1H), 7.58 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.15 (t, J = 7.2 Hz, 1H), 7.09 (t, J = 7.4 Hz, 1H), 6.98 (s, 1H), 4.43 (d, J = 9.3 Hz, 1H), 4.14 – 3.61 (m, 1H), 2.89 (dd, J = 15.3, 5.7 Hz, 1H), 2.76 – 2.50 (m, 1H), 1.78 (q, J = 9.7 Hz, 6H), 1.37 (s, 9H), 1.23 (d, J = 2.9 Hz, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) (mixture of rotamers) δ 155.9, 136.3, 128.0, 122.3, 121.8, 119.2, 118.9, 112.5, 111.2, 83.5, 83.0, 75.2, 51.3, 49.6, 48.1, 28.5, 25.0, 24.9, 24.7.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.4.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 3337, 2976, 1690, 1511, 1457, 1436, 1403, 1391, 1366, 1307, 1248, 1197, 1167, 1143, 1110, 1045, 1027, 951, 855, 740, 666.

**HRMS** (ESI-TOF) calcd for (C<sub>26</sub>H<sub>37</sub>BN<sub>2</sub>O<sub>4</sub>Na) [M+Na]<sup>+</sup> 475.2744, found 475.2756.



**2-(3-(Adamantan-1-yl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (**4q**, 70.2 mg, 89%).

Prepared following **GP-B** and purified by column chromatography (30% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 1.93 – 1.90 (m, 3H), 1.66 (d, J = 12.5 Hz, 3H), 1.64 (s, 6H), 1.57 (d, J = 10.5 Hz, 3H), 1.36 (s, 6H), 1.23 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 83.1, 46.7, 38.3, 37.8, 37.0, 31.6, 28.2, 24.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2963, 2903, 2869, 2848, 1474, 1448, 1372, 1330, 1287, 1253, 1212, 1198, 1146, 1009, 982, 952, 852, 698, 674.

**HRMS** (ESI-TOF) calcd for (C<sub>21</sub>H<sub>34</sub>BO<sub>3</sub>) [M+H]<sup>+</sup> 329.2652, found 329.2635.

Melting point: 93 - 95 °C.



4,4,5,5-Tetramethyl-2-(3-(1-methylcyclohexyl)bicyclo[1.1.1]pentan-1-yl)-1,3,2-dioxaboro lane (4r)

Prepared following **GP-B** and purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a colorless oil (45.2 mg, 52%).

Prepared following **GP-C** and purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a colorless oil (59.3 mg, 68%).

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 1.67 (s, 6H), 1.58 – 1.51 (m, 1H), 1.51 – 1.43 (m, 2H), 1.38 – 1.28 (m, 2H), 1.22 (s, 12H), 1.17 – 1.11 (m, 4H), 1.09 (dt, J = 12.3, 3.9 Hz, 1H), 0.75 (s, 3H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 83.3, 54.6, 47.5, 33.2, 32.3, 26.6, 24.9, 22.2, 19.3.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.0.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2972, 2925, 2869, 1707, 1515, 1474, 1373, 1328, 1264, 1246, 1218, 1200, 1145, 1009, 982, 952, 851, 698, 674.

**HRMS** (EI-TOF) calcd for (C<sub>17</sub>H<sub>28</sub>BO<sub>2</sub>) [M-CH<sub>3</sub>]<sup>+</sup> 275.2182, found 275.2186.



**2-(3-(1-Chloro-2-methylpropan-2-yl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-di** oxaborolane (4s, 51.0 mg, 60%).

Prepared following **GP-B** and purified by column chromatography (15% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 3.33 (s, 2H), 1.75 (s, 6H), 1.22 (s, 12H), 0.87 (s, 6H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 83.5, 54.1, 48.5, 35.3, 25.2, 24.9, 21.3.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.6.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2964, 2869, 1466, 1437, 1402, 1390, 1380, 1372, 1352, 1314, 1204, 1167, 1140, 1014, 996, 963, 855, 822, 717, 667.

**HRMS** (EI-TOF) calcd for (C<sub>14</sub>H<sub>23</sub>BClO<sub>2</sub>) [M-CH<sub>3</sub>]<sup>+</sup> 269.1480, found 269.1485.

Melting point: 89 - 91 °C.



Methyl 4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)bicyclo[2.2.2]octane-1-carboxylate (4t, 55.0 mg, 51%).

Prepared following **GP-C** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 3.62 (s, 3H), 1.73 - 1.66 (m, 6H), 1.59 (dd, J = 10.3, 5.0 Hz, 6H), 1.30 (s, 6H), 1.21 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 178.9, 83.3, 51.7, 47.6, 38.9, 30.2, 28.3, 26.6, 26.5, 24.9, 24.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 31.8.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2954, 2862, 1722, 1508, 1438, 1408, 1372, 1350, 1311, 1236, 1199, 1145, 1073, 1018, 964, 856, 666.

**HRMS** (ESI-TOF) calcd for  $(C_{21}H_{34}BNO_4)$  [M+H]<sup>+</sup> 361.2550, found 361.2545.

Melting point: 160 – 163 °C.



### Methyl 1-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)cyclo propane-1-carboxylate (4u)

Prepared following **GP-B** with the following modification: 3 equiv of [1.1.1.]propellane were used. The compound was purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a white solid (36 mg, 41%).

Prepared following **GP-F** and purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a white solid (42 mg, 50%).

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 3.64 (s, 3H), 1.82 (s, 6H), 1.23 (s, 12H), 1.05 (q, J = 3.8 Hz, 2H), 0.73 (q, J = 3.8 Hz, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 175.4, 83.4, 51.7, 50.6, 45.3, 24.9, 24.3, 13.4.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.7.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2979, 2955, 2908, 2870, 1714, 1406, 1311, 1214, 1196, 1139, 665.

**HRMS** (ESI-TOF) calcd for (C<sub>16</sub>H<sub>26</sub>BO<sub>4</sub>) [M+H]<sup>+</sup> 293.1924, found 293.1934.

Melting point 110 - 113 °C.



#### **4,4,5,5-Tetramethyl-2-(3-(1-phenylcyclopropyl)bicyclo[1.1.1]pentan-1-yl)-1,3,2dioxaborolane** (**4v**, 39.0 mg, 42%).

Prepared following **GP-B** with the following modification: 3 equiv of [1.1.1.]propellane were used. The compound was purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.26 – 7.22 (m, 4H), 7.19 – 7.13 (m, 1H), 1.61 (s, 6H), 1.20 (s, 12H), 0.72 (td, *J* = 6.6, 2.1 Hz, 2H), 0.66 (td, *J* = 5.6, 2.5 Hz, 2H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 143.2, 130.1, 127.9, 126.1, 83.3, 49.7, 49.6, 27.9, 24.8, 9.4.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.6.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2974, 2870, 1780, 1475, 1445, 1372, 1329, 1209, 1166, 1144, 1076, 1009, 981, 952, 851, 761, 743, 700.

**HRMS** (EI-TOF) calcd for  $(C_{20}H_{27}BO_2)$  [M]<sup>+</sup> 310.2104, found 310.2107.

Melting point: 103 °C.



Methyl 3'-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-bi(bicyclo[1.1.1]pentane)]-3-carboxylate (4w, 41.3 mg, 43%)

Prepared following **GP-B** with the following modifications: 3 equiv of [1.1.1.]propellane and 1.2 equiv of  $B_2pin_2$  were used. The compound was purified by C18 column chromatography (80% MeCN/H<sub>2</sub>O). The product was obtained as a white solid.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 3.64 (s, 3H), 1.84 (s, 6H), 1.72 (s, 6H), 1.22 (s, 12H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 171.3, 83.5, 51.7, 50.4, 50.2, 44.9, 40.0, 36.7, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.0.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2960, 2907, 2873, 1725, 1504, 1441, 1418, 1380, 1349, 1311, 1219, 1203, 1140, 1113, 1055, 971, 857, 790, 666.

**HRMS** (EI-TOF) calcd for (C<sub>17</sub>H<sub>24</sub>BO<sub>4</sub>) [M-CH<sub>3</sub>]<sup>+</sup> 303.1768, found 303.1750.

Melting point: 179 - 182 °C.



## 4,4,5,5-Tetramethyl-2-(3-(2,2,2-trifluoro-1-methoxy-1-phenylethyl)bicyclo[1.1.1] pentan-1-yl)-1,3,2-dioxaborolane (4x, 47 mg, 41%).

Prepared following **GP-B** with the following modification: 3 equiv of [1.1.1.]propellane were used. The compound was purified by column chromatography (15% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.40 – 7.31 (m, 5H), 3.31 (d, *J* = 1.7 Hz, 3H), 1.92 – 1.75 (m, 6H), 1.19 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 133.9, 128.2, 128.1, 127.2 (d, *J* = 2.2 Hz), 126.8 (q, *J* = 295.8 Hz), 83.5, 81.4 (q, *J* = 25.3 Hz), 54.0, 50.4, 50.2, 47.9 (d, *J* = 82.6 Hz), 24.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.8.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -66.89.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2978, 1437, 1405, 1314, 1205, 1168, 1143, 1106, 964, 854, 728.

**HRMS** (EI-TOF) calcd for  $(C_{20}H_{26}BF_3O_3)$  [M]<sup>+</sup> 382.1927, found 382.1931.

**Melting point:** 113 – 115 °C.



**2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)pyridine** (4y, 33.7 mg, 41%).

Prepared following **GP-B** with the following modification: 3 equiv of [1.1.1]propellane were used. The compound was purified by column chromatography (55% EtOAc/hexanes). The product was obtained as a white solid.

Prepared following **GP-F** with the following modification: 1.5 equiv of [1.1.1]propellane were used. The compound was purified by C18 column chromatography (65% MeCN/H<sub>2</sub>O). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 8.55 (d, *J* = 5.2 Hz, 1H), 7.63 – 7.59 (m, 1H), 7.17 (d, *J* = 7.5 Hz, 1H), 7.14 – 7.09 (m, 1H), 2.25 (s, 6H), 1.27 (s, 12H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 160.3, 149.3, 136.5, 121.7, 120.5, 83.6, 53.0, 48.0, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.9.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2974, 2911, 2871, 1592, 1567, 1512, 1474, 1430, 1407, 1373, 1314, 1209, 1146, 1121, 1005, 972, 854, 811, 762, 666.

**HRMS** (ESI-TOF) calcd for (C<sub>16</sub>H<sub>23</sub>BNO<sub>2</sub>) [M+H]<sup>+</sup> 272.1822, found 272.1808.

Melting point: 137 - 139 °C.



*tert*-Butyl 4-(2-((Methoxymethoxy)methyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bi cyclo[1.1.1]pentan-1-yl)piperidine-1-carboxylate (4z, 43.2 mg, 48%).

Prepared following **GP-D** and purified by column chromatography (45% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>)) δ 4.61 (s, 2H), 4.10 (br, J = 23.7 Hz, 2H), 3.70 (d, J = 7.1 Hz, 2H), 3.36 (s, 3H), 2.57 (br, 2H), 2.40 (q, J = 6.9 Hz, 1H), 2.21 (dd, J = 9.9, 3.2 Hz, 1H), 1.69 (dd, J = 6.4, 3.2 Hz, 1H), 1.65 (d, J = 1.9 Hz, 1H), 1.57 (dd, J = 9.9, 1.9 Hz, 1H), 1.54 – 1.49 (m, 2H), 1.44 (s, 9H), 1.38 – 1.32 (m, 1H), 1.21 (s, 12H), 1.06 – 0.99 (m, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 155.0, 96.7, 83.4, 79.4, 64.9, 60.3, 55.3, 50.9, 48.5, 44.1, 37.3, 28.7, 28.1, 24.9, 24.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.7.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2976, 2928, 1692, 1416, 1389, 1366, 1310, 1274, 1234, 1214, 1193, 1169, 1144, 1107, 1044, 982, 949, 918, 872, 856.

**HRMS** (ESI-TOF) calcd for (C<sub>24</sub>H<sub>43</sub>BNO<sub>6</sub>) [M+H]<sup>+</sup> 452.3183, found 452.3172.



*tert*-Butyl 2-(2-((Methoxymethoxy)methyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bi cyclo[1.1.1]pentan-1-yl)pyrrolidine-1-carboxylate (4aa, 33.6 mg, 38%).

Prepared following **GP-D** and purified by column chromatography (50% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) (1:1 mixture of diastereomers and mixture of rotamers) δ 4.60 (s, 2H), 3.77 – 3.70 (m, 2H), 3.68 – 3.62 (m, 1H), 3.35 (s, 3H), 3.27 – 3.24 (m, 2H), 2.53 – 2.39 (m, 1H), 2.35 – 2.25 (m, 1H), 1.78 – 1.74 (m, 5H), 1.70 (s, 1H), 1.67 – 1.58 (m, 1H), 1.46 (s, 9H), 1.21 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) (1:1 mixture of diastereomers and mixture of rotamers) δ 155.2, 155.1, 96.7, 96.6, 83.5, 79.4, 79.3, 64.8, 64.6, 61.1, 60.8, 60.4, 57.7, 57.3, 56.7, 55.3, 55.2, 50.4, 49.8, 49.7, 49.2, 46.6, 46.4, 46.3, 45.9, 45.6, 28.7, 24.9, 24.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.6.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 2930, 2887, 1693, 1389, 1366, 1311, 1254, 1196, 1165, 1145, 1108, 1045, 950, 917, 856, 771, 667, 579

**HRMS** (ESI-TOF) calcd for (C<sub>23</sub>H<sub>41</sub>BNO<sub>6</sub>) [M+H]<sup>+</sup> 438.3027, found 438.3020.



2-(3-(1-Chloro-2-methylpropan-2-yl)-2-((methoxymethoxy)methyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4ab, 27.1 mg, 38%).

Prepared following **GP-D** and purified by C18 column chromatography (90% MeCN/H<sub>2</sub>O). The product was obtained as a colorless oil. \*C18 silica gel chromatography was used due to difficult separation between the product and  $B_2pin_2$ .

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 4.62 (s, 2H), 3.77 – 3.65 (m, 2H), 3.37 (s, 3H), 3.35 (s, 2H), 2.48 (q, J = 6.9 Hz, 1H), 2.29 (dd, J = 9.9, 3.3 Hz, 1H), 1.75 (dd, J = 6.3, 3.3 Hz, 1H), 1.71 (d, J = 2.0 Hz, 1H), 1.64 (dd, J = 9.9, 1.9 Hz, 1H), 1.21 (s, 12H), 0.87 (d, J = 4.4 Hz, 6H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  96.8, 83.5, 65.1, 60.6, 55.5, 54.1, 53.7, 48.1, 43.6, 35.8, 24.9, 24.8, 21.7, 21.6.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) 29.9

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2974, 2931, 2891, 1468, 1438, 1402, 1389, 1372, 1313, 1214, 1199, 1144, 1107, 1045, 997, 949, 918, 855, 824, 719

**HRMS** (ESI-TOF) calcd for (C<sub>18</sub>H<sub>33</sub>BClO<sub>4</sub>) [M+H]<sup>+</sup> 359.2160, found 359.2167.



2-(3-(Adamantan-1-yl)-2-((methoxymethoxy)methyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetra methyl-1,3,2-dioxaborolane (4ac, 18.5 mg, 23%).

Prepared following **GP-D** and purified by C18 column chromatography (100% MeCN). The product was obtained as a colorless oil. \*C18 silica gel chromatography was used due to difficult separation between the product and  $B_2pin_2$ .

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 4.67 – 4.53 (m, 2H), 3.71 (dd, J = 7.3, 2.9 Hz, 2H), 3.37 (s, 3H), 2.43 (dt, J = 8.2, 6.4 Hz, 1H), 2.20 (dd, J = 9.9, 3.2 Hz, 1H), 1.90 (s, 3H), 1.65 (d, J = 12.3 Hz, 3H), 1.63 – 1.61 (m, 1H), 1.59 (d, J = 1.6 Hz, 1H), 1.56 (d, J = 11.9 Hz, 3H), 1.52 (dd, J = 9.9, 1.8 Hz, 1H), 1.35 (s, 6H), 1.22 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 96.6, 83.3, 65.3, 59.7, 55.6, 55.3, 46.3, 41.3, 38.5, 37.2, 32.4, 28.4, 24.9, 24.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.2.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2976, 2903, 2847, 1438, 1415, 1389, 1309, 1214, 1195, 1146, 1107, 1079, 1050, 918, 857, 669

**HRMS** (ESI-TOF) calcd for (C<sub>24</sub>H<sub>39</sub>BO<sub>4</sub>Na) [M+Na]<sup>+</sup> 425.2839, found 425.2843.



4,4,5,5-Tetramethyl-2-(3-(2-(3-methylcyclopentyl)propan-2-yl)bicyclo[1.1.1]pentan-1-yl)-1,3,2-dioxaborolane (4ad, 80.7 mg, 85%).

Prepared following **GP-B** using RAE **S-1v** and purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) (1.3:1 mixture of diastereomers) δ 1.88 (tt, J = 10.0, 7.8 Hz, 0.57H), 1.84 – 1.75 (m, 1.43H), 1.73 – 1.66 (m, 1.43H), 1.71 (s, 6H), 1.66 – 1.57 (m, 0.57H), 1.57 – 1.47 (m, 1H), 1.41 – 1.34 (m, 0.43H), 1.28 – 1.18 (m, 1.13H), 1.22 (s, 12H), 1.12 (ddd, J = 13.0, 9.6, 7.0 Hz, 0.57H), 1.04 – 0.94 (m, 0.87H), 0.93 (d, J = 6.5 Hz, 1.3H), 0.91 (d, J = 6.7 Hz, 1.7H), 0.68 (s, 1.3H), 0.67 (s, 1.7H), 0.67 (s, 1.7H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) (1.3:1 mixture of diastereomers) δ 83.2, 54.5, 54.5, 49.1, 47.1, 45.6, 38.0, 36.0, 35.4, 34.9, 34.8, 34.7, 34.4, 34.3, 28.8, 27.1, 24.9, 21.4, 21.3, 21.2, 20.7, 20.2, 20.1.
<sup>11</sup>B NMR (128 MHz, CDCl<sub>3</sub>) δ 30.1.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2961, 2870, 1778, 1724, 1474, 1455, 1372, 1362, 1328, 1260, 1205, 1145, 1009, 982, 952, 927, 851, 698, 673.

**HRMS** (EI-TOF) calcd for (C<sub>19</sub>H<sub>32</sub>BO<sub>2</sub>) [M-CH<sub>3</sub>]<sup>+</sup> 303.2495, found 303.2506.



# (*E*)-7-Hydroxy-5-methoxy-4-methyl-6-(3-methyl-5-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)pent-2-en-1-yl)isobenzofuran-1(3*H*)-one (4ae, 59.0 mg, 43%).

Prepared following **GP-B** and purified by column chromatography (40% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.65 (s, 1H), 5.18 (s, 2H), 5.16 (dt, J = 5.5, 1.3 Hz, 1H), 3.75 (s, 3H), 3.36 (d, J = 6.9 Hz, 2H), 2.13 (s, 3H), 1.88 (dd, J = 10.3, 6.3 Hz, 2H), 1.75 (d, J = 1.3 Hz, 3H), 1.69 (s, 6H), 1.43 – 1.37 (m, 2H), 1.21 (s, 12H).

 $^{13}\textbf{C}$  NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  173.0, 163.8, 153.8, 143.9, 136.3, 122.7, 121.4, 116.8, 106.4, 83.3, 70.1, 61.1, 51.4, 46.1, 36.1, 31.6, 25.0, 24.8, 22.7, 16.4, 11.7.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.6.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 1733, 1472, 1451, 1409, 1370, 1328, 1273, 1251, 1219, 1195, 1141, 1100, 1078, 1030, 1008, 981, 968, 851.

**HRMS** (ESI-TOF) calcd for (C<sub>27</sub>H<sub>37</sub>BNaO<sub>4</sub>) [M+Na]<sup>+</sup> 491.2581, found 491.2595.



**1-([1,1'-Biphenyl]-4-yl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pent an-1-yl)propan-1-one** (**4af**, 66.3 mg, 55%).

Prepared following **GP-B** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid (86.1 mg, 71%).

Prepared following **GP-C** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid (66.3 mg, 55%).

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 8.03 – 7.99 (m, 2H), 7.70 – 7.65 (m, 2H), 7.65 – 7.60 (m, 2H), 7.50 – 7.44 (m, 2H), 7.43 – 7.37 (m, 1H), 2.92 (t, J = 7.3 Hz, 2H), 1.83 (t, J = 7.6 Hz, 2H), 1.79 (s, 6H), 1.23 (s, 12H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  200.0, 145.7, 140.1, 136.0, 129.1, 128.8, 128.3, 127.4, 127.4, 83.4, 51.4, 45.6, 35.4, 28.0, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2961, 2905, 2867, 1682, 1604, 1511, 1435, 1404, 1371, 1343, 1308, 1198, 1145, 1034, 1005, 856, 765, 750, 696, 666.

**HRMS** (ESI-TOF) calcd for  $(C_{26}H_{32}BO_3)$  [M+H]<sup>+</sup> 403.2445, found 403.2430.

Melting point: 99 - 100 °C.



(4-Chlorophenyl)(5-methoxy-2-methyl-3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)methyl)-1*H*-indol-1-yl)methanone (4ag, 62.0 mg, 41%).

Prepared following **GP-B** with the following modification: 3 equiv of [1.1.1.]propellane were used. The compound was purified by C18 column chromatography (95% MeCN/H<sub>2</sub>O). The product was obtained as a yellow solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.62 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 6.92 (d, J = 9.0 Hz, 1H), 6.85 (d, J = 2.5 Hz, 1H), 6.63 (dd, J = 9.0, 2.6 Hz, 1H), 3.82 (s, 3H), 2.72 (s, 2H), 2.24 (s, 3H), 1.76 (s, 6H), 1.19 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 168.5, 156.0, 139.0, 134.6, 134.3, 131.9, 131.2, 131.1, 129.2, 117.8, 115.0, 111.2, 101.8, 83.4, 55.8, 52.0, 45.6, 28.6, 24.9, 13.5.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.0.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2955, 2861, 1678, 1477, 1455, 1434, 1400, 1370, 1355, 1310, 1289, 1248, 1213, 1195, 1143, 1088, 1064, 923, 854, 835, 753, 730.

**HRMS** (ESI-TOF) calcd for (C<sub>29</sub>H<sub>34</sub>BCINO<sub>4</sub>) [M+H]<sup>+</sup> 506.2269, found 506.2255.

Melting point: 149 - 150 °C.



2-(3-((2,4-Dichlorophenoxy)methyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4ah, 53.6 mg, 48%).

Prepared following **GP-B** with the following modification: 3 equiv of [1.1.1.]propellane were used. The compound was purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.33 (d, *J* = 2.6 Hz, 1H), 7.12 (dd, *J* = 8.8, 2.6 Hz, 1H), 6.77 (d, *J* = 8.8 Hz, 1H), 3.89 (s, 2H), 1.94 (s, 6H), 1.24 (s, 12H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl\_3)  $\delta$  153.6, 130.0, 127.5, 125.5, 124.0, 114.3, 83.6, 69.8, 51.0, 43.5, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.7.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 2910, 2873, 1483, 1410, 1379, 1312, 1201, 1144, 855, 665.

**HRMS** (EI-TOF) calcd for  $(C_{18}H_{23}BCI_2O_3)$  [M]<sup>+</sup> 368.1117, found 368.1110.

Melting point 141 - 142 °C.



(1R,4R)-4,7,7-Trimethyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1] pentan-1-yl)-2-oxabicyclo[2.2.1]heptan-3-one (4ai).

Prepared following **GP-B** and purified by column chromatography (25% EtOAc/hexanes). The product was obtained as a white solid (35.2 mg, 34%).

Prepared following **GP-C** and purified by column chromatography (25% EtOAc/hexanes). The product was obtained as a white solid (22.2 mg, 21%).

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 2.06 – 1.98 (m, 6H), 1.92 (ddd, *J* = 13.9, 10.0, 4.0 Hz, 1H), 1.67 (dddd, *J* = 28.4, 13.4, 9.8, 4.4 Hz, 2H), 1.55 (ddd, *J* = 12.0, 8.7, 4.1 Hz, 1H), 1.22 (s, 12H), 1.01 (s, 3H), 0.95 (s, 3H), 0.89 (s, 3H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  180.9, 92.0, 83.6, 54.9, 52.3, 51.3, 43.9, 28.9, 28.7, 24.9, 17.2, 16.9, 9.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.0.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2972, 2912, 2876, 1772, 1443, 1414, 1393, 1372, 1356, 1316, 1273, 1211, 1168, 1144, 1117, 1075, 1021969, 910, 855.

**HRMS** (ESI-TOF) calcd for  $(C_{20}H_{32}BO_4)$  [M+H]<sup>+</sup> 347.2434, found 347.2411.

Melting point: 169 - 171 °C.



(1*S*,2*S*,4*aR*,4*bR*,7*S*,9*aR*,10*R*,10*aR*)-1-Methyl-8-methylene-13-oxo-10-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)-1,2,5,6,8,9,10,10a-octahydro-4a,1-(epoxymethano)-7,9a-methanobenzo[*a*]azulene-2,7(4*bH*)-diyl diacetate (4aj).

Prepared following **GP-B** and purified by column chromatography (40% EtOAc/hexanes). The product was obtained as a white solid. (111.9 mg, 60%).

Prepared following **GP-C** and purified by column chromatography (40% EtOAc/hexanes). The product was obtained as a white solid. (95.2 mg, 55%).

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 6.40 (dd, J = 9.2, 0.8 Hz, 1H), 5.79 (dd, J = 9.2, 3.7 Hz, 1H), 5.32 (dd, J = 3.7, 0.8 Hz, 1H), 4.97 (d, J = 2.0 Hz, 2H), 3.10 (dt, J = 15.1, 3.1 Hz, 1H), 2.61 (d, J = 8.4 Hz, 1H), 2.35 (dd, J = 10.6, 2.5 Hz, 1H), 2.27 – 2.21 (m, 1H), 2.12 (s, 3H), 2.09 – 2.06 (m, 1H), 1.97 (s, 3H), 1.96 (dd, J = 9.6, 2.1 Hz, 3H), 1.94 – 1.90 (m, 1H), 1.87 (dd, J = 9.7, 2.1 Hz, 3H), 1.83 (d, J = 8.5 Hz, 2H), 1.80 – 1.76 (m, 2H), 1.73 – 1.66 (m, 1H), 1.22 (s, 12H), 1.19 (s, 3H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  177.9, 170.1, 169.7, 152.1, 134.9, 129.0, 106.2, 90.6, 84.3, 83.6, 71.9, 54.5, 53.1, 52.1, 52.0, 48.6, 47.4, 45.8, 44.5, 42.8, 36.8, 24.9, 24.9, 22.3, 21.1, 17.7, 15.5.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.8.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2972, 2912, 2876, 1772, 1443, 1414, 1393, 1372, 1356, 1316, 1273, 1211, 1168, 1144, 1117, 1075, 1021, 969, 910, 855.

**HRMS** (ESI-TOF) calcd for (C<sub>33</sub>H<sub>43</sub>BO<sub>8</sub>Na) [M+Na]<sup>+</sup> 601.2949, found 601.2958.

Melting point: 242 - 243 °C.



(5S, 8R, 9S, 10S, 13R, 14S, 17R)-10, 13-Dimethyl-17-((R)-4-(3-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)butan-2-yl)dodecahydro-3*H*-cyclopenta[*a*]phenanthrene-3, 7, 12(2*H*, 4*H*)-trione (4ak).

Prepared following **GP-B** and purified by column chromatography (70% EtOAc/hexanes). The product was obtained as a white solid (99.5 mg, 60%).

Prepared following **GP-C** and purified by column chromatography (70% EtOAc/hexanes). The product was obtained as a white solid (96.2 mg, 58%).

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 2.94 – 2.86 (m, 2H), 2.85 – 2.75 (m, 1H), 2.37 – 2.26 (m, 2H), 2.24 – 2.19 (m, 2H), 2.17 – 2.12 (m, 2H), 2.10 – 2.06 (m, 2H), 2.04 – 1.91 (m, 4H), 1.80 (td, J = 11.5, 7.5 Hz, 1H), 1.68 (s, 6H), 1.61 – 1.53 (m, 3H), 1.37 (s, 3H), 1.25 – 1.22 (m, 5H), 1.20 (s, 12H), 1.03 (s, 3H), 0.76 (d, J = 6.4 Hz, 3H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 212.3, 209.3, 209.0, 83.3, 57.0, 51.9, 51.4, 50.3, 49.1, 47.0, 45.7, 45.1, 42.9, 38.8, 36.6, 36.1, 35.9, 35.4, 31.6, 29.9, 27.9, 25.3, 25.0, 24.9, 22.0, 19.0, 12.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.0.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2962, 2868, 1707, 1448, 1404, 1380, 1335, 1305, 1272, 1251, 1195, 1167, 1144, 1121, 1008, 912, 852, 729, 674, 647.

**HRMS** (ESI-TOF) calcd for (C<sub>34</sub>H<sub>51</sub>BO<sub>5</sub>Na) [M+Na]<sup>+</sup> 573.3727, found 573.3719.

Melting point:174 - 175 °C.



(4a*R*,6a*S*,6b*R*,8a*R*,10*S*,12a*S*,12b*R*,14b*R*)-10-Hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)-1,3,4,4a,5,6,6a,6b,7, 8,8a,9,10,11,12,12a,12b,14b-octadecahydropicen-13(2*H*)-one (4al).

Prepared following **GP-B** and purified by column chromatography (45% EtOAc/hexanes). The product was obtained as a white solid (107.8 mg, 58%).

Prepared following **GP-C** and purified by column chromatography (45% EtOAc/hexanes). The product was obtained as a white solid (100.8 mg, 54%).

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) (2.1:1 mixture of diastereomers) δ 5.59 (s, 0.67H), 5.55 (s, 0.32H), 3.21 (ddd, J = 11.3, 8.8, 5.0 Hz, 1H), 2.80 – 2.75 (m, 1H), 2.31 (d, J = 2.3 Hz, 1H), 2.24 – 2.17 (m, 0.54H), 2.08 – 2.02 (m, 0.28H), 1.97 (td, J = 13.7, 4.3 Hz, 1H), 1.80 (s, 4H), 1.83 – 1.74 (m, 2H), 1.65 (s, 2H), 1.64 – 1.55 (m, 5H), 1.52 – 1.44 (m, 2H), 1.43 – 1.35 (m, 4H), 1.31 (s, 3H), 1.33 – 1.24 (m, 2H), 1.22 (s, 12H), 1.11 (s, 6H), 0.99 (s, 3H), 0.97 – 0.93 (m, 1H), 0.78 (s, 6H), 0.70 (s, 3H), 0.69 – 0.62 (m, 1H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) (2.1:1 mixture of diastereomers) δ 200.5, 200.3, 170.9, 170.5, 134.4, 128.3, 123.7, 83.4, 83.4, 78.9, 78.9, 61.9, 61.9, 55.1, 55.1, 54.1, 54.0, 52.2, 50.4, 47.7, 47.1, 47.1, 45.6, 45.4, 43.6, 43.4, 41.2, 39.3, 39.3, 38.7, 37.3, 37.2, 36.9, 36.0, 33.2, 33.2, 33.0, 32.9, 32.6, 32.2, 30.2, 29.4, 28.9, 28.4, 28.3, 27.8, 27.7, 27.5, 27.2, 26.5, 26.4, 24.9, 23.4, 23.3, 18.9, 18.9, 17.6, 17.6, 16.6, 16.5, 15.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.9.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2954, 2867, 1651, 1454, 1402, 1390, 1372, 1307, 1202, 1167, 1142, 1039, 1008, 994, 908, 854, 728, 688, 667, 647.

**HRMS** (ESI-TOF) calcd for  $(C_{40}H_{64}BO_4)$  [M+H]<sup>+</sup> 619.4898, found 619.4904.

Melting point: 205 - 207 °C.



### 2-(3-(5-(2,5-Dimethylphenoxy)-2-methylpentan-2-yl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetra methyl-1,3,2-dioxaborolane (4am).

Prepared following **GP-B** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid (96.1 mg, 80%).

Prepared following **GP-C** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a white solid (98.2 mg, 82%).

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.02 (d, J = 7.7 Hz, 1H), 6.67 (d, J = 7.3 Hz, 1H), 6.64 (s, 1H), 3.91 (t, J = 6.6 Hz, 2H), 2.33 (s, 3H), 2.19 (s, 3H), 1.80 – 1.73 (m, 2H), 1.75 (s, 6H), 1.35 – 1.30 (m, 2H), 1.26 (s, 12H), 0.81 (s, 6H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  157.3, 136.5, 130.4, 123.8, 120.7, 112.2, 83.3, 68.9, 54.1, 48.1, 34.8, 32.5, 24.9, 24.9, 22.7, 21.6, 15.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 31.0.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2957, 2867, 1509, 1437, 1403, 1390, 1379, 1371, 1307, 1284, 1264, 1214, 1202, 1141, 1130, 1043, 1011, 994, 855, 802.

**HRMS** (ESI-TOF) calcd for  $(C_{25}H_{40}BO_3)$  [M+H]<sup>+</sup> 399.3071, found 399.3065.

Melting point: 116 - 117 °C.



## **2-(3-(1-(2-Fluoro-[1,1'-biphenyl]-4-yl)ethyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (4an, 41.0 mg, 35%).

Prepared following **GP-B** with the following modification: 3 equiv of [1.1.1.]propellane were used. The compound was purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a colorless, waxy solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.54 (dt, J = 8.1, 1.5 Hz, 2H), 7.46 – 7.40 (m, 2H), 7.37 – 7.29 (m, 2H), 6.95 (dd, J = 7.9, 1.7 Hz, 1H), 6.90 (dd, J = 12.0, 1.7 Hz, 1H), 2.78 (q, J = 7.1 Hz, 1H), 1.70 (s, 6H), 1.25 – 1.19 (m, 15H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 159.7 (d, J = 247.0 Hz), 146.0 (d, J = 7.2 Hz), 136.1, 130.2 (d, J = 4.0 Hz), 129.1, 128.5, 127.4, 126.4 (d, J = 13.5 Hz), 123.6 (d, J = 3.1 Hz), 114.9 (d, J = 22.6 Hz), 83.4, 49.5, 49.4, 41.8, 24.9, 16.2.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.8.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -119.00.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2964, 2906, 2869, 1483, 1415, 1372, 1330, 1266, 1249, 1197, 1143, 1126, 911, 870, 851, 832, 766, 725, 697.

HRMS (EI-TOF) calcd for (C<sub>25</sub>H<sub>30</sub>BFO<sub>2</sub>) [M]<sup>+</sup> 392.2323, found 392.2324.



### 4,4,5,5-Tetramethyl-2-(3-(1-phenylcyclopentyl)bicyclo[1.1.1]pentan-1-yl)-1,3,2dioxaborolane (4ao, 38.0 mg, 37%).

Prepared following **GP-E** and purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.22 (t, J = 7.4 Hz, 2H), 7.13 (d, J = 7.3 Hz, 1H), 7.03 (d, J = 7.4 Hz, 2H), 2.31 (d, J = 10.6 Hz, 1H), 2.24 – 2.12 (m, 1H), 2.07 – 1.95 (m, 1H), 1.75 – 1.65 (m, 6H), 1.60 – 1.55 (m, 1H), 1.50 – 1.30 (m, 3H), 1.19 (s, 12H), 0.93 – 0.83 (m, 1H).

 $^{13}\textbf{C}$  NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  143.8, 128.5, 127.8, 125.6, 83.3, 55.3, 51.3, 42.2, 32.9, 32.3, 26.1, 24.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.9.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2958, 2906, 2868, 1509, 1450, 1402, 1371, 1309, 1250, 1196, 1144, 1111, 1033, 983, 960, 853, 763, 705, 667.

**HRMS** (EI-TOF) calcd for  $(C_{22}H_{31}BO_2)$  [M]<sup>+</sup> 338.2417, found 338.2442.

Melting point: 104 – 105 °C.



(S)-2,2-Dimethyl-5-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1] pentan-1-yl)methyl)-1,3-dioxolan-4-one (4ap, 51 mg, 53%).

Prepared following **GP-E** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 4.35 (dd, *J* = 8.3, 3.4 Hz, 1H), 1.98 (dd, *J* = 14.9, 3.5 Hz, 1H), 1.88 – 1.83 (m, 6H), 1.77 (dd, *J* = 14.9, 8.3 Hz, 1H), 1.60 (s, 3H), 1.51 (s, 3H), 1.22 (s, 12H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 173.6, 110.6, 83.4, 72.9, 52.4, 43.1, 34.9, 27.4, 25.6, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 32.6.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 2910, 2872, 1725, 1474, 1448, 1373, 1331, 1251, 1142, 1009, 981, 952, 904, 851, 726, 683.

**HRMS** (ESI-TOF) calcd for (C<sub>17</sub>H<sub>28</sub>BO<sub>5</sub>) [M+H]<sup>+</sup> 323.2030, found 323.2011.



(3aS,4S,6aR)-4-(4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)butyl)tetrahydro-1*H*-thieno[3,4-*d*]imidazol-2(3*H*)-one (4aq, 51.8 mg, 44%).

Prepared following **GP-E** and purified by column chromatography (70% MeCN/ $H_2O$ ). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 5.11 (s, 1H), 5.07 (s, 1H), 4.50 (dd, J = 7.8, 4.8 Hz, 1H), 4.32 – 4.28 (m, 1H), 3.19 – 3.11 (m, 1H), 2.92 (dd, J = 12.8, 5.0 Hz, 1H), 2.72 (d, J = 12.8 Hz, 1H), 1.72 (s, 6H), 1.67 – 1.61 (m, 2H), 1.44 – 1.28 (m, 6H), 1.23 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 163.3, 83.4, 62.1, 60.3, 55.7, 51.6, 46.2, 40.7, 33.1, 29.4, 28.8, 26.2, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.1.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 3211, 2958, 2924, 2866, 1697, 1471, 1434, 1405, 1379, 1372, 1306, 1270, 1251, 1196, 1166, 1145, 1110, 856, 732, 666.

**HRMS** (ESI-TOF) calcd for  $(C_{20}H_{34}BN_2O_3S)$  [M+H]<sup>+</sup> 393.2383, found 393.2362.

Melting point: 119 - 120 °C.



# (*R*)-5-Bromo-4-(4-chlorobenzyl)-7-fluoro-3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)methyl)-1,2,3,4-tetrahydrocyclopenta[b]indole (4ar, 74 mg, 42%).

Prepared following **GP-E** and purified by column chromatography (5% EtOAc/hexanes). The product was obtained as a white crystalline solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.24 – 7.21 (m, 2H), 7.02 (ddd, *J* = 12.2, 8.8, 2.5 Hz, 2H), 6.81 (d, *J* = 8.4 Hz, 2H), 5.86 (d, *J* = 17.1 Hz, 1H), 5.36 (d, *J* = 17.2 Hz, 1H), 3.01 (t, *J* = 9.5 Hz, 1H), 2.82 (ddd, *J* = 14.4, 5.6, 3.7 Hz, 1H), 2.73 – 2.68 (m, 1H), 2.66 – 2.60 (m, 1H), 2.18 (tdd, *J* = 9.5, 6.5, 3.3 Hz, 1H), 1.80 – 1.70 (m, 6H), 1.60 (dd, *J* = 14.5, 2.2 Hz, 2H), 1.47 (dd, *J* = 14.4, 10.1 Hz, 1H), 1.22 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 157.0 (d, *J* = 238.7 Hz), 152.8, 138.0, 134.2, 133.1, 128.9, 127.4 (d, *J* = 9.9 Hz), 127.2, 119.3 (d, *J* = 4.7 Hz), 114.0 (d, *J* = 28.5 Hz), 103.5 (d, *J* = 22.4 Hz), 103.1 (d, *J* = 12.0 Hz), 83.4, 52.3, 48.5, 45.1, 37.6, 36.7, 35.1, 24.9, 23.2.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 32.0.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -123.85.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2959, 2904, 2865, 1583, 1486, 1448, 1404, 1371, 1347, 1310, 1198, 1176, 1143, 1093, 1033, 1014, 964, 854, 809.

**HRMS** (ESI-TOF) calcd for (C<sub>30</sub>H<sub>34</sub>BBrCIFNO<sub>2</sub>) [M+H]<sup>+</sup> 584.1539, found 584.1552.

**Melting point:** 147 – 149 °C.



**2-(3-(3-Chloropropyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (5a, 42.3 mg, 52%).

Prepared following **GP-F** and purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a clear oil.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 3.51 (t, *J* = 6.8 Hz, 2H), 1.75 (s, 6H), 1.74 – 1.65 (m, 2H), 1.52 – 1.42 (m, 2H), 1.23 (s, 12H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 83.4, 51.5, 45.5, 45.4, 30.7, 29.7, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.0.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2958, 2905, 2868, 1512, 1436, 1405, 1390, 1379, 1372, 1346, 1309, 1275, 1198, 1166, 1145, 1111, 1034, 960, 856, 666.

HRMS (ESI-TOF) calcd for (C<sub>14</sub>H<sub>25</sub>BCIO<sub>2</sub>) [M+H]<sup>+</sup> 271.1636, found 271.1624.



**4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)butyl** Acetate (**5b**, 42.5 mg, 46%).

Prepared following **GP-F** and purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a clear oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 4.03 (t, *J* = 6.8 Hz, 2H), 2.04 (s, 3H), 1.73 (s, 6H), 1.63 – 1.57 (m, 2H), 1.36 – 1.32 (m, 2H), 1.30 – 1.25 (m, 2H), 1.23 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 171.4, 83.3, 64.8, 51.5, 46.1, 32.9, 28.9, 24.9, 22.7, 21.2.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.1.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2958, 2867, 1741, 1512, 1436, 1406, 1371, 1309, 1244, 1197, 1145, 1031, 856, 666.

**HRMS** (ESI-TOF) calcd for (C<sub>17</sub>H<sub>29</sub>BO<sub>4</sub>Na) [M+Na] <sup>+</sup> 331.2057, found 331.2074.



Methyl (S)-2-((*tert*-Butoxycarbonyl)amino)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)propanoate (5c, 50.0 mg, 42 %).

Prepared following **GP-F** and purified by column chromatography (50% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 4.94 (d, *J* = 8.2 Hz, 1H), 4.25 (td, *J* = 7.7, 4.6 Hz, 1H), 3.70 (s, 3H), 1.90 (dd, *J* = 14.6, 4.8 Hz, 1H), 1.80 (s, 6H), 1.76 – 1.68 (m, 1H), 1.42 (s, 9H), 1.20 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 173.5, 155.2, 83.4, 79.8, 52.3, 52.3, 52.1, 43.2, 35.2, 28.4, 24.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.8.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 1744, 1715, 1510, 1435, 1404, 1391, 1366, 1308, 1249, 1199, 1162, 1144, 1111, 1045, 1032, 995, 855, 732.

**HRMS** (ESI-TOF) calcd for (C<sub>20</sub>H<sub>34</sub>BNaNO<sub>6</sub>) [M+Na]<sup>+</sup> 418.2377, found 418.2317.

**Melting point:** 107 – 108 °C.



**2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)ethan-1-ol** (5d, 32.9 mg, 46%).

Prepared following **GP-F** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a clear oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 3.64 (t, *J* = 6.8 Hz, 2H), 1.80 (s, 6H), 1.63 (t, *J* = 6.8 Hz, 2H), 1.22 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 83.4, 77.4, 77.2, 77.0, 61.2, 52.1, 43.9, 36.2, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.8.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 3375, 2959, 2905, 2867, 1512, 1471, 1435, 1404, 1379, 1372, 1343, 1306, 1197, 1167, 1144, 1110, 1037, 978, 961, 855, 666.

**HRMS** (ESI-TOF) calcd for (C<sub>13</sub>H<sub>24</sub>BO<sub>3</sub>) [M+H]<sup>+</sup> 239.1819, found 239.1835.



**4,4,5,5-Tetramethyl-2-(3-(2,2,2-trifluoroethyl)bicyclo[1.1.1]pentan-1-yl)-1,3,2dioxaborolane** (**5e**, 42.1 mg, 51%).

Prepared following **GP-F** and purified by column chromatography (5% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 2.25 – 2.14 (m, 2H), 1.95 (s, 6H), 1.25 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 126.5 (q, J = 277.4 Hz), 83.5, 52.7, 50.2, 39.1, 37.2 (q, J = 27.4 Hz), 24.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.8.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -64.1.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2967, 2854, 1463.

**HRMS** (EI-TOF) calcd for  $(C_{13}H_{20}BF_{3}O_{2})$  [M]<sup>+</sup> 276.1508, found 276.1528.



**2-(3-(3,5-Bis(trifluoromethyl)benzyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (5f**, 43.3 mg, 34%).

Prepared following **GP-F** and purified by column chromatography (5% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.69 (s, 1H), 7.50 (s, 2H), 2.79 (s, 2H), 1.71 (s, 6H), 1.19 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 141.9, 131.5 (q, *J* = 33.1 Hz), 129.1 (d, *J* = 3.8 Hz), 123.6 (d, *J* = 272.5 Hz), 119.9 (p, *J* = 3.9 Hz), 83.5, 51.3, 45.0, 40.4, 24.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.1.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ –62.9.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2965, 2871, 1436, 1404, 1391, 1375, 1349, 1331, 1276, 1198, 1169, 1130, 1029, 921, 893, 855, 842, 708, 682.

**HRMS** (EI-TOF) calcd for  $(C_{20}H_{23}BF_5O_4)$  [M-F]<sup>+</sup> 401.1711, found 401.1721.

**Melting point:**  $66 - 67^{\circ}$ C.



(2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)bicyclo[1.1.1]pentan-1-yl)tetrahydro-2H-pyran-3,4,5-triyl Triacetate (5g, 93 mg, 59%).

Prepared following **GP-F** and purified by column chromatography (30% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 5.48 (t, *J* = 9.5 Hz, 1H), 5.03 (dd, *J* = 10.0, 6.2 Hz, 1H), 4.92 (t, *J* = 9.2 Hz, 1H), 4.18 – 4.01 (m, 3H), 3.97 (d, *J* = 6.2 Hz, 1H), 2.15 – 1.97 (m, 18H), 1.23 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 170.8, 170.2, 169.9, 169.7, 83.7, 71.3, 71.2, 70.6, 70.3, 69.0, 62.7, 53.3, 50.1, 45.0, 24.9, 20.9, 20.9, 20.8, 20.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 2874, 1745, 1438, 1369, 1312, 1208, 1157, 1142, 1097, 1085, 1032, 955, 913, 854, 730, 666, 599.

**HRMS** (ESI-TOF) calcd for (C<sub>25</sub>H<sub>37</sub>BNaNO<sub>11</sub>) [M+Na]<sup>+</sup> 547.2320, found 547.2329.



*tert*-Butyl 3-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)pyrrolidine-1-carboxylate (5h, 48.1 mg, 44%).

Prepared following **GP-F** and purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (500 MHz, CDCl<sub>3</sub>) δ 3.43 - 3.35 (m, 1H), 3.35 - 3.28 (m, 1H), 3.28 - 3.16 (m, 1H), 3.02 (t, *J* = 8.9 Hz, 1H), 2.15 - 2.05 (m, 1H), 1.85 - 1.77 (m, 1H), 1.75 (d, *J* = 1.6 Hz, 6H), 1.65 - 1.56 (m, 1H), 1.45 (s, 9H), 1.23 (s, 12H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 154.8, 83.5, 79.1, 50.0, 48.1, 46.5, 45.8, 40.1, 28.7, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 1698, 1401, 1311, 1202, 1169, 1145, 1112.

**HRMS** (EI-TOF) calcd for (C<sub>16</sub>H<sub>26</sub>BNO<sub>4</sub>) [M-C(CH<sub>3</sub>)<sub>3</sub>+H]<sup>+</sup> 307.1955, found 307.1974.

Melting point: 125 - 127 °C.



*tert*-Butyl 3-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)azeti dine-1-carboxylate (5i, 43 mg, 41%).

Prepared following **GP-F** and purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 3.84 (t, *J* = 8.4 Hz, 2H), 3.60 (dd, *J* = 8.4, 5.5 Hz, 2H), 2.44 (tt, *J* = 8.4, 5.4 Hz, 1H), 1.77 (s, 6H), 1.42 (s, 9H), 1.23 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 156.6, 83.5, 79.3, 50.2, 49.1, 46.6, 46.2, 30.3, 28.5, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2963, 2907, 2872, 1702, 1512, 1479, 1436, 1390, 1367, 1346, 1310, 1255, 1201, 1165, 1141, 1060, 963, 855, 773.

**HRMS** (EI-TOF) calcd for (C<sub>15</sub>H<sub>24</sub>BNO<sub>4</sub>) [M-*t*-Bu]<sup>+</sup> 293.1798, found 293.1801.



(1*R*,3*S*,5*S*,7*S*)-5-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)adamantan-2-one (5j, 42 mg, 41%).

Prepared following **GP-F** and purified by column chromatography (60% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 2.49 (t, *J* = 2.9 Hz, 2H), 2.11 – 2.09 (m , 1H), 1.92 (t, *J* = 2.9 Hz, 4H), 1.74 – 1.70 (m, 2H), 1.67 (s, 6H), 1.64 (t, *J* = 1.6 Hz, 1H), 1.61 (d, *J* = 3.2 Hz, 2H), 1.22 (s, 12H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 218.9, 83.3, 51.7, 47.1, 46.1, 39.6, 38.7, 36.9, 31.9, 27.5, 24.7.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.9.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2957, 2917, 2855, 1721, 1510, 1438, 1404, 1371, 1349, 1311, 1251, 1201, 1166, 1145, 1111, 1083, 1058, 988, 855.

**HRMS** (ESI-TOF) calcd for (C<sub>21</sub>H<sub>31</sub>BO<sub>3</sub>) [M+H]<sup>+</sup> 342.2366, found 342.2372.

Melting point: 155 – 158 °C.



**4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzonitrile** (5k, 60.6 mg, 68%).

Prepared following **GP-G** with the following modification: 1.5 equiv of [1.1.1]propellane was used. The compound was purified by column chromatography (50% CH<sub>2</sub>Cl<sub>2</sub>/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.56 (d, *J* = 8.4 Hz, 2H), 7.26 (d, *J* = 8.3 Hz, 2H), 2.17 (s, 6H), 1.26 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 147.2, 132.2, 126.8, 119.3, 110.2, 83.7, 53.2, 47.1, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 31.0.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 2227, 1607, 1434, 1403, 1382, 1373, 1357, 1321, 1272, 1208, 1168, 1146, 1105, 970, 853, 833, 790, 664, 563.

**HRMS** (EI-TOF) calcd for (C<sub>18</sub>H<sub>22</sub>BNO<sub>2</sub>) [M]<sup>+</sup> 295.1744, found 295.1735.

Melting point: 178 - 180 °C.



**4,4,5,5-Tetramethyl-2-(3-(4-(trifluoromethyl)phenyl)bicyclo[1.1.1]pentan-1-yl)-1,3,2-diox** aborolane (**5I**, 47.9 mg, 47%).

Prepared following **GP-G** with the following modification: 1.5 equiv of [1.1.1]propellane were used. The compound was purified by C18 column chromatography (85% MeCN/H<sub>2</sub>O). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.53 (d, *J* = 8.0 Hz, 2H), 7.29 (d, *J* = 7.9 Hz, 2H), 2.19 (s, 6H), 1.27 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 146.0, 128.8 (q, *J* = 32.2 Hz), 126.3, 125.2 (q, *J* = 3.8 Hz), 124.5 (q, *J* = 271.9 Hz), 83.7, 53.2, 47.1, 25.0.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -62.4.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.4.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2965, 1439, 1410, 1391, 1383, 1373, 1352, 1324, 1210, 1160, 1141, 1114, 1066, 1016, 970, 849, 833, 791, 666, 600.

**HRMS** (EI-TOF) calcd for (C<sub>17</sub>H<sub>19</sub>BF<sub>3</sub>O<sub>2</sub>) [M-CH<sub>3</sub>]<sup>+</sup> 323.1430, found 323.1419.

Melting point: 136 - 138 °C.



**Methyl 4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzo ate (5m**, 51.7 mg, 53%).

Prepared following **GP-G** and purified by C18 column chromatography (85% MeCN/H<sub>2</sub>O). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.95 (d, *J* = 8.3 Hz, 2H), 7.24 (d, *J* = 8.2 Hz, 2H), 3.89 (s, 3H), 2.18 (s, 6H), 1.27 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 167.3, 147.2, 129.7, 128.3, 126.0, 83.7, 53.2, 52.2, 47.4, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.5.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2970, 2872, 1721, 1610, 1568, 1437, 1411, 1349, 1309, 1277, 1210, 1144, 1098, 1019, 969856, 823, 761, 703, 666.

**HRMS** (ESI-TOF) calcd for  $(C_{19}H_{26}BO_4)$  [M+H]<sup>+</sup> 329.1924, found 329.1906.

Melting point: 135 - 137 °C.



**2-(3-(4-Chlorophenyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (**5n**, 43.7 mg, 48%).

Prepared following **GP-G** and purified by C18 column chromatography (90% MeCN/H<sub>2</sub>O). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.24 (d, *J* = 8.4 Hz, 2H), 7.11 (d, *J* = 8.4 Hz, 2H), 2.14 (s, 6H), 1.26 (s, 12H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 140.8, 132.3, 128.4, 127.4, 83.6, 53.2, 47.0, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.9.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2967, 2870, 1488, 1436, 1407, 1380, 1349, 1313, 1209, 1144, 1087, 1014, 969, 854, 788, 726, 666, 517.

**HRMS** (EI-TOF) calcd for  $(C_{17}H_{22}BCIO_2)$  [M]<sup>+</sup> 304.1401, found 304.1403.

Melting point: 130 - 131 °C.



**2-(3-([1,1'-Biphenyl]-4-yl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (**5o**, 54.9 mg, 53%).

Prepared following **GP-G** and purified by column chromatography (15% EtOAc/hexanes). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.51 (d, *J* = 7.5 Hz, 2H), 7.47 (d, *J* = 8.0 Hz, 2H), 7.38 (t, *J* = 7.6 Hz, 2H), 7.29 (d, *J* = 7.4 Hz, 1H), 7.27 – 7.18 (m, 2H), 2.16 (s, 6H), 1.23 (s, 12H).

<sup>13</sup>**C NMR** (101 MHz, CDCl<sub>3</sub>) δ 141.4, 139.6, 128.9, 127.3, 127.3, 127.1, 126.4, 83.6, 53.3, 47.4, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.8.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 3043, 2965, 2907, 2869, 1487, 1438, 1408, 1390, 1310, 1208, 1144, 1107, 969, 855, 760, 726, 697, 666, 566.

**HRMS** (EI-TOF) calcd for  $(C_{23}H_{27}BO_2)$  [M]<sup>+</sup> 346.2104, found 346.2084.

Melting point: 135 - 137 °C.



**4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)phenyl 4-Methylbenzenesulfonate (5p**, 50.5 mg, 38%).

Prepared following **GP-G** and purified by C18 column chromatography (65% MeCN/H<sub>2</sub>O). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.71 (d, *J* = 7.9 Hz, 2H), 7.31 (d, *J* = 7.9 Hz, 2H), 7.08 (d, *J* = 8.1 Hz, 2H), 6.87 (d, *J* = 8.2 Hz, 2H), 2.45 (s, 3H), 2.12 (s, 6H), 1.25 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 148.3, 145.4, 141.3, 132.8, 129.9, 128.7, 127.2, 122.1, 83.6, 53.2, 46.9, 24.9, 21.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.9.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2969, 1497, 1437, 1407, 1392, 1372, 1311, 1209, 1197, 1175, 1146, 1094, 864, 815, 795, 748, 723, 667, 570, 552.

**HRMS** (EI-TOF) calcd for  $(C_{24}H_{29}BO_5S)$  [M]<sup>+</sup> 440.1829, found 440.1820.

Melting point: 176 - 177 °C.



**4,4,5,5-Tetramethyl-2-(4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pent an-1-yl)phenyl)-1,3,2-dioxaborolane** (**5q**, 50.7 mg, 43%).

Prepared following **GP-G** and purified by C18 column chromatography (85% MeCN/H<sub>2</sub>O). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.74 (d, *J* = 7.8 Hz, 2H), 7.19 (d, *J* = 7.7 Hz, 2H), 2.16 (s, 6H), 1.33 (s, 12H), 1.26 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 145.2, 134.7, 125.1, 83.7, 83.4, 53.0, 47.5, 24.8, 24.8.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.6.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2976, 2870, 1611, 1522, 1439, 1396, 1359, 1316, 1267, 1210, 1143, 1113, 1085, 1020, 962, 854, 830, 740, 657, 578

**HRMS** (EI-TOF) calcd for  $(C_{23}H_{34}B_2O_4)$  [M]<sup>+</sup> 396.2643, found 396.2640.

Melting point: 214 - 216 °C.



*tert*-Butyl (4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)phen yl)carbamate (5r, 48.3 mg, 42%).

Prepared following **GP-G** and purified by C18 column chromatography (85% MeCN/H<sub>2</sub>O). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.25 (d, *J* = 7.4 Hz, 2H), 7.10 (d, *J* = 8.5 Hz, 2H), 6.43 (br, 1H), 2.13 (s, 6H), 1.50 (s, 9H), 1.26 (s, 12H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 152.9, 137.3, 136.8, 126.5, 118.6, 83.6, 53.3, 47.2, 28.5, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.9.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 3337, 2976, 2869, 1728, 1708, 1594, 1529, 1508, 1438, 1407, 1392, 1368, 1312, 1232, 1208, 1162, 1105, 1052, 1027, 969, 855.

**HRMS** (ESI-TOF) calcd for (C<sub>24</sub>H<sub>35</sub>BN<sub>2</sub>O<sub>4</sub>Na) [M+Na+CH<sub>3</sub>CN]<sup>+</sup> 449.2592, found 449.2596.

Melting point: 208 - 210 °C.



**2-(3-(4-Methoxyphenyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (**5s**, 30.3 mg, 34%).

Prepared following **GP-G** and purified by C18 column chromatography (80% MeCN/H<sub>2</sub>O). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.12 (d, *J* = 8.1 Hz, 2H), 6.83 (d, *J* = 8.0 Hz, 2H), 3.78 (s, 3H), 2.14 (s, 6H), 1.27 (s, 12H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 158.4, 134.9, 127.0, 113.7, 83.5, 55.5, 53.3, 47.1, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 31.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2962, 2907, 2869, 1611, 1503, 1437, 1407, 1311, 1246, 1208, 1172, 1145, 1105, 1036, 969, 856, 831, 792, 666, 602.

**HRMS** (EI-TOF) calcd for (C<sub>18</sub>H<sub>25</sub>BO<sub>3</sub>) [M]<sup>+</sup> 300.1897, found 300.1907.

Melting point: 110 - 112 °C.



(3-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)phenyl)methan ol (5t, 28.7 mg, 32%).

Prepared following **GP-G** and purified by C18 column chromatography (80% MeCN/H<sub>2</sub>O). The product was obtained as a pale-yellow oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.29 (t, *J* = 7.7 Hz, 1H), 7.20 (d, *J* = 3.8 Hz, 2H), 7.14 (d, *J* = 7.7 Hz, 1H), 4.68 (s, 2H), 2.17 (s, 6H), 1.27 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 142.7, 140.9, 128.6, 125.3, 125.3, 124.5, 83.6, 53.2, 47.4, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 31.5.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 3413, 2965, 2907, 2868, 1512, 1435, 1406, 1373, 1344, 1310, 1212, 1167, 1144, 1106, 1021, 855, 806, 776, 703, 666.

**HRMS** (EI-TOF) calcd for (C<sub>18</sub>H<sub>25</sub>BO<sub>3</sub>) [M]<sup>+</sup> 300.1897, found 300.1909.



**2-(3-(2-Bromophenyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (**5u**, 56.4 mg, 54%).

Prepared following **GP-G** and purified by C18 column chromatography (90% MeCN/ $H_2O$ ). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.46 (d, *J* = 7.9 Hz, 1H), 7.22 (t, *J* = 7.4 Hz, 1H), 7.15 (d, *J* = 7.4 Hz, 1H), 7.05 (d, *J* = 7.8 Hz, 1H), 2.38 (s, 6H), 1.27 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 140.1, 133.5, 129.4, 128.4, 127.2, 122.6, 83.6, 53.3, 49.2, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.7.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2977, 2910, 2872, 1510, 1469, 1435, 1407, 1372, 1312, 1209, 1144, 1114, 1027, 969, 854, 749, 697, 667.

**HRMS** (EI-TOF) calcd for (C<sub>16</sub>H<sub>19</sub>BBrO<sub>2</sub>) [M-CH<sub>3</sub>]<sup>+</sup> 333.0661, found 333.0660.

Melting point: 106 - 108 °C.



**4,4,5,5-Tetramethyl-2-(3-(naphthalen-2-yl)bicyclo[1.1.1]pentan-1-yl)-1,3,2-dioxaborolane** (**5v**, 44.2 mg, 46%).

Prepared following **GP-G** and purified by C18 column chromatography (85% MeCN/H<sub>2</sub>O). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.49 – 7.41 (m, 4H), 7.09 (dt, *J* = 20.1, 7.2 Hz, 2H), 7.03 (d, *J* = 8.3 Hz, 1H), 1.92 (s, 6H), 0.95 (s, 12H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl\_3)  $\delta$  139.8, 133.5, 132.4, 127.9, 127.8, 127.8, 126.2, 125.5, 124.4, 124.2, 83.6, 53.3, 47.8, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.6.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2967, 2868, 1505, 1436, 1407, 1391, 1380, 1372, 1348, 1311, 1207, 1167, 1144, 1090, 855, 820, 794, 744, 666, 476.

**HRMS** (EI-TOF) calcd for  $(C_{21}H_{25}BO_2)$  [M]<sup>+</sup> 320.1948, found 320.1951.

Melting point: 131 - 132 °C.



2-(3-(4-Bromo-3-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2dioxaborolane (5w, 41.4 mg, 38%)

Prepared following **GP-G** and purified by C18 column chromatography (85% MeCN/H<sub>2</sub>O). The product was obtained as a pale-yellow solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.43 (dd, *J* = 8.1, 7.0 Hz, 1H), 6.92 (dd, *J* = 9.3, 1.9 Hz, 1H), 6.84 (dd, *J* = 8.1, 1.9 Hz, 1H), 2.14 (s, 6H), 1.26 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  159.1 (d, *J* = 247.7 Hz), 144.2 (d, *J* = 6.0 Hz), 133.3, 122.9 (d, *J* = 3.3 Hz), 114.2 (d, *J* = 21.5 Hz), 106.8 (d, *J* = 21.1 Hz), 83.7, 53.2, 46.7, 25.0.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -108.1.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 2871, 1575, 1481, 1439, 1412, 1314, 1219, 1201, 1144, 1038, 856, 666.

**HRMS** (EI-TOF) calcd for (C<sub>17</sub>H<sub>21</sub>BBrFO<sub>2</sub>) [M]<sup>+</sup> 366.0802, found 366.0801.

Melting point: 73 - 74 °C.



(*R*)-5-((1*H*-1,2,3-Triazol-1-yl)methyl)-3-(3-fluoro-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxa borolan -2-yl)bicyclo[1.1.1]pentan-1-yl)phenyl)oxazolidin-2-one (5x, 26.7 mg, 20%).

Prepared following **GP-G** with the following modification: 2:1 MeOH-acetone (0.1 M) mixed solvent was used. The compound was purified by C18 column chromatography (65% MeCN/H<sub>2</sub>O). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.78 (s, 1H), 7.74 (s, 1H), 7.18 (dd, J = 12.0, 2.2 Hz, 1H), 7.03 (t, J = 8.3 Hz, 1H), 6.97 (dd, J = 8.3, 2.3 Hz, 1H), 5.10 – 4.99 (m, 1H), 4.86 – 4.71 (m, 2H), 4.12 (t, J = 9.1 Hz, 1H), 3.88 (dd, J = 9.4, 6.1 Hz, 1H), 2.22 (s, 6H), 1.26 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 161.9 (d, J = 247.5 Hz), 153.3, 137.2 (d, J = 10.6 Hz), 134.7, 129.2 (d, J = 6.8 Hz), 125.3 (d, J = 17.8 Hz), 125.2, 113.4 (d, J = 3.4 Hz), 106.4 (d, J = 27.2 Hz), 83.6, 70.5, 53.7, 53.3, 52.2, 47.4, 24.9.

<sup>19</sup>**F NMR** (376 MHz, CDCl<sub>3</sub>) δ -114.5.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.1.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2973, 2909, 2872, 1739, 1628, 1576, 1505, 1486, 1414, 1311, 1214, 1200, 1146, 1116, 1043, 972, 856, 808, 753, 666.

**HRMS** (ESI-TOF) calcd for (C<sub>23</sub>H<sub>29</sub>BFN<sub>4</sub>O<sub>4</sub>) [M+H]<sup>+</sup> 455.2266, found 455.2267.

Melting point: 179 - 182 °C.



**3-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)pyridine** (5y, 39.4 mg, 48%).

Prepared following **GP-G** with the following modification: 1.5 equiv of [1.1.1]propellane were used. The compound was purified by C18 column chromatography (65% MeCN/H<sub>2</sub>O). The product was obtained as a yellow oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 8.44 (s, 2H), 7.50 (d, *J* = 7.3 Hz, 1H), 7.22 (dd, *J* = 7.8, 4.8 Hz, 1H), 2.20 (s, 6H), 1.26 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 147.5, 147.4, 137.4, 133.9, 123.3, 83.7, 53.2, 45.4, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.2.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2966, 2908, 2866, 1478, 1408, 1380, 1316, 1272, 1212, 1194, 1145, 1113, 1062, 1030, 969, 854, 815, 785, 713, 666.

**HRMS** (ESI-TOF) calcd for (C<sub>16</sub>H<sub>23</sub>BNO<sub>2</sub>) [M+H]<sup>+</sup> 272.1822, found 272.1825.



**4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)pyridine** (5z, 35.2 mg, 43%).

Prepared following **GP-G** with the following modification: 1.5 equiv of [1.1.1]propellane were used. The compound was purified by C18 column chromatography (65% MeCN/Water). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 8.51 (d, *J* = 6.0 Hz, 2H), 7.11 (d, *J* = 6.0 Hz, 2H), 2.18 (s, 6H), 1.27 (s, 12H).
<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 150.6, 149.3, 121.3, 83.8, 53.0, 46.4, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 31.0.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2961, 2864, 1625, 1409, 1213, 1156, 1112, 106, 970, 787.

**HRMS** (ESI-TOF) calcd for  $(C_{16}H_{23}BNO_2)$  [M+H]<sup>+</sup> 272.1822, found 272.1818.

Melting point: 237 - 239 °C.



**2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)pyrimidine** (5aa, 54.3 mg, 67%).

Prepared following **GP-G** with the following modification: 1.5 equiv of [1.1.1]propellane were used. The compound was purified by C18 column chromatography (50% MeCN/H<sub>2</sub>O). The product was obtained as a pale-yellow solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 8.68 (d, *J* = 4.9 Hz, 2H), 7.12 (t, *J* = 4.9 Hz, 1H), 2.32 (s, 6H), 1.27 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 168.0, 157.2, 119.1, 83.7, 53.0, 48.3, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.5.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2976, 2917, 2873, 1559, 1424, 1400, 1314, 1211, 1167, 1140, 1007, 976, 854, 772, 716, 666, 633.

**HRMS** (ESI-TOF) calcd for (C<sub>15</sub>H<sub>22</sub>BN<sub>2</sub>O<sub>2</sub>) [M+H]<sup>+</sup> 273.1774, found 273.1775.

Melting point: 144 - 146 °C.



**4,4,5,5-Tetramethyl-2-(3-(thiophen-3-yl)bicyclo[1.1.1]pentan-1-yl)-1,3,2-dioxaborolane** (5ab, 27.9 mg, 34%).

Prepared following **GP-G** and purified by C18 column chromatography (100% MeCN). The product was obtained as a white solid.

 $^{1}$ H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.24 – 7.20 (m, 1H), 6.97 – 6.93 (m, 2H), 2.16 (s, 6H), 1.26 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 144.4, 126.5, 125.6, 120.2, 83.6, 54.0, 44.0, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 29.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2962, 2907, 2868, 1438, 1418, 1401, 1372, 1349, 1316, 1213, 1197, 1167, 1142, 1095, 1070, 854, 809, 770, 638.

**HRMS** (EI-TOF) calcd for  $(C_{15}H_{21}BO_2S)$  [M]<sup>+</sup> 276.1355, found 276.1360.

Melting point: 119 °C.



**5-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)-1-tosyl-1***H***-<b>indole (5ac**, 53.0 mg, 38%).

Prepared following **GP-G** and purified by C18 column chromatography (75% MeCN/H<sub>2</sub>O). The product was obtained as a red solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.89 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 8.3 Hz, 2H), 7.53 (d, J = 3.8 Hz, 1H), 7.32 (s, 1H), 7.20 (d, J = 8.0 Hz, 2H), 7.16 (d, J = 8.4 Hz, 1H), 6.60 (d, J = 3.6 Hz, 1H), 2.32 (s, 3H), 2.16 (s, 6H), 1.27 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 145.0, 137.7, 135.5, 133.8, 130.9, 130.0, 127.0, 126.8, 122.8, 118.4, 113.3, 109.1, 83.6, 53.4, 52.4, 25.0, 21.7.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2965, 1460, 1437, 1407, 1371, 1310, 1247, 1210, 1190, 1168, 1132, 1094, 1078, 854, 813, 725, 707, 666, 588, 540.

**HRMS** (ESI-TOF) calcd for (C<sub>26</sub>H<sub>31</sub>BNO<sub>4</sub>S) [M+H]<sup>+</sup> 464.2067, found 464.2047.

Melting point: 133 - 135 °C.



**2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)benzo[***d***]thia zole** (**5ad**, 29.5 mg, 30%).

Prepared following **GP-G** and purified by C18 column chromatography (85% MeCN/H<sub>2</sub>O). The product was obtained as a white solid.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.94 (d, J = 8.2 Hz, 1H), 7.76 (d, J = 8.3 Hz, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.27 (d, J = 7.5 Hz, 1H), 2.32 (s, 6H), 1.20 (s, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 170.9, 153.8, 135.4, 126.2, 125.1, 123.2, 121.8, 83.8, 54.4, 44.7, 25.0.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.5.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2976, 2909, 2873, 1499, 1436, 1404, 1391, 1372, 1315, 1267, 1242, 1209, 1143, 1017, 930, 891, 854, 759, 730.

**HRMS** (ESI-TOF) calcd for (C<sub>18</sub>H<sub>23</sub>BNO<sub>2</sub>S) [M+H]<sup>+</sup> 328.1543, found 328.1544.

Melting point: 157 - 159 °C.



*tert*-Butyl 3-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)bicyclo[1.1.1]pentan-1-yl)-1*H*-pyrazole-1-carboxylate (5ae, 26.7 mg, 25%).

Prepared following **GP-G** and purified by C18 column chromatography (75% MeCN/H<sub>2</sub>O). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.90 (d, *J* = 2.8 Hz, 1H), 6.18 (d, *J* = 2.8 Hz, 1H), 2.23 (s, 6H), 1.61 (s, 9H), 1.25 (s, 12H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 157.4, 147.7, 131.3, 107.2, 85.2, 83.6, 53.6, 49.8, 28.1, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.2.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2975, 2914, 2871, 1770, 1745, 1512, 1397, 1371, 1353, 1296, 1255, 1215, 1199, 1142, 1049, 960, 854, 842, 768, 666.

**HRMS** (ESI-TOF) calcd for  $(C_{19}H_{30}BN_2O_4)$  [M+H]<sup>+</sup> 361.2299, found 361.2288.



**4,4,5,5-Tetramethyl-2-(3-(oct-1-en-1-yl)bicyclo[1.1.1]pentan-1-yl)-1,3,2-dioxaborolane** (1:1 mixture of E/Z isomers, **5af**, 29.0 mg, 32%).

Prepared following **GP-G** and purified by C18 column chromatography (100% MeCN). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 5.44 (d, J = 15.6 Hz, 0.5H), 5.41 – 5.28 (m, 1H), 5.23 (d, J = 11.3 Hz, 0.5H), 2.12 (q, J = 7.0 Hz, 1H), 2.04 (s, 3H), 1.96 (q, J = 6.8 Hz, 1H), 1.87 (s, 3H), 1.38 – 1.25 (m, 8H), 1.23 (s, 12H), 0.87 (d, J = 6.7 Hz, 3H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 132.5, 131.2, 130.6, 129.3, 83.4, 83.4, 54.9, 52.9, 46.5, 45.2, 32.4, 32.0, 31.9, 30.3, 29.4, 29.2, 29.1, 27.3, 24.9, 22.8, 22.8, 14.3, 14.3.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.2.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2960, 2926, 2868, 1509, 1438, 1406, 1379, 1372, 1345, 1309, 1200, 1145, 1111, 1040, 962, 856, 666.

**HRMS** (EI-TOF) calcd for (C<sub>19</sub>H<sub>33</sub>BO<sub>2</sub>) [M]<sup>+</sup> 304.2574, found 304.2587.

## 5. Procedure for Gram-Scale Synthesis of BCP Bpin

## 5.1 Three-component Borylation with RAE



To a 120 mL ACE pressure tube containing an appropriately-sized stirrer bar was added RAE **1b** (1.00 g, 2.7 mmol, 1 equiv) followed by dry  $B_2pin_2$  (2.03 g, 8.0 mmol, 3 equiv). DMA (27 mL) was then added to allow the solid materials to dissolve. Once dissolved, [1.1.1]propellane (4.01 mL, 4.0 mmol, 1.5 equiv, 1.0 M solution in Et<sub>2</sub>O) was added quickly. The reaction vessel was sparged with argon for 30 s and then sealed with a threaded cap. The reaction mixture was placed between two 52 W 390 nm Kessil LED lamps at 100% power facing each other or between four 52 W 390 nm Kessil<sup>®</sup> LED lamps at 50% power. The lamps were placed 1 inch from the reaction vessel. The reaction was then irradiated under vigorous stirring for 16 h. Room temperature was maintained by the use of two fans. When judged complete (*Note:* after completion, the reaction mixture is generally orange), the mixture was then partitioned between Et<sub>2</sub>O (50 mL) and satd aq NH<sub>4</sub>Cl (50 mL). The organic layer was washed two more times with brine (30 mL × 2), dried (MgSO<sub>4</sub>), filtered, and further dried under vacuum. The crude mixture was then purified by SiO<sub>2</sub> flash column chromatography. (642 mg, 64%)



**Figure S5.** Gram-scale synthesis using 4 Kessil<sup>®</sup> LEDs at 50% power with 2 fans facing each other for cooling



**Figure S6.** Gram-scale synthesis using 2 Kessil<sup>®</sup> LEDs at 100% power with 2 fans facing each other for cooling

#### 5.2 Three-component Borylation with an Organo lodide



To a 120 mL ACE pressure tube containing an appropriately-sized stirrer bar was added *N*-Boc-4-iodopiperidine **2b** (1.50 g, 4.82 mmol, 1 equiv) followed by powder  $K_3PO_4$  (512 g, 2.41 mmol, 0.5 equiv). The reaction vessel was capped with a rubber septum and then was evacuated and backfilled with nitrogen three times. Dry MeOH (30 mL) was then added to the reaction vessel followed by PhMe<sub>2</sub>Si-Bpin (2.53 g, 9.64 mmol, 2.0 equiv). Lastly, [1.1.1]propellane (9.6 mL, 9.6 mmol, 2 equiv, 1.0 M solution in Et<sub>2</sub>O) was added quickly. The reaction vessel was sparged with argon for 30 s and then sealed with a threaded cap. The reaction mixture was placed between four 52 W 390 nm Kessil LED lamps at 100% power. The lamps were placed 1 inch from the reaction vessel. The reaction was then irradiated under vigorous stirring for 16 h. Room temperature was maintained by the use of two fans. When judged complete after 16 h, the mixture was dried under vacuum. The crude mixture was then purified by SiO<sub>2</sub> flash column chromatography. (1.24 g, 68%)



**Figure S7.** Gram-scale synthesis using 4 Kessil<sup>®</sup> LEDs at 100% power with 2 fans facing each other for cooling

# 6. Synthesis and Characterization of BCP Trifluoroborate 6

# 6.1 Synthesis of Organotrifluoroborate 6 from 4k



*tert*-Butyl 4-(3-(Trifluoro-I4-boraneyl)bicyclo[1.1.1]pentan-1-yl)piperidine-1-carboxylate, Potassium Salt 6 was prepared based on modified literature procedures.<sup>26,27</sup> To a stirred soln of boronate ester 4k (377 mg, 1 mmol) in 5 mL of MeOH was added KHF<sub>2</sub> (1 mL of 4.5 M satd aq soln, 9 mmol, 4.5 equiv) dropwise. The reaction mixture was stirred at rt. After 4 h, the solvents were removed under vacuum. The residue was redissolved in a mixture of MeOH/H<sub>2</sub>O (3:2, 10 mL). Volatile materials were removed by evaporation *in vacuo*. The solubilization/evaporation cycle was repeated 10 times to remove all the pinacol. The residue was triturated with acetone (4 mL). The liquid was collected by filtration. The inorganic salt residue was washed with acetone three times (3 X 1 mL). The combined liquid phases were evaporated to afford product (290 mg, 81%) as a white solid.

<sup>1</sup>**H NMR** (400 MHz, DMSO- $d_6$ )  $\delta$  3.93 (d, J = 12.9 Hz, 2H), 2.69 – 2.53 (m, 2H), 1.43 (d, J = 13.2 Hz, 2H), 1.38 (d, J = 1.4 Hz, 9H), 1.25 – 1.17 (m, 1H), 1.15 (s, 6H), 0.83 (qd, J = 12.7, 4.3 Hz, 2H).

<sup>13</sup>**C NMR** (101 MHz, acetone-*d*<sub>6</sub>) δ 154.9, 78.9, 47.6, 47.6, 45.8, 44.5, 39.0, 28.9, 28.4.

<sup>19</sup>**F NMR** (376 MHz, DMSO-*d*<sub>6</sub>) δ -142.2.

<sup>11</sup>**B NMR** (128 MHz, Acetone- $d_6$ )  $\delta$  2.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2923, 2905, 2855, 1682, 1428, 1336, 1237, 1156, 1130, 1109, 1017, 934.

**HRMS** (ESI-TOF) calcd for (C<sub>15</sub>H<sub>24</sub>BF<sub>3</sub>NO<sub>2</sub>) [M-K]<sup>-</sup> 318.1852, found 318.1879.

Melting point: 234 °C (decomposes).

# 6.2 Telescoped Gram-Scale Synthesis of BCP BF<sub>3</sub>K (6)



To a 120 mL ACE pressure tube with an appropriately-sized stirrer bar was added RAE **1b** (2.00 g, 5.3 mmol, 1 equiv) followed by dry  $B_2pin_2$  (4.07 g, 16.0 mmol, 3 equiv). DMA (30 mL) was then added to allow the solid materials dissolve. Once dissolved, [1.1.1]propellane (8.01 mL, 8.0 mmol, 1.5 equiv, 1.0 M solution in Et<sub>2</sub>O) was added quickly. The reaction vessel was sparged with argon for 30 s and then sealed with a threaded cap. The reaction mixture was placed between two 52

W 390 nm Kessil LED lamps at 100% power facing each other. The lamps were placed 1 inch from the reaction vessel. The reaction was then irradiated with vigorous stirring for 16 h. Room temperature was maintained by the use of two fans. After 16 h, the mixture was then partitioned between  $Et_2O$  (50 mL) and satd aq NH<sub>4</sub>Cl (100 mL). The aq phase was washed with  $Et_2O$  (50 mL × 2), and the combined organic layers were washed with brine (50 mL), and then passed through a plug of silica. The filtrate was then concentrated under reduced pressure and further dried under vacuum. The crude, pale-yellow solid material was dissolved in MeOH (40 mL)/H<sub>2</sub>O (20 mL), and then KHF<sub>2</sub> (30 mL, 135 mmol, 25.5 equiv, 4.5 M aq soln) was added dropwise at ambient temperature. The reaction mixture was stirred vigorously at rt for 3 h. After 3 h, the solvents were evaporated to dryness under reduced pressure. The resulting crude material was extracted with hot acetone (3×50 mL), followed by filtration. The combined filtrates were concentrated and then triturated with approximately 100 mL of  $Et_2O$ . The resultant precipitate was collected by vacuum filtration and dried under vacuum to afford BCP BF<sub>3</sub>K (**6**) as a brown solid (1.08 g, 57%). Characterization data matched the data reported in **6.1**.

# 6.3 Cyclic Voltammogram of BCP BF<sub>3</sub>K (6)

Cyclic voltammetry was conducted on a CH Instruments 600E Series Electrochemical Analyzer. Voltammograms were recorded using a glassy carbon working electrode, a platinum counter electrode, and a silver reference electrode in a 0.1 M [<sup>n</sup>Bu<sub>4</sub>N][ClO<sub>4</sub>] supporting electrolyte MeCN solution, with ferrocene as an internal reference ( $E^{0}_{1/2}$  = + 0.40 V vs SCE). Cyclic voltammograms were recorded with a step potential of 0.001 V at a scan rate of 0.2 V/s.



Figure S8. Cyclic voltammetry study on compound 6

Based on the CV result, the oxidation potential of BCP BF<sub>3</sub>K  $\mathbf{6}$  is +1.36 V vs SCE.

# 7. Post-functionalizations

# i) Hydro-alkylation with Acrylonitrile



In a sealable tube was added Ir[dF(CF<sub>3</sub>)ppy]<sub>2</sub>(bpy)PF<sub>6</sub> (4.3 mg, 0.0043 mmol, 0.02 equiv), BCP BF<sub>3</sub>K **6** (71.5 mg, 0.2 mmol, 1 equiv), acrylonitrile (31.8 mg, 39.5  $\mu$ L, 0.6 mmol, 3 equiv), Na<sub>2</sub>HPO<sub>4</sub> (85.2 mg, 0.600 mmol, 3 equiv), and THF (2 mL). The mixture was irradiated with a 34 W blue LED for 16 h. Solvent was removed *in vacuo*, and the crude material was purified by column chromatography (25% EtOAc/hexanes). The product was obtained as a colorless oil. (7, 38.0 mg, 77%)



# tert-Butyl 4-(3-(2-Cyanoethyl)bicyclo[1.1.1]pentan-1-yl)piperidine-1-carboxylate

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 4.10 (d, J = 12.7 Hz, 2H), 2.62 (t, J = 12.9 Hz, 2H), 2.27 (t, J = 7.3 Hz, 2H), 1.81 (t, J = 7.3 Hz, 2H), 1.55 - 1.52 (m, 2H), 1.51 (s, 6H), 1.49 – 1.45 (m, 1H), 1.44 (s, 9H), 1.04 (qd, J = 12.6, 4.4 Hz, 2H).

 $^{13}\textbf{C}$  NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  154.9, 120.0, 79.4, 47.9, 43.8, 42.8, 37.8, 36.5, 28.6, 28.4, 27.8, 14.6.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2962, 2928, 2865, 1687, 1478, 1422, 1365, 1324, 1289, 1255, 1234, 1173, 1149, 1112,1093, 1013, 984, 871.

**HRMS** (ESI-TOF) calcd for (C<sub>18</sub>H<sub>28</sub>NaN<sub>2</sub>O<sub>2</sub>) [M+Na]<sup>+</sup> 327.2048, found 327.2047.

## ii) Hydro-alkylation with Dehydroalanine



In a sealable tube was added  $Ir[dF(CF_3)ppy]_2(bpy)PF_6$  (4.3 mg, 0.0043 mmol, 0.02 equiv), BF<sub>3</sub>K **6** (71.5 mg, 0.2 mmol, 1 equiv), methyl 2-(bis(*tert*-butoxycarbonyl)amino)acrylate (39.5  $\mu$ L, 0.6 mmol, 3 equiv) and Na<sub>2</sub>HPO<sub>4</sub> (28.4 mg, 0.200 mmol, 1 equiv) in THF (2 mL). The mixture was

irradiated with blue LEDs for 16 h. Solvent was removed *in vacuo*, and the crude was purified by column chromatography (25% EtOAc/hexanes). The product was obtained as a colorless oil (**8**, 54.7 mg, 48%).



#### *tert*-Butyl 4-(3-(2-(bis(tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)bicyclo[1.1.1]

#### pentan-1-yl)piperidine-1-carboxylate

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 4.91 (dd, J = 9.8, 4.5 Hz, 1H), 4.09 (s, 2H), 3.69 (s, 3H), 2.61 (s, 2H), 2.29 (dd, J = 15.1, 4.6 Hz, 1H), 2.07 (dd, J = 15.1, 9.8 Hz, 1H), 1.53-1.47 (m, 20H), 1.46 (d, J = 1.9 Hz, 6H), 1.44 (s, 9H), 1.42-1.37 (m, 1H), 1.07 – 0.96 (m, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 171.7, 155.0, 152.1, 83.1, 79.3, 56.7, 52.3, 48.6, 43.8, 43.0, 36.8, 36.7, 32.0, 28.6, 28.5, 28.2.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2976, 2932, 2865, 1747, 1695, 1423, 1366, 1273, 1234, 1173, 1152, 1128, 1035, 942, 873, 850, 811, 769.

**HRMS** (ESI-TOF) calcd for (C<sub>29</sub>H<sub>48</sub>NaN<sub>2</sub>O<sub>8</sub>) [M+Na]<sup>+</sup> 575.3308, found 575.3291.

#### iii) Minisci reaction



Following the reported procedure in the literature<sup>28</sup>: In a scintillation vial were added to a soln of methyl isoquinoline-3-carboxylate (20.6 mg, 0.110 mmol, 1.1 equiv) in MeCN/H<sub>2</sub>O (1 mL, 1:1) trifluoroacetic acid (8  $\mu$ L, 0.11 mmol, 1.1 equiv) followed by 4-CzIPN (4.0 mg, 0.005 mmol, 0.05 equiv), K<sub>2</sub>S<sub>2</sub>O<sub>8</sub> (54 mg, 0.200 mmol, 2 equiv) and compound **6** (35.7 mg, 0.100 mmol, 1 equiv). The mixture was allowed to stir at rt under the irradiation of a compact fluorescent light bulb (24 W CFL). After 48 h, a satd aq soln of NaHCO<sub>3</sub> was added, and the mixture was removed *in vacuo*. The crude material was purified by column chromatography (40% EtOAc/hexanes). The product was obtained as a colorless oil. (**9**, 13 mg, 30%)



# Methyl 1-(3-(1-(*tert*-Butoxycarbonyl)piperidin-4-yl)bicyclo[1.1.1]pentan-1-yl)isoquinoline-3-carboxylate

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 8.49 (d, *J* = 8.0 Hz, 1H), 8.45 (s, 1H), 7.95 (d, *J* = 7.7 Hz, 1H), 7.77 – 7.68 (m, 2H), 4.19 (d, *J* = 12.5 Hz, 2H), 4.02 (s, 3H), 2.71 (t, *J* = 13.0 Hz, 2H), 2.31 (s, 6H), 1.75 – 1.65 (m, 3H), 1.47 (s, 9H), 1.21 (dd, *J* = 12.5, 4.3 Hz, 2H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 166.5, 159.2, 154.9, 140.6, 136.0, 130.3, 128.9, 128.8, 128.7, 126.2, 123.3, 79.3, 52.7, 51.5, 43.7, 42.9, 36.4, 28.4, 28.3. (1C missing)

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 1737, 1717, 1685, 1445, 1423, 1392, 1296, 1274, 1232, 1202, 1171, 1146, 1096, 993, 793, 775, 749, 734.

**HRMS** (ESI-TOF) calcd for (C<sub>26</sub>H<sub>33</sub>N<sub>2</sub>O<sub>4</sub>) [M+H]<sup>+</sup> 437.2440, found 437.2421.

# iv) Photoredox Chan-Lam C-N Coupling

#### **Reaction Optimizations and Control Experiments**



To an 8 mL reaction vial equipped with a stirrer bar was added **6** (35.7 mg, 0.1 mmol, 2 equiv), 5bromo-1*H*-indole (9.8 mg, 0.05 mmol, 1 equiv),  $Ir[dF(CF_3)ppy]_2(bpy)PF_6$  (1.0 mg, 0.001 mmol, 2 mol%),  $Cu(acac)_2$  (6.5 mg, 0.025 mmol, 50 mol%), base (0.15 mmol, 3 equiv) and dioxane (1 mL, 0.1 M). The vial was then sealed with a cap containing a TFE-lined silicone septum with an 18 G needle as air inlet. The reaction mixture was then irradiated under vigorous stirring at 34 W 456 nm using a Kessil lamp at 1 inch distance for 4 h. Room temperature was maintained by the use of fans. When judged complete the crude mixture had turned into a dark color, and the crude material was passed through a pad of Celite<sup>®</sup> and eluted with another 10 mL of acetone. The filtrate was concentrated under reduced pressure and purified by SiO<sub>2</sub> column chromatography.

Entry	Base	Yield (%)			
1	TMG	23			
2	BTMG	16			
3	Cs <sub>2</sub> CO <sub>3</sub>	83			
Ľ	Derivation from Entry 3				
4	No light	0			
5	No [lr] catalyst	0			

Table S4: Reaction optimizations of the photoredox Chan-Lam coupling

\*TMG = 1,1,3,3-BTMG = 2-*tert*-butyl-1,1,3,3-tetramethylguanidine

tetramethylguanidine

## Procedure for Chan-Lam C-N Coupling



To an 8 mL reaction vial equipped with a stirrer bar was added **6** (35.7 mg, 0.1 mmol, 2 equiv), 5bromo-1*H*-indole (9.8 mg, 0.05 mmol, 1 equiv),  $Ir[dF(CF_3)ppy]_2(bpy)PF_6$  (1.0 mg, 0.001 mmol, 2 mol %),  $Cu(acac)_2$  (6.5 mg, 0.025 mmol, 50 mol %),  $Cs_2CO_3$  (48.9 mg, 0.15 mmol, 3 equiv) and dioxane (1 mL, 0.1 M). The vial was then sealed with a cap containing a TFE-lined silicone septum with an 18 G needle as an air inlet. The reaction mixture was then irradiated under vigorous stirring at 34 W 456 nm using a Kessil lamp at 1 inch distance for 4 h. Room temperature was maintained by the use of fans. When judged complete, the crude mixture had turned into a dark color, and the crude material was passed through a pad of Celite<sup>®</sup> and eluted with another 10 mL of acetone. The filtrate was concentrated under reduced pressure and purified by SiO<sub>2</sub> column chromatography. (**10**,18.5 mg, 83%)

*Note*: The surface area and the head space in the reaction vial are important for maintaining good reaction efficiency for this heterogeneous reaction. In this case, the 8 mL reaction vial is optimal for performing reaction at 0.05 mmol scale, and performing a larger scale in this vial resulted in dramatically reduced yield.



## tert-Butyl 4-(3-(5-Bromo-1H-indol-1-yl)bicyclo[1.1.1]pentan-1-yl)piperidine-1-carboxylate

Purified by  $SiO_2$  column chromatography (10% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.72 (d, J = 1.9 Hz, 1H), 7.37 (d, J = 8.7 Hz, 1H), 7.25 (d, J = 1.9 Hz, 1H), 7.04 (d, J = 3.2 Hz, 1H), 6.39 (d, J = 3.2 Hz, 1H), 4.18 (br, 2H), 2.69 (br, 2H), 2.20 (s, 6H), 1.75 – 1.69 (m, 1H), 1.69 – 1.63 (m, 2H), 1.47 (s, 9H), 1.21 – 1.14 (m, 2H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  155.0, 134.6, 131.1, 127.5, 124.6, 123.6, 113.1, 112.4, 101.1, 79.6, 51.1, 49.7, 43.8, 40.1, 35.4, 28.7.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2974, 2916, 2872, 1689, 1518, 1460, 1424, 1391, 1365, 1323, 1291, 1276, 1236, 1215, 1173, 1155, 1096, 884, 755, 719.

**HRMS** (ESI-TOF) calcd for  $(C_{23}H_{30}BrN_2O_2)$  [M+H]<sup>+</sup> 445.1491, found 445.1475.

## v) Dicarbofunctionalization of Alkene



Following the reported procedure in the literature<sup>29</sup>: in a scintillation vial, under inert atmosphere was added Ni(bpy)Br<sub>2</sub> (4.1 mg, 0.011 mmol, 0.05 equiv), Ir[dF(CF<sub>3</sub>)ppy<sub>2</sub>(bpy)]PF<sub>6</sub> (4.4 mg, 0.004 mmol, 0.02 equiv), BCP BF<sub>3</sub>K **6** (118 mg, 0.33 mmol, 1.5 equiv), 4-bromobenzonitrile (40.0 mg, 0.220 mmol, 1 equiv) and dried K<sub>2</sub>HPO<sub>4</sub> (115 mg, 0.660 mmol, 3 equiv). The vial was evacuated and backfilled with argon three times. Distilled THF (2 mL) was added followed by vinyl-Bpin (67.8 mg, 75  $\mu$ L, 0.440 mmol, 2 equiv). The reaction vessel was sealed and irradiated with blue LEDs for 16 h. The solvent was then removed under vacuum, and the crude product was purified by column chromatography (20% EtOAc/hexanes). The product was obtained as a colorless oil (**11**, 45.0 mg, 41%).



# *tert*-Butyl 4-(3-(2-(4-Cyanophenyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) ethyl)bicyclo[1.1.1]pentan-1-yl)piperidine-1-carboxylate

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ7.51 (d, J = 8.3 Hz, 2H), 7.28 (d, J = 8.3 Hz, 2H), 4.08 (t, J = 7.0 Hz, 2H), 2.60 (d, J = 16.6 Hz, 2H), 2.41 (t, J = 7.6 Hz, 1H), 2.07 (dd, J = 14.1, 8.0 Hz, 1H), 1.83 (dd, J = 14.0, 7.3 Hz, 1H), 1.65 (d, J = 9.1 Hz, 1H), 1.43 (s, 9H), 1.35 – 1.27 (m, 6H), 1.24 (t, J = 1.9 Hz, 2H), 1.14 (d, J = 7.1 Hz, 12H), 0.99 (dt, J = 12.7, 6.3 Hz, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 155.0, 149.8, 132.1, 128.9, 119.5, 108.9, 83.8, 79.3, 48.4, 42.8, 39.0, 36.6, 33.7, 28.6, 28.5, 24.7, 24.7.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 31.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2974, 2863, 2227, 1691, 1606, 1423, 1365, 1329, 1236, 1170, 1145, 825. **HRMS** (ESI-TOF) calcd for (C<sub>30</sub>H<sub>44</sub>BN<sub>2</sub>O<sub>4</sub>) [M+H]<sup>+</sup> 507.3394, found 507.3387.

#### 8. Mechanistic Investigations

8.1 Studies of Radicals with Varied s Character

## 8.1.1 Competition Experiments of Radicals with B<sub>2</sub>pin<sub>2</sub>



To a 4 mL reaction vial equipped with a stirrer bar was added RAE (**1a/b/c/d/e**) (0.1 mmol, 1 equiv), RAE **1f** (25.4 mg, 0.1 mmol, 1 equiv) and dry  $B_2pin_2$  (25.4 mg, 0.1 mmol, 1 equiv). The reaction vessel was sealed with a cap containing a TFE-lined silicone septum and then was evacuated and backfilled with argon three times. When done, degassed DMA (1 mL, 0.1 M) was added, and then the vial was quickly sealed with Parafilm<sup>®</sup>. The reaction mixture was then irradiated under vigorous stirring at one 52 W 390 nm using a Kessil lamp at 1 inch distance for 16 h. Room temperature was maintained by the use of two fans. After 16 h, the mixture was partitioned between Et<sub>2</sub>O (10 mL) and satd aq NH<sub>4</sub>Cl (10 mL). The organic layer was washed two more times with brine (10 mL × 2), dried (MgSO<sub>4</sub>), filtered, and further dried under vacuum. The yield of each product as well as the remaining starting materials (RSM) was determined by <sup>1</sup>H NMR using 1,3,5-trimethoxybenzene as an internal standard.

Table S5.	Competition	Experiment	Data with	B <sub>2</sub> pin <sub>2</sub>
-----------	-------------	------------	-----------	---------------------------------

	R-Bpin/%	RSM <b>1a</b> /%	BCP-Bpin/%	RSM 1f/%
RAE 1a	0	46.5	30.5	3.5
RAE 1b	0	67.5	24.3	10.5
RAE 1c	11.3	21.8	35.5	4.3
RAE 1d	22.5	0	22.2	2.8
RAE 1e	50.8	12.8	20.0	9.8



#### 8.1.2 Competition Experiments of Radicals with B<sub>2</sub>cat<sub>2</sub>



To a 4 mL reaction vial equipped with a stirrer bar was added RAE (**1a/b/c/d/e**) (0.1 mmol, 1 equiv), RAE **1f** (25.4 mg, 0.1 mmol, 1 equiv) and dry  $B_2cat_2$  (23.8 mg, 0.1 mmol, 1 equiv). The reaction vessel was sealed with a cap containing a TFE-lined silicone septum and then was evacuated and backfilled with argon three times. When done, degassed DMA (1 mL, 0.1 M) was added, and then the vial was quickly sealed with Parafilm<sup>®</sup>. The reaction mixture was then irradiated under vigorous stirring at one 45 W 427 nm using a Kessil lamp at 1 inch distance for 16 h. Room temperature was maintained by the use of two fans. After 16 h, the mixture was added pinacol (47.2 mg, 0.4 mmol, 4 equiv) and NEt<sub>3</sub> (1 mL). The mixture was allowed to stir under dark for 1 h. It was then partitioned between  $Et_2O$  (10 mL) and satd aq NH<sub>4</sub>Cl (10 mL). The organic layer was washed two more times with brine (10 mL × 2), dried (MgSO<sub>4</sub>), filtered, and further dried under vacuum. The yield of each product as well as the remaining starting materials (RSM) was determined by <sup>1</sup>H NMR using 1,3,5-trimethoxybenzene as an internal standard.

	R-Bpin/%	RSM <b>1a</b> /%	BCP-Bpin/%	RSM <b>1f</b> /%
RAE 1a	0	0	19.8	1.5
RAE 1b	0	9.0	34.5	0.5
RAE 1c	7.0	8.3	20.0	1.3
RAE 1d	7.5	0	4.0	1.8
RAE 1e	34.0	4.0	18.3	1.5

Table S6. Competition Experiment Data with B<sub>2</sub>cat<sub>2</sub>



#### 8.1.3 Reactivity of Radicals with B<sub>2</sub>pin<sub>2</sub>



To a 4 mL reaction vial equipped with a stirrer bar was added RAE **1** (0.1 mmol, 1 equiv) followed by dry  $B_2pin_2$  (76.1 mg, 0.3 mmol, 3 equiv). The reaction vessel was sealed with a cap containing a TFE-lined silicone septum and then was evacuated and backfilled with argon three times. When done, degassed DMA (1 mL, 0.1 M) was added, and then the vial was quickly sealed with Parafilm<sup>®</sup>. The reaction mixture was then irradiated under vigorous stirring at 52 W 390 nm using a Kessil lamp at 1 inch distance for 16 h. Room temperature was maintained by the use of two fans. After 16 h, the mixture was partitioned between Et<sub>2</sub>O (10 mL) and satd aq NH<sub>4</sub>Cl (10 mL). The organic layer was washed two more times with brine (10 mL × 2), dried (MgSO<sub>4</sub>), filtered, and further dried under vacuum. The yield was determined by <sup>1</sup>H NMR using 1,3,5-trimethoxybenzene as an internal standard.



Figure S9. Reactivity studies of radicals bearing different s character with Bpin acceptor

For radicals with little to no angle strain, the reactivity shows a similar trend to that demonstrated in Li's work,<sup>11</sup> with diminished yields mainly due to a difference in solvents. When the angle strain significantly increased, the efficiency of borylation increased by the degree of angle strain. The results here demonstrated that a higher *s* character in the radical center induced by angle strain can lead to more favorable borylation with B<sub>2</sub>pin<sub>2</sub>.

#### 8.2 TEMPO-trapping Experiments

#### 8.2.1 With RAE:

A TEMPO trapping experiment was carried out using RAE **1b** by following **GP-B**, with the addition of 2 equiv of TEMPO. After 16 h, the reaction was analyzed by LC-MS, and only *N*-Boc-piperidine-TEMPO adduct **12** was found while BCP Bpin **4k** was not present.



Figure S10. a) MS ES+ TIC spectra of 4k; b) MS ES+ TIC spectra of the crude mixture with TEMPO showing no formation of product and remaining starting material; c) MS ES+ at 0.877 min, mass detected

341.472, [M+H]<sup>+</sup> calculated: 341.516 d) MS ES+ at 1.502 min, the mass does not correspond to the mass of 4k

#### 8.2.2 With organohalide:

A TEMPO trapping experiment was carried out using RAE **1b** by following **GP-E**, with the addition of 2 equiv of TEMPO. After 16 h, the reaction was analyzed by LC-MS, and only *N*-Boc-piperidine-TEMPO adducts werefound while BCP-Bpin **4k** was not found.



**Figure S11.** a) MS ES+ TIC spectra of **4j**; b) MS ES+ TIC spectra of the crude mixture with TEMPO showing no formation of product and remaining starting material; c) MS ES+ at 0.859 min, mass detected 341.496, [M+H]<sup>+</sup> calculated: 341.516

## 8.3 Radical Clock Experiments

## 8.3.1 Radical Clock Experiments with RAE

To study the rate of addition of the alkyl radical to propellane, two redox active ester radical clocks were synthesized from the corresponding carboxylic acids.

## **Radical ring opening**



1 equiv

Radical clock experiment with RAE 1i followed GP-B. Only ring-opened product 13 was found.



**2-(3-(But-3-en-1-yl)bicyclo[1.1.1]pentan-1-yl)-4,4,5-trimethyl-1,3,2-dioxaborolane** (**13**, 43.0 mg, 58%).

Prepared following **GP-B** and purified by column chromatography (10% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 5.87 – 5.74 (m, 1H), 4.98 (dt, J = 17.1, 2.0 Hz, 1H), 4.90 (d, J = 10.2 Hz, 1H), 1.98 (q, J = 7.4 Hz, 2H), 1.74 (s, 6H), 1.42 (td, J = 7.7, 1.5 Hz, 2H), 1.25 – 1.19 (m, 12H).

<sup>13</sup>**C NMR** (151 MHz, CDCl<sub>3</sub>) δ 139.3, 114.1, 83.3, 51.6, 46.1, 32.5, 30.6, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2977, 2868, 1778, 1475, 1452, 1372, 1328, 1251, 1217, 1167, 1144, 1083, 1009, 981, 952, 925, 851, 697, 673.

**HRMS** (EI-TOF) calcd for (C<sub>14</sub>H<sub>22</sub>BO<sub>2</sub>) [M-CH<sub>3</sub>]<sup>+</sup> 233.1713, found 233.1724.

#### **Radical cyclization**



Radical clock experiment with RAE S-1ag followed GP-B. Only ring-opened product was found.



**2-(3-(2-Allylbenzyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (S-4a, 41.0 mg, 42%).

Prepared following **GP-B** and purified by column chromatography (5% EtOAc/hexanes). The product was obtained as a colorless oil.

<sup>1</sup>**H NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.14 – 7.09 (m, 3H), 7.03 – 7.00 (m, 1H), 5.93 (ddt, J = 16.7, 10.1, 6.4 Hz, 1H), 5.06 – 5.02 (m, 1H), 4.98 (dt, J = 17.1, 1.8 Hz, 1H), 3.37 – 3.33 (m, 2H), 2.71 (s, 2H), 1.71 (s, 6H), 1.20 (s, 12H).

 $^{13}\textbf{C}$  NMR (151 MHz, CDCl\_3)  $\delta$  137.8, 137.5, 130.4, 129.4, 126.1, 126.1, 115.7, 83.3, 51.7, 45.9, 37.1, 37.0, 24.8. 1C missing

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.1.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2972, 2905, 2868, 1475, 1450, 1372, 1328, 1273, 1251, 1216, 1193, 1166, 1144, 1079, 1008, 981, 913, 851, 754, 672.

**HRMS** (EI-TOF) calcd for  $(C_{21}H_{29}BO_2)$  [M]<sup>+</sup> 324.2261, found 324.2282.

## 8.3.2 Radical Clock Experiment with Organohalide



Radical clock experiment with the organobromide followed **GP-F**. Only 5-exo-trig cyclized product **15** was found.



**2-(3-(Cyclopentylmethyl)bicyclo[1.1.1]pentan-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane** (**15**, 14.4 mg, 16%).

Prepared following **GP-F** and purified by column chromatography (5% EtOAc/hexanes). The product was obtained as a clear oil.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 1.82 – 1.70 (m, 9H), 1.58 – 1.51 (m, 2H), 1.50 – 1.42 (m, 2H), 1.35 (d, *J* = 5.9 Hz, 2H), 1.23 (s, 12H), 1.09 – 0.96 (m, 2H).

<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 83.3, 52.4, 46.5, 40.2, 37.8, 33.4, 25.5, 24.9.

<sup>11</sup>**B NMR** (128 MHz, CDCl<sub>3</sub>) δ 30.3.

**FT-IR** (cm<sup>-1</sup>, neat, ATR) 2954, 2904, 2866, 1511, 1435, 1405, 1390, 1379, 1371, 1345, 1307, 1275, 1197, 1166, 1145, 1111, 1033, 960, 856, 666.

**HRMS** (EI-TOF) calcd for (C <sub>17</sub>H<sub>26</sub>BO<sub>2</sub>) [M-CH<sub>3</sub>]<sup>+</sup> 261.2026, found 261.2005.

#### Comments:

These experiments, along with the 5-exo-trig cyclization result of **4ad**, gave us useful information about the rate of addition of alkyl radical to [1.1.1]propellane.



Scheme S1. Values for the radical clock used in our experiments<sup>30</sup>

Given the above values (Scheme S1), the bimolecular process of radical addition onto [1.1.1]propellane appears to be faster than the unimolecular cyclization of the benzylic radical but slower than the cyclization of the hexenyl radical and ring-opening of cyclopropylmethyl radical. The addition to [1.1.1]propellane is comparable to radical additions to substituted alkenes at room temperature.

#### 8.4 UV-vis Studies

UV/vis Absorption spectra were measured in a 1 cm quartz cuvette using a JASCO-V-650 spectrophotometer. Absorption spectra of individual reaction components and mixtures thereof were recorded at 20 °C in the range of 300-700 nm [temperature controlled by a Peltier (Koolance liquid cooling system)].

#### 8.4.1 For the RAEs:



The stock solutions were prepared as following:

- 0.1 M RAE 1b in DMA/Et<sub>2</sub>O (10:1) mixture
- 0.3 M B<sub>2</sub>pin<sub>2</sub> **3a** in DMA/Et<sub>2</sub>O (10:1) mixture
- Solution of **1b** (0.1 M) and **3a** (0.3 M) in DMA/Et<sub>2</sub>O (10:1) mixture





The stock solutions were prepared as following:

- 0.01 M RAE **1b** in DMA/Et<sub>2</sub>O (10:1) mixture
- 0.03 M B<sub>2</sub>pin<sub>2</sub> **3a** in DMA/Et<sub>2</sub>O (10:1) mixture
- Solution of **1a** (0.01 M) and **3a** (0.03 M) in DMA/Et<sub>2</sub>O (10:1) mixture





The stock solutions were prepared as following:

- 0.001 M RAE **1b** in DMA/Et<sub>2</sub>O (10:1) mixture
- 0.003 M B<sub>2</sub>pin<sub>2</sub> **3a** in DMA/Et<sub>2</sub>O (10:1) mixture
- Solution of 1a (0.001 M) and 3a (0.003 M) in DMA/Et<sub>2</sub>O (10:1) mixture

\*Due to the high molar absorptivity of RAE **1b**, all experiments used diluted solutions to avoid saturation of UV-vis signals.





The stock solutions were prepared as following:

- Pure Et<sub>2</sub>O
- 10:1 DMA:Et<sub>2</sub>O
- Pure DMA

The solvents show no noticeable absorption comparing with the absorption of the reaction mixture.

# 8.4.2 For the alkyl halides:



The stock solutions were prepared as following:

- 0.1 M **2b** in MeOH/Et<sub>2</sub>O (10:1) mixture
- 0.2 M Me<sub>2</sub>PhSiBpin **3b** in MeOH/Et<sub>2</sub>O (10:1) mixture
- Solution of **2b** (0.1 M) and **3b** (0.2 M) in MeOH/Et<sub>2</sub>O (10:1) mixture



#### 8.4.3 For the aryl halides:



- 1 M 4-iodobenzonitrile (Arl) in MeOH/Et<sub>2</sub>O (10:1) mixture
- 2 M PhMe<sub>2</sub>SiBpin **3b** in MeOH/Et<sub>2</sub>O (10:1) mixture
- Solution of 4-iodobenzonitrile (ArI) (1 M) and **3b** (2 M) in MeOH/Et<sub>2</sub>O (10:1) mixture

\*Et<sub>2</sub>O were added to maintain the dielectric constant of the reaction mixtures.

\*Because of the low molar absorptivity of the aryl iodide, all experiments used concentrated solutions to obtain better UV-vis signals.



## 8.5 Influence of Through-space Interactions on Chemoselectivity

To a 4 mL reaction vial equipped with a stirrer bar was added BCP RAE (0.3 mmol, 1 equiv) followed by dry  $B_2pin_2$  (91.4 mg, 0.36 mmol, 1.2 equiv). The reaction vessel was sealed with a cap containing a TFE-lined silicone septum and then was evacuated and backfilled with argon three times. When done, degassed DMA (3 mL, 0.1 M) was added, and [1.1.1]propellane (0.75 mL, 0.9 mmol, 3 equiv, 1.2 M solution in Et<sub>2</sub>O) was added quickly. The vial was quickly sealed with Parafilm<sup>®</sup>. The reaction mixture was then irradiated under vigorous stirring at 52 W 390 nm using a Kessil lamp at 1 inch distance for 16 h. Room temperature was maintained by the use of two fans. After 16 h, the mixture was partitioned between Et<sub>2</sub>O (10 mL) and satd aq NH<sub>4</sub>Cl (10 mL). The organic layer was washed two more times with brine (10 mL × 2), dried (MgSO<sub>4</sub>), filtered, and further dried under vacuum. The NMR yields of **17**, **18** and **19** are determined by <sup>1</sup>H NMR using 1,3,5-trimethoxybenzene as an internal standard. **4w** was isolated by C18 chromatography.

#### Note:

- 1. The stoichiometry of [1.1.1]propellane and  $B_2pin_2$  were modified to increase the yield of 4w.
- 2. In <sup>1</sup>H NMR, only [1.1.1]propellane monomer and dimer [2]staffane were observed.

Results show that the electronic properties of substituents on the BCP radicals have a profound impact on the chemoselectivity of BCP radical borylation vs. oligomerization. In both cases, only monomer and dimer were observed, with no other oligomer noticeable by <sup>1</sup>H NMR. We reason that the C<sub>1</sub> substituent on the BCP radical affects the C<sub>1</sub>-C<sub>3</sub> distance,<sup>31</sup> which ultimately affects the electrophilicity through transannular effect and the geometry and hybridization of the BCP radical. Further investigations are necessary to elucidate the reason behind this observation. We hypothesize that when C<sub>1</sub> is an electron-withdrawing group, the BCP radical is more electrophilic by the transannular interaction and we think the increased electrophilicity in BCP radical leads to favorable addition to the electron-rich [1.1.1]propellane. Once the [2]staffanyl radical is formed, the electron-withdrawing group has less influence on the radical because of the elongated distance, and [2]staffanyl radical would not tend to add to another [1.1.1]propellane but forms [2]staffanyl Bpin as the product.

## 8.6 Kinetic Studies

Because there is no pre-added Lewis base other than solvent DMA when use  $B_2pin_2$  **3a** as boron reagent, the species serving as a Lewis base in the reaction mixture was uncertain at first. In control experiments (Table S1.), we have shown that DMA-boryl radical is not an on-cycle species because non-amide type solvents also give product formation, and the reaction cannot be carried out under thermal conditions. We propose that the phthalimide anion, derived from the reaction by-product, is the Lewis base promoting the reaction. Kinetic studies on the effect of phthalimide anion were conducted:

#### Procedure:

To a 4 mL reaction vial equipped with a stirrer bar was added RAE **1b** (37.4 mg, 0.1 mmol, 1.0 equiv),  $B_2pin_2$  **3a** (76.2 mg, 0.3 mmol, 3 equiv), and potassium phthalimide (KPhth). The reaction vessel was sealed with a cap containing a TFE-lined silicone septum and then was evacuated and backfilled with argon three times. Once done, dry DMA (1 mL) was added, followed by [1.1.1]propellane (0.15 mmol, 1.5 equiv). The vessel was sealed with Parafilm<sup>®</sup> and placed in a sonicator for 1 min to make a suspension. It was then irradiated with a 52 W 390 nm LED for specific amounts of time at a distance of ~2 cm. The reaction was maintained at room temperature via two fans. Once done, the vessel was removed from the light source, and the NMR internal standard 1,3,5-trimethoxybenzene (0.05 mmol, 8.4 mg) was added. The reaction mixture was poured into 10 mL of satd aq NH<sub>4</sub>Cl. The aq phase was extracted with Et<sub>2</sub>O (2 x 5 mL) and the combined organic layers were dried by a plug of Na<sub>2</sub>SO<sub>4</sub>. The dried organic solution was concentrated under reduced pressure, and the yield of product is determined by <sup>1</sup>H NMR against 1,3,5-trimethoxybenzene. Each data point represents the average of two parallel runs.

KPhth/mol% time/min yield/%	0	5	10	20
5	0			
10	1	9	25	31
20	4			
25	12			
30	20	35	49	67

Table S	<b>57</b> .	Data	of	initial	product	formation
over time	е					



Figure S12. Plot of initial rates vs. the amount of potassium phthalimide indicates the participation of phthalimide in this multi-component borylation

#### **Results:**

Initial rates are calculated based on < 30% product formation. Linear regression shows that the initial rates have a positive correlation with the amount of phthalimide anion in the reaction mixture. Because the rate enhancement by the phthalimide anion is very significant, we propose that phthalimide anion, which can exist in equilibrium with adventitious water, can serve as the Lewis base to stabilize boryl radical and sustain the chain propagation.

# 8.7 <sup>11</sup>B NMR Studies

<sup>11</sup>B NMR studies with  $B_2pin_2$  (0.1 M) suggest that there is no noticeable interaction between  $B_2pin_2$ and DMA (Figure S13i), because the <sup>11</sup>B signal is identical to the control (Figure S13ii). Adding RAE **1b** (0.1 M), which makes a 1:1 ratio of  $B_2pin_2$  **3a** and **1b** in DMA, also did not lead to a noticeable change in the <sup>11</sup>B NMR signal (Figure S13iii). This suggests that under the reaction conditions, there is no interaction between  $B_2pin_2$  and **1b**, which confirms the UV-Vis studies that there is no EDA complex formation between  $B_2pin_2$  and **1b**. To confirm our proposed idea that the phthalimide anion could serve as a base to form ate complex with  $B_2pin_2$ , a 0.1 M  $B_2pin_2$  solution in DMA with 10 mol% of potassium phthalimide was prepared, and a sharp peak was found at 6.9 ppm with slight peak broadening at ~35 ppm (Figure S13iv), suggesting the formation of phthalimide-  $B_2pin_2$  ate complex.



Figure S13. <sup>11</sup>B NMR data with RAE and B<sub>2</sub>pin<sub>2</sub>

\*The small sharp peaks at ~20 ppm are assigned to HO-Bpin, which is probably formed by air oxidation of  $B_2pin_2$  during sample preparations since the peaks are in all cases.

\*For ii, iii and iv, 10% of CDCl<sub>3</sub> was added for lock and shim.

<sup>11</sup>B NMR studies with Me<sub>2</sub>PhSiBpin **3b** (0.1 M) give a similar result. There is no noticeable interaction between **3b** and MeOH (Figure S14i) because the <sup>11</sup>B signal is identical to the control (Figure S14ii). Addition of alkyl iodide **2b** does not lead to a change in <sup>11</sup>B NMR signal (Figure S14iii). This suggests that under the reaction condition, there is no interaction between **3b** and

**2b**, which confirms the UV-Vis studies that there is no EDA complex formation between **3b** and **2b**. Lastly, adding 100 mol % of  $K_3PO_4$  to 0.1 M **3b** in MeOH (0.1 M) results in a change in the <sup>11</sup>B NMR signal by forming sharp peaks at 4.9 ppm and 2.4 ppm (Figure S14iv). This is indicative of ate complexes of **3b**. The two peaks are likely to be  $K_3PO_4$ -**3b** and MeOK-**3b** (small amount of methoxides are from deprotonation of MeOH by  $K_3PO_4$ ). Because control studies suggest the ate complex cannot reduce organohalides in the reaction (Table S3), these ate-complexes are likely to be off-cycle species.



Figure S14. <sup>11</sup>B NMR data with organohalide and boronate 3b

\*The small sharp peaks at ~20 ppm are assigned to HO-Bpin, which is probably formed by air oxidation of  $B_2pin_2$  during sample preparations because the peaks are in all samples.

## 8.8 Determinations of Quantum Yields

## Photon flux measurement:

We determined the photon flux of a 52 W PR160 390nm Kessil lamp by standard ferrioxalate actinometry following a procedure reported in the literature<sup>32</sup>:

- 0.15 M ferrioxalate solution: dissolving 1.811 g of potassium ferrioxalate trihydrate in 0.05 M H<sub>2</sub>SO<sub>4</sub> by using a 25.0 mL volumetric flask. During the preparation, the flask was protected from light using aluminum foil, and the solution was stored in the dark.
- Buffer solution: dissolving 28.5 mg phenanthroline hydrate and 5.855 g of sodium acetate in 0.5 M H<sub>2</sub>SO<sub>4</sub> by using a 25.0 mL volumetric flask.

#### Determination of the absorbance of the irradiated solution:

A vial containing 3 mL of the ferrioxalate solution was irradiated by a 52 W 390 nm Kessil LED for 60 seconds at 1 inch distance. After, 1 mL of this solution was taken to a vial covered with aluminum foil containing 1 mL of the buffer solution and 4 mL of distilled water. The mixture was stirred in the dark for 1 h to allow complexation. The absorbance of the solution was measured at 510 nm.

#### Determination of the absorbance of the non-irradiated solution:

In a vial protected from light covered with aluminum foil was added 1 mL of the ferrioxalate solution, 1 mL of the buffer solution, and 4 mL of  $H_2O$ . The mixture was stirred in the dark for 1 h. The absorbance of the solution was measured at 510 nm.

#### Absorbance curves

To ensure reproducibility, the experiment has was carried out in quadruplicate.



UV-Vis for Quantum Yield Determination

Figure S15. Absorbance curves of the 4 irradiated solution and of the non-irradiated solution

Photon flux determination

$$mol\left(Fe^{2+}\right) = \frac{V \times \Delta A}{l \times \varepsilon} = \frac{0.006L \times 3 \times 2.91}{1cm \times 11000L \times mol^{-1} \times cm^{-1}} = 4.76 \times 10^{-6} \ mol$$

Photon 
$$flux = \frac{mol(Fe^{2+})}{\phi \times t \times f} = \frac{4.76 \times 10^{-6} mol}{1.13 \times 60s \times 1} = 7.02 \times 10^{-8} einstein s^{-1}$$

*V* is the total volume of the solution; *l* is the path length (1 cm);  $\Delta A$  the difference of absorbance between the irradiated sample and non-irradiated sample at 510 nm;  $\varepsilon$  the molar absorptivity at 510 nm (11000*L* × *mol*<sup>-1</sup> × *cm*<sup>-1</sup>);  $\phi$  is the quantum yield of the ferrioxalate actinometer at 390 nm ( $\phi$  = 1.13); *t* is the time of irradiation and *f* = 1 – 10<sup>-Abs</sup> is the fraction of light absorbed at 390 nm (~1 since abs > 3.5).

#### Quantum yield of the reactions

The quantum yields of the reaction were determined using the following equation:

$$\phi = \frac{mol \ product}{photon \ flux \times t \times f}$$

#### Determination of the reaction quantum yield with RAE 1b:

To a 4 mL reaction vial equipped with a stirrer bar was added RAE (95 mg, 0.255 mmol, 1 equiv) followed by dry  $B_2pin_2$  (194 mg, 0.765 mmol, 3 equiv). The reaction vessel was sealed with a cap containing a TFE-lined silicone septum and then was evacuated and backfilled with argon three times. When done, degassed DMA (2.5 mL) was added. Next, freshly prepared and titrated [1.1.1]propellane (425  $\mu$ L, 0.383 mmol, 1.5 equiv, 0.9 M solution in Et<sub>2</sub>O) was then added, and the vial was quickly sealed with Parafilm<sup>®</sup>. The reaction mixture was then irradiated under vigorous stirring at 52 W 390 nm using the same Kessil lamp for photon flux measurement at 1 inch distance for specific time. Room temperature was maintained by the use of two fans. When the desired reaction time was reached, 1,3,5-trimethoxybenzene was added to the reaction mixture as the internal standard. The mixture was then partitioned between Et<sub>2</sub>O (10 mL) and satd aq NH<sub>4</sub>Cl (10 mL). The organic layer was dried (MgSO<sub>4</sub>), filtered, and further dried under vacuum. The product yield was determined by <sup>1</sup>H NMR usinge 1,3,5-trimethoxybenzene as an internal standard. Each time point was run in triplicate.

\* Quantum yield  $\Phi$  is calculated based on conversion from 20 – 30 min as there is an induction period in the first 20 min.

For RAE **1b**, the abs of the reaction mixture is 0.36, so *f* is calculated as the following:

$$f = 1 - 10^{-Abs} = 0.56$$

$$\phi = \frac{mol \ product}{photon \ flux \times t \times f} = \frac{0.000255 mol \times 0.169 \ (yield)}{7.02 \times 10^{-8} einstein \ s^{-1} \times 600s \times 0.56} = 1.82$$

#### Determination of the reaction quantum yield with an aryl iodide:

To a 4 mL reaction vial equipped with a stirrer bar was added 4-iodobenzonitrile (45.8 mg, 0.2 mmol, 1 equiv) followed by  $K_3PO_4$  (21.2 mg, 0.1 mmol, 0.5 equiv) and Me<sub>2</sub>PhSi-Bpin (104.9 mg, 0.4 mmol, 2 equiv). The reaction vessel was sealed with a cap containing a TFE-lined silicone septum and then was evacuated and backfilled with argon three times. When done, degassed MeOH (2 mL) was added. Next, freshly prepared and titrated [1.1.1]propellane (1.0 mL, 0.6 mmol, 3 equiv, 0.6 M solution in Et<sub>2</sub>O) was then added, and the vial was quickly sealed with Parafilm<sup>®</sup>. The reaction mixture was then irradiated under vigorous stirring at 52 W 390 nm LED using the same Kessil lamp for photon flux measurement at 1 inch distance for specific time. Room temperature was maintained by the use of two fans. When the desired reaction time was reached, 1,3,5-trimethoxybenzene was added to the reaction mixture as the internal standard. The mixture was then passed through a plug of Celite<sup>®</sup> and concentrated under reduced pressure. The product yield was determined by <sup>1</sup>H NMR using 1,3,5-trimethoxybenzene as an internal standard. Each time point was run in triplicate.

\* Quantum yield  $\Phi$  is calculated based on conversion from the first 30 min.

For 4-iodobenzonitrile, the abs of the reaction mixture is 0.0276, so *f* is calculated as the following:

$$f = 1 - 10^{-Abs} = 0.0615$$

 $\phi = \frac{mol \ product}{photon \ flux \times t \times f} = \frac{0.000200 mol \times 0.343 \ (yield)}{7.02 \times 10^{-8} einstein \ s^{-1} \times 1800s \times 0.0615} = 8.83$ 

#### 9. X-ray Structure Determination of Compound 4ar

A crystal of **4ar** suitable for X-ray diffraction was obtained as following: 30 mg of **4ar** were solubilized in 1 mL of chloroform in a 20 mL scintillation vial and the solution was allowed to slowly evaporate at 25 °C for 2 days.



Compound **4ar**,  $C_{30}H_{33}BBrCIFNO_2$ , crystallizes in the triclinic space group P1 with a=9.4324(3)Å, b=13.5284(4)Å, c=23.6555(4)Å,  $\alpha$ =97.609(2)°,  $\beta$ =91.972(2)°,  $\gamma$ =110.314(3)°, V=2795.39(14)Å<sup>3</sup>, Z=4, and d<sub>calc</sub>=1.389 g/cm<sup>3</sup>. X-ray intensity data were collected on a Rigaku XtaLAB Synergy-S diffractometer<sup>33</sup> equipped with an HPC area detector (HyPix-6000HE) and employing confocal multilayer optic-monochromated Cu-K $\alpha$  radiation ( $\lambda$ =1.54184 Å) at a temperature of 100K. Preliminary indexing was performed from a series of sixty 0.5° rotation frames with exposures of 0.25 seconds for  $\theta = \pm 47.291^{\circ}$  and 1 second for  $\theta = 107.75^{\circ}$ . A total of 14936 frames (127 runs) were collected employing  $\omega$  scans with a crystal to detector distance of 40.0 mm, rotation widths of 0.5° and exposures of 1 second for  $\theta = \pm 42.644^{\circ}$ , 42°, 46°, 54°, 58°, 62°, and -66° and 3 seconds for  $\theta = -70^{\circ}$ , -74°, -78°, -82°, -86°, -90°, and 111.75°.

The crystal grew as a non-merohedral twin. The Ewald Explorer extension in CrysAlisPro<sup>34</sup> was used to index the diffraction images and to determine the twinning mechanism. The crystal was twinned by a rotation of 180° about the 100 real direction. Rotation frames were integrated using CrysAlisPro<sup>34</sup>, producing a listing of unaveraged F<sup>2</sup> and  $\sigma$ (F<sup>2</sup>) values. A total of 120127 reflections were measured over the ranges  $7.052 \le 2\theta \le 136.77^\circ$ ,  $-11 \le h \le 11$ ,  $-16 \le k \le 16$ , -28 $\leq$  I  $\leq$  28 yielding 33731 unique reflections (R<sub>int</sub> = 0.099). The intensity data were corrected for Lorentz and polarization effects and for absorption using SCALE3 ABSPACK<sup>35</sup> (minimum and maximum transmission 0.7621, 1.0000). The structure was solved fby direct methods -SHELXT<sup>36</sup>. The asymmetric unit consists of four molecules of the title compound. Refinement was by full-matrix least squares based on F<sup>2</sup> using SHELXL<sup>37</sup>. All reflections were used during refinement. The weighting scheme used was  $w=1/[\sigma^2(F_0^2)+(0.1862P)^2+4.1814P]$  where P =  $(F_0^2 + 2F_c^2)/3$ . Non-hydrogen atoms were refined anisotropically and hydrogen atoms were refined using a riding model. Refinement converged to R1=0.0906 and wR2=0.2510 for 30822 observed reflections for which  $F > 4\sigma(F)$  and R1=0.0993 and wR2=0.2709 and GOF =1.039 for all 33731 unique, non-zero reflections and 1425 variables. The maximum  $\Delta/\sigma$  in the final cycle of least squares was 0.004 and the two most prominent peaks in the final difference Fourier were +1.97 and -0.97 e/Å<sup>3</sup>. The twinning parameter refined to a value of 0.4209(18).

Table S8 lists cell information, data collection parameters, and refinement data. Final positional and equivalent isotropic thermal parameters are given in Tables S9 and S10. Anisotropic thermal parameters are in Table S11. Tables S12 and S13 list bond distances and bond angles. Figure S16 is an ORTEP representation of the molecule with 50% probability thermal ellipsoids displayed.
### \*Author Note on *Alert level B* in the CheckCIF Report:

PLAT341\_ALERT\_3\_B Low Bond Precision on C-C Bonds ...... 0.02577 Ang.

#### Author Response: This alert is generated due to low quality data and the Bpin disorder.



Figure S16. ORTEP drawing of molecule no. 1 with 50% thermal ellipsoids.

#### Table S8. Summary of Structure Determination of Compound 4ar

Empirical formula	C <sub>30</sub> H <sub>33</sub> BBrCIFNO <sub>2</sub>
CCDC	2105768
Formula weight	584.74
Diffractometer	Rigaku XtaLAB Synergy-S (HyPix-6000HE)
Temperature/K	100
Crystal system	triclinic
Space group	P1
а	9.4324(3)Å
b	13.5284(4)Å
С	23.6555(4)Å
α	97.609(2)°
β	91.972(2)°
γ	110.314(3)°
Volume	2795.39(14)ų
Z	4
d <sub>calc</sub>	1.389 g/cm <sup>3</sup>
μ	3.159 mm <sup>-1</sup>
F(000)	1208.0
Crystal size, mm	0.16 × 0.13 × 0.04
20 range for data collection	7.052 - 136.77°
Index ranges	-11 ≤ h ≤ 11, -16 ≤ k ≤ 16, -28 ≤ l ≤ 28
Reflections collected	120127
Independent reflections	33731[R(int) = 0.099]
Data/restraints/parameters	33731/267/1425
Goodness-of-fit on F <sup>2</sup>	1.039
Final R indexes $[I>=2\sigma(I)]$	$R_1 = 0.0906$ , $wR_2 = 0.2510$
Final R indexes [all data]	$R_1 = 0.0993$ , $wR_2 = 0.2709$
Largest diff. peak/hole	1.97/-0.97 eÅ <sup>-3</sup>
Flack parameter	0.01(2)

Atom	X	У	z	U(eq)
Br1	0.7981(2)	0.23683(16)	0.56854(8)	0.0699(5)
CI1	1.2596(7)	0.6087(6)	0.4705(2)	0.096(2)
F1	0.3196(12)	0.2616(10)	0.6574(6)	0.085(3)
01	1.8183(16)	0.7959(12)	0.8669(5)	0.070(3)
02	1.7069(15)	0.8565(12)	0.9384(5)	0.070(3)
N1	0.9405(16)	0.3936(10)	0.6986(5)	0.048(3)
C1	0.7883(17)	0.3537(12)	0.6789(5)	0.045(3)
C2	0.703(2)	0.2889(14)	0.6284(7)	0.057(4)
C3	0.547(2)	0.2610(15)	0.6215(9)	0.063(4)
C4	0.4727(19)	0.2928(16)	0.6635(10)	0.066(5)
C5	0.546(2)	0.3608(16)	0.7157(9)	0.067(5)
C6	0.704(2)	0.3893(13)	0.7227(7)	0.050(4)
C7	0.815(2)	0.4504(15)	0.7682(8)	0.064(4)
C8	0.829(2)	0.5184(16)	0.8258(7)	0.066(5)
C9	0.992(3)	0.5330(19)	0.8474(7)	0.078(6)
C10	1.083(2)	0.5164(13)	0.7955(6)	0.053(3)
C11	0.9529(18)	0.4522(13)	0.7517(6)	0.049(3)
C12	1.0663(19)	0.3769(13)	0.6710(6)	0.051(3)
C13	1.1167(16)	0.4383(14)	0.6226(6)	0.050(3)
C14	1.0765(19)	0.5285(15)	0.6149(7)	0.057(4)
C15	1.120(2)	0.5763(17)	0.5678(7)	0.063(4)
C16	1.203(3)	0.5438(19)	0.5289(8)	0.077(6)
C17	1.250(2)	0.462(2)	0.5355(9)	0.078(6)
C18	1.205(2)	0.4070(16)	0.5836(8)	0.064(4)
C19	1.189(2)	0.6159(14)	0.7739(7)	0.066(5)
C20	1.336(2)	0.6651(14)	0.8101(6)	0.057(4)
C21	1.366(2)	0.6985(15)	0.8770(6)	0.058(4)
C22	1.453(2)	0.7772(15)	0.8072(8)	0.068(5)
C23	1.466(2)	0.6251(14)	0.8143(8)	0.064(5)
C24	1.526(2)	0.7342(15)	0.8540(7)	0.063(4)
C25	1.871(2)	0.8942(17)	0.9586(8)	0.067(5)
C26	1.941(2)	0.8837(17)	0.9031(8)	0.064(4)
C27	1.887(3)	0.810(2)	0.9946(9)	0.086(7)
C28	1.916(2)	1.0002(16)	0.9942(9)	0.068(5)
C29	2.081(2)	0.8556(18)	0.9023(8)	0.068(5)
C30	1.971(3)	0.985(2)	0.8735(11)	0.087(7)
B1	1.686(2)	0.7967(16)	0.8888(7)	0.053(4)
Br1'	1.75049(16)	0.21419(12)	0.08065(6)	0.0553(4)
CI1'	1.5558(6)	0.5365(4)	-0.05019(17)	0.0679(11)
F1'	2.2621(10)	0.2767(8)	0.1896(4)	0.056(2)

 Table S9. Refined Positional Parameters for Compound 4ar

01'	1.2865(16)	0.8014(12)	0.3865(7)	0.080(4)
O2'	1.5236(17)	0.9141(13)	0.4159(7)	0.083(4)
N1'	1.7673(13)	0.4020(11)	0.1959(5)	0.043(3)
C1'	1.8798(15)	0.3572(12)	0.1875(5)	0.040(3)
C2'	1.8966(19)	0.2847(13)	0.1448(7)	0.052(4)
C3'	2.0256(18)	0.2557(14)	0.1442(7)	0.052(3)
C4'	2.1401(16)	0.3075(14)	0.1891(7)	0.048(3)
C5'	2.1332(18)	0.3834(14)	0.2324(7)	0.051(3)
C6'	2.0048(15)	0.4105(12)	0.2313(6)	0.043(3)
C7'	1.9560(16)	0.4860(12)	0.2660(6)	0.044(3)
C8'	2.018(2)	0.5779(15)	0.3162(6)	0.057(4)
C9'	1.8751(18)	0.6042(15)	0.3277(7)	0.054(4)
C10'	1.7652(17)	0.5682(13)	0.2710(6)	0.048(3)
C11'	1.8183(15)	0.4820(13)	0.2442(6)	0.043(3)
C12'	1.6165(15)	0.3661(13)	0.1679(6)	0.043(3)
C13'	1.6048(16)	0.4162(12)	0.1159(5)	0.041(3)
C14'	1.4654(17)	0.3772(13)	0.0825(6)	0.047(3)
C15'	1.4483(18)	0.4144(13)	0.0314(6)	0.051(3)
C16'	1.5735(17)	0.4918(13)	0.0152(6)	0.048(3)
C17'	1.7119(19)	0.5337(14)	0.0482(7)	0.055(4)
C18'	1.7280(18)	0.4968(13)	0.0992(7)	0.054(4)
C19'	1.6011(19)	0.5423(13)	0.2795(7)	0.052(3)
C20'	1.5628(17)	0.6307(12)	0.3127(6)	0.045(3)
C21'	1.5916(18)	0.6725(13)	0.3778(6)	0.053(3)
C22'	1.395(2)	0.6253(13)	0.3179(7)	0.054(3)
C23'	1.605(2)	0.7477(14)	0.3040(7)	0.060(4)
C24'	1.4963(17)	0.7316(13)	0.3540(6)	0.049(3)
C25'	1.428(2)	0.9622(15)	0.4464(8)	0.061(4)
C26'	1.265(2)	0.8930(16)	0.4186(7)	0.062(4)
C27'	1.485(3)	1.0781(19)	0.4381(14)	0.093(7)
C28'	1.457(3)	0.958(3)	0.5086(10)	0.118(12)
C29'	1.210(3)	0.947(2)	0.3750(11)	0.101(8)
C30'	1.151(3)	0.855(2)	0.4603(12)	0.097(8)
B1'	1.434(2)	0.8176(15)	0.3864(7)	0.048(4)
Br2	-0.0674(2)	0.30677(17)	0.95621(8)	0.0751(6)
Cl2	-0.6706(6)	0.0045(5)	1.0512(2)	0.0825(15)
F2	0.3616(11)	0.3246(8)	0.8278(4)	0.063(2)
O3	-1.072(2)	-0.2570(18)	0.5842(8)	0.068(4)
O3*	-1.086(4)	-0.305(3)	0.6097(17)	0.058(6)
04	-1.1886(19)	-0.2136(15)	0.6614(8)	0.063(4)
O4*	-1.190(4)	-0.183(3)	0.6324(19)	0.059(6)
N2	-0.2610(16)	0.1759(11)	0.8276(5)	0.052(3)
C31	-0.100(2)	0.2244(13)	0.8354(6)	0.054(4)

C32	0.001(2)	0.2804(15)	0.8824(6)	0.060(4)
C33	0.150(2)	0.3135(15)	0.8784(7)	0.063(4)
C34	0.207(2)	0.2906(13)	0.8301(6)	0.055(4)
C35	0.1202(19)	0.2266(14)	0.7808(7)	0.054(4)
C36	-0.0397(18)	0.1932(12)	0.7862(5)	0.045(3)
C37	-0.1712(18)	0.1249(12)	0.7464(6)	0.046(3)
C38	-0.206(2)	0.0532(16)	0.6899(7)	0.061(4)
C39	-0.378(2)	0.0214(14)	0.6809(6)	0.057(4)
C40	-0.4392(17)	0.0389(13)	0.7415(6)	0.047(3)
C41	-0.2954(16)	0.1181(12)	0.7743(6)	0.046(3)
C42	-0.364(2)	0.2184(13)	0.8580(6)	0.052(3)
C43	-0.4430(18)	0.1583(13)	0.9038(6)	0.049(3)
C44	-0.4204(19)	0.0709(13)	0.9175(6)	0.052(3)
C45	-0.4935(19)	0.0206(15)	0.9633(8)	0.060(4)
C46	-0.587(2)	0.0619(16)	0.9919(6)	0.058(4)
C47	-0.615(3)	0.1486(16)	0.9780(7)	0.070(5)
C48	-0.545(2)	0.1947(15)	0.9328(7)	0.062(4)
C49	-0.582(2)	0.0635(14)	0.7416(6)	0.054(4)
C50	-0.723(2)	-0.0177(13)	0.7073(6)	0.050(3)
C51	-0.7489(19)	-0.0632(14)	0.6431(7)	0.057(4)
C52	-0.877(2)	-0.0077(14)	0.7026(7)	0.056(4)
C53	-0.8048(19)	-0.1358(13)	0.7177(6)	0.054(3)
C54	-0.9013(18)	-0.1209(12)	0.6673(6)	0.048(3)
C55	-1.235(3)	-0.3011(17)	0.5666(9)	0.067(4)
C55*	-1.237(5)	-0.351(3)	0.5789(19)	0.063(6)
C56	-1.300(2)	-0.3046(17)	0.6254(9)	0.061(4)
C56*	-1.317(5)	-0.276(4)	0.604(2)	0.066(6)
C57	-1.270(3)	-0.412(2)	0.5307(13)	0.070(6)
C57*	-1.294(6)	-0.473(4)	0.576(3)	0.067(10)
C58	-1.276(3)	-0.224(2)	0.5325(12)	0.078(7)
C58*	-1.197(9)	-0.342(7)	0.516(2)	0.081(11)
C59	-1.317(3)	-0.408(2)	0.6489(14)	0.077(6)
C59*	-1.395(9)	-0.325(6)	0.656(3)	0.084(11)
C60	-1.453(3)	-0.287(2)	0.6248(12)	0.062(5)
C60*	-1.435(7)	-0.237(6)	0.578(3)	0.088(13)
B2	-1.058(2)	-0.2013(14)	0.6364(6)	0.054(4)
Br2'	1.8815(2)	1.38518(15)	0.42888(8)	0.0681(5)
Cl2'	2.0228(8)	1.0498(6)	0.55849(19)	0.0932(19)
F2'	1.3493(12)	1.3148(11)	0.3351(6)	0.081(3)
O3'	2.0858(19)	0.6804(12)	0.0909(6)	0.085(5)
O4'	2.3124(18)	0.7851(13)	0.1374(7)	0.091(5)
N2'	1.8446(16)	1.1947(11)	0.3109(5)	0.049(3)
C31'	1.7312(17)	1.2339(15)	0.3257(7)	0.051(4)

C32'	1.7225(18)	1.3111(13)	0.3704(6)	0.049(3)
C33'	1.588(2)	1.3330(15)	0.3712(9)	0.064(4)
C34'	1.473(2)	1.2858(17)	0.3325(9)	0.067(5)
C35'	1.4736(19)	1.2096(16)	0.2883(8)	0.060(4)
C36'	1.6049(19)	1.1816(14)	0.2843(7)	0.052(4)
C37'	1.6449(19)	1.1084(14)	0.2464(7)	0.053(4)
C38'	1.588(2)	1.0306(17)	0.1944(8)	0.067(5)
C39'	1.713(2)	0.9845(16)	0.1858(7)	0.062(4)
C40'	1.8567(19)	1.0517(13)	0.2256(6)	0.052(3)
C41'	1.7903(19)	1.1199(13)	0.2628(7)	0.051(3)
C42'	1.9975(18)	1.2277(14)	0.3407(7)	0.052(4)
C43'	1.9984(19)	1.1753(15)	0.3932(6)	0.053(4)
C44'	2.130(2)	1.2158(16)	0.4320(7)	0.063(4)
C45'	2.140(2)	1.1777(18)	0.4803(7)	0.068(5)
C46'	2.013(2)	1.0952(17)	0.4935(6)	0.065(5)
C47'	1.882(2)	1.0509(19)	0.4581(7)	0.067(5)
C48'	1.8777(18)	1.0925(14)	0.4057(6)	0.053(3)
C49'	1.9288(19)	0.9849(13)	0.2546(6)	0.053(3)
C50'	1.994(2)	0.9188(13)	0.2141(7)	0.056(4)
C51'	1.912(3)	0.8215(16)	0.1673(7)	0.068(5)
C52'	2.097(3)	0.8558(18)	0.2316(8)	0.075(5)
C53'	2.111(3)	0.9611(15)	0.1682(8)	0.074(5)
C54'	2.082(2)	0.8373(13)	0.1645(6)	0.054(4)
C55'	2.187(2)	0.6258(16)	0.0717(7)	0.065(4)
C56'	2.347(3)	0.7024(16)	0.1010(8)	0.073(5)
C57'	2.178(4)	0.605(2)	0.0081(8)	0.129(13)
C58'	2.134(3)	0.518(2)	0.0923(13)	0.095(8)
C59'	2.454(3)	0.761(2)	0.0577(9)	0.090(7)
C60'	2.437(5)	0.658(2)	0.1355(13)	0.144(16)
B2'	2.164(3)	0.7687(16)	0.1311(8)	0.060(5)

Atom	X	У	z	U(eq)
H3	0.491899	0.219261	0.586956	0.076
H5	0.490629	0.385081	0.743725	0.08
H8a	0.754106	0.480888	0.85114	0.079
H8b	0.8185	0.587406	0.821793	0.079
H9a	0.989338	0.48076	0.873297	0.093
H9b	1.04218	0.605581	0.869135	0.093
H10	1.142653	0.470949	0.804368	0.064
H12a	1.037529	0.299943	0.656363	0.061
H12b	1.153439	0.396697	0.700136	0.061
H14	1.020739	0.554654	0.641957	0.069
H15	1.090375	0.634793	0.562053	0.076
H17	1.311673	0.440729	0.508882	0.094
H18	1.236534	0.348852	0.588717	0.077
H19a	1.208515	0.596167	0.733957	0.079
H19b	1.137727	0.668746	0.77411	0.079
H21a	1.332122	0.75649	0.893716	0.07
H21b	1.343655	0.639275	0.899776	0.07
H22a	1.420927	0.838033	0.820999	0.082
H22b	1.504008	0.785497	0.771438	0.082
H23a	1.517714	0.620435	0.778998	0.077
H23b	1.446548	0.561674	0.833666	0.077
H27a	1.993053	0.829502	1.009037	0.129
H27b	1.852809	0.739667	0.970626	0.129
H27c	1.823986	0.807168	1.027001	0.129
H28a	2.013038	1.015561	1.016313	0.102
H28b	1.838063	1.000782	1.020498	0.102
H28c	1.926578	1.054607	0.969522	0.102
H29a	2.118388	0.858918	0.864157	0.102
H29b	2.057125	0.783211	0.911277	0.102
H29c	2.159164	0.906178	0.930779	0.102
H30a	2.039593	1.048088	0.899121	0.13
H30b	1.875051	0.995069	0.865039	0.13
H30c	2.018295	0.976292	0.837771	0.13
H3'	2.035371	0.203797	0.114914	0.062
H5'	2.213253	0.415967	0.261942	0.061
H8'a	2.100318	0.639354	0.30522	0.069
H8'b	2.056247	0.554796	0.349801	0.069
H9'a	1.903085	0.681794	0.340192	0.065
H9'b	1.823528	0.5664	0.358481	0.065
H10'	1.796294	0.627476	0.247575	0.057

 Table S10. Positional Parameters for Hydrogens in Compound 4ar

H12c	1.5479	0.381912	0.19552	0.052
H12d	1.580966	0.287779	0.156528	0.052
H14'	1.381204	0.324646	0.094934	0.056
H15'	1.354209	0.387508	0.00853	0.061
H17'	1.795017	0.587403	0.035955	0.066
H18'	1.821436	0.52585	0.122482	0.065
H19c	1.566958	0.479461	0.299572	0.062
H19d	1.543123	0.522003	0.241452	0.062
H21c	1.541011	0.620531	0.403095	0.063
H21d	1.697673	0.716648	0.391996	0.063
H22c	1.340469	0.630636	0.282672	0.065
H22d	1.332096	0.570345	0.339471	0.065
H23c	1.563154	0.759854	0.267592	0.072
H23d	1.711723	0.794322	0.314833	0.072
H27d	1.470723	1.082793	0.397497	0.139
H27e	1.593501	1.110689	0.451116	0.139
H27f	1.428895	1.11598	0.460447	0.139
H28d	1.394034	0.989723	0.531154	0.177
H28e	1.564406	0.998125	0.520934	0.177
H28f	1.432027	0.88367	0.51431	0.177
H29d	1.17943	1.003423	0.39477	0.152
H29e	1.123412	0.894089	0.350796	0.152
H29f	1.292445	0.977429	0.351224	0.152
H30d	1.186096	0.814098	0.485245	0.145
H30e	1.053507	0.808853	0.439581	0.145
H30f	1.137752	0.916038	0.483589	0.145
H33	0.217332	0.354107	0.910844	0.076
H35	0.162858	0.207298	0.747163	0.065
H38a	-0.176369	-0.009712	0.691685	0.073
H38b	-0.154923	0.091632	0.659217	0.073
H39a	-0.424262	-0.054421	0.663168	0.068
H39b	-0.404098	0.065658	0.65516	0.068
H40	-0.461266	-0.029179	0.757463	0.056
H42a	-0.441763	0.220657	0.829624	0.062
H42b	-0.30544	0.292817	0.875726	0.062
H44	-0.355332	0.042676	0.896526	0.062
H45	-0.477096	-0.040467	0.973351	0.072
H47	-0.680591	0.176263	0.99891	0.083
H48	-0.568019	0.25266	0.921272	0.074
H49a	-0.561158	0.132154	0.72716	0.064
H49b	-0.605922	0.074413	0.781859	0.064
H51a	-0.690092	-0.108492	0.629671	0.068
H51b	-0.751299	-0.012611	0.616751	0.068

H52a	-0.886232	0.046764	0.679962	0.067
H52b	-0.928492	-0.00803	0.738391	0.067
H53a	-0.749557	-0.185254	0.708229	0.065
H53b	-0.853253	-0.144573	0.754114	0.065
H57a	-1.229234	-0.402936	0.493325	0.106
H57b	-1.379627	-0.449617	0.525287	0.106
H57c	-1.221881	-0.45252	0.55066	0.106
H57d	-1.216833	-0.500366	0.561097	0.101
H57e	-1.388261	-0.505645	0.551557	0.101
H57f	-1.311622	-0.490582	0.615038	0.101
H58a	-1.286356	-0.165625	0.559019	0.117
H58b	-1.372011	-0.262681	0.509041	0.117
H58c	-1.195455	-0.195573	0.507603	0.117
H58d	-1.229485	-0.287399	0.50296	0.122
H58e	-1.249987	-0.411079	0.492094	0.122
H58f	-1.087555	-0.323041	0.514781	0.122
H59a	-1.234423	-0.432412	0.637592	0.116
H59b	-1.414728	-0.463245	0.633326	0.116
H59c	-1.314396	-0.395461	0.690754	0.116
H59d	-1.482938	-0.388821	0.642241	0.127
H59e	-1.32257	-0.34311	0.67948	0.127
H59f	-1.427567	-0.27221	0.67933	0.127
H60a	-1.486114	-0.283548	0.66361	0.093
H60b	-1.529695	-0.345399	0.599352	0.093
H60c	-1.44107	-0.219119	0.610916	0.093
H60d	-1.418697	-0.164148	0.596951	0.132
H60e	-1.536946	-0.284118	0.583588	0.132
H60f	-1.423302	-0.236469	0.537133	0.132
H33'	1.579751	1.384464	0.401091	0.077
H35'	1.388337	1.176348	0.26099	0.071
H38c	1.573412	1.06541	0.161474	0.08
H38d	1.490778	0.974599	0.199484	0.08
H39c	1.737851	0.982959	0.145484	0.074
H39d	1.676916	0.91031	0.194037	0.074
H40'	1.93275	1.097706	0.202717	0.063
H42c	2.037145	1.306089	0.352163	0.062
H42d	2.066037	1.209209	0.31395	0.062
H44'	2.215402	1.272361	0.423129	0.075
H45'	2.229914	1.205819	0.50535	0.082
H47'	1.797084	0.995072	0.467943	0.081
H48'	1.789964	1.062119	0.37935	0.063
H49c	2.010984	1.032961	0.283243	0.064
H49d	1.851453	0.936569	0.275399	0.064

H51c	1.849098	0.755725	0.181241	0.081
H51d	1.862742	0.83646	0.133574	0.081
H52c	2.198584	0.899864	0.250393	0.09
H52d	2.046053	0.792429	0.249934	0.09
H53c	2.070794	0.982827	0.134549	0.089
H53d	2.21345	1.010632	0.183726	0.089
H57g	2.0861	0.543934	-0.006235	0.193
H57h	2.267435	0.588928	-0.003967	0.193
H57i	2.175696	0.668045	-0.007274	0.193
H58g	2.142237	0.528395	0.134239	0.142
H58h	2.197828	0.477557	0.078217	0.142
H58i	2.028352	0.478014	0.077658	0.142
H59g	2.551219	0.808016	0.077976	0.135
H59h	2.406527	0.804146	0.039132	0.135
H59i	2.470705	0.708771	0.028562	0.135
H60g	2.433738	0.589448	0.115225	0.216
H60h	2.394881	0.648541	0.17252	0.216
H60i	2.542642	0.707798	0.141809	0.216

Atom	<b>U</b> 11	U <sub>22</sub>	U <sub>33</sub>	<b>U</b> <sub>23</sub>	<b>U</b> <sub>13</sub>	<b>U</b> <sub>12</sub>
Br1	0.0678(10)	0.0740(12)	0.0533(9)	-0.0110(8)	-0.0042(7)	0.0154(9)
CI1	0.087(4)	0.119(5)	0.059(2)	0.032(3)	0.007(2)	-0.002(3)
F1	0.046(5)	0.078(8)	0.133(10)	0.031(7)	0.008(6)	0.018(5)
O1	0.081(9)	0.074(9)	0.054(6)	-0.009(6)	-0.008(6)	0.034(7)
O2	0.064(7)	0.083(9)	0.062(7)	-0.008(6)	-0.005(5)	0.032(7)
N1	0.062(7)	0.035(6)	0.053(6)	0.009(5)	-0.002(5)	0.024(6)
C1	0.053(8)	0.045(8)	0.042(6)	0.013(6)	0.003(6)	0.023(7)
C2	0.07(1)	0.047(9)	0.059(8)	0.029(7)	0.000(7)	0.021(8)
C3	0.066(10)	0.049(10)	0.075(11)	0.022(8)	-0.007(8)	0.018(8)
C4	0.045(8)	0.062(11)	0.103(14)	0.034(10)	0.012(9)	0.028(8)
C5	0.056(10)	0.059(11)	0.095(13)	0.016(9)	0.025(9)	0.031(9)
C6	0.063(9)	0.044(8)	0.058(8)	0.023(7)	0.020(7)	0.030(7)
C7	0.080(12)	0.047(9)	0.072(10)	0.011(8)	0.014(9)	0.031(9)
C8	0.091(13)	0.058(11)	0.055(9)	0.007(7)	0.019(8)	0.032(10)
C9	0.122(18)	0.088(14)	0.041(8)	0.015(8)	0.001(9)	0.058(14)
C10	0.072(10)	0.051(9)	0.038(6)	0.006(6)	-0.004(6)	0.023(8)
C11	0.055(8)	0.049(9)	0.040(6)	0.002(6)	-0.005(6)	0.016(7)
C12	0.057(8)	0.053(9)	0.049(7)	0.003(6)	-0.001(6)	0.030(7)
C13	0.041(7)	0.058(9)	0.049(7)	0.001(6)	-0.007(6)	0.017(7)
C14	0.058(9)	0.064(10)	0.049(8)	0.012(7)	-0.005(6)	0.021(8)
C15	0.060(9)	0.079(13)	0.056(9)	0.020(8)	-0.004(7)	0.028(9)
C16	0.074(12)	0.074(14)	0.056(10)	0.019(9)	-0.018(9)	-0.008(10)
C17	0.058(10)	0.085(15)	0.068(11)	-0.008(10)	0.020(9)	0.001(10)
C18	0.080(12)	0.059(11)	0.059(9)	0.011(8)	0.014(8)	0.031(9)
C19	0.091(13)	0.053(10)	0.048(8)	0.013(7)	-0.018(8)	0.020(9)
C20	0.077(11)	0.058(10)	0.040(7)	0.002(6)	-0.015(7)	0.033(9)
C21	0.084(11)	0.06(1)	0.037(7)	0.004(6)	-0.002(7)	0.037(9)
C22	0.090(13)	0.056(11)	0.056(9)	0.010(8)	-0.015(8)	0.024(9)
C23	0.092(13)	0.05(1)	0.058(9)	0.007(7)	-0.010(8)	0.035(9)
C24	0.092(13)	0.053(10)	0.045(8)	0.002(7)	-0.001(8)	0.031(9)
C25	0.06(1)	0.076(13)	0.064(10)	-0.009(9)	-0.006(8)	0.030(9)
C26	0.070(11)	0.071(12)	0.058(9)	0.001(8)	0.001(8)	0.038(10)
C27	0.101(16)	0.082(15)	0.070(12)	0.035(11)	-0.016(11)	0.020(12)
C28	0.061(10)	0.060(11)	0.078(11)	-0.008(9)	-0.003(8)	0.023(9)
C29	0.066(10)	0.090(14)	0.059(9)	0.006(9)	-0.002(8)	0.046(11)
C30	0.088(14)	0.096(17)	0.096(15)	0.053(13)	0.022(12)	0.042(13)
B1	0.073(11)	0.057(11)	0.042(8)	0.010(7)	0.009(7)	0.037(10)
Br1'	0.0560(9)	0.0631(10)	0.0442(7)	-0.0025(6)	-0.0055(6)	0.0227(8)
CI1'	0.089(3)	0.065(3)	0.0495(18)	0.0156(17)	-0.0100(18)	0.027(2)
F1'	0.041(4)	0.056(5)	0.076(6)	0.013(4)	0.001(4)	0.025(4)

Table S11. Refined Thermal Parameters (U's) for Compound 4ar

O1'	0.057(7)	0.063(9)	0.109(11)	-0.025(7)	0.010(7)	0.019(6)
O2'	0.073(9)	0.085(10)	0.089(9)	-0.025(8)	-0.017(7)	0.041(8)
N1'	0.034(5)	0.056(7)	0.042(6)	0.009(5)	-0.004(4)	0.020(5)
C1'	0.038(7)	0.045(8)	0.032(6)	0.004(5)	-0.003(5)	0.010(6)
C2'	0.057(9)	0.049(9)	0.049(8)	0.017(6)	0.003(6)	0.016(7)
C3'	0.048(8)	0.048(9)	0.060(9)	0.011(7)	0.005(6)	0.017(7)
C4'	0.037(7)	0.054(9)	0.062(8)	0.010(7)	0.007(6)	0.026(7)
C5'	0.045(8)	0.051(9)	0.049(7)	0.007(6)	-0.010(6)	0.010(7)
C6'	0.034(6)	0.044(8)	0.046(7)	0.010(6)	-0.002(5)	0.007(6)
C7'	0.040(7)	0.041(8)	0.047(7)	-0.002(6)	0.000(5)	0.014(6)
C8'	0.060(9)	0.058(10)	0.041(7)	-0.011(6)	-0.013(6)	0.015(8)
C9'	0.043(7)	0.067(11)	0.049(8)	0.005(7)	-0.005(6)	0.017(7)
C10'	0.043(7)	0.048(9)	0.053(8)	0.006(6)	0.000(6)	0.018(7)
C11'	0.036(6)	0.055(9)	0.039(6)	0.007(6)	-0.004(5)	0.018(6)
C12'	0.039(7)	0.051(9)	0.039(6)	0.017(6)	0.000(5)	0.013(6)
C13'	0.045(7)	0.045(8)	0.033(6)	0.002(5)	-0.002(5)	0.018(6)
C14'	0.048(7)	0.054(9)	0.039(7)	0.009(6)	-0.001(5)	0.019(7)
C15'	0.060(8)	0.063(9)	0.035(6)	0.006(6)	-0.008(6)	0.030(8)
C16'	0.047(7)	0.056(9)	0.044(7)	0.003(6)	-0.010(5)	0.027(7)
C17'	0.053(8)	0.058(10)	0.053(8)	0.019(7)	-0.002(6)	0.017(7)
C18'	0.056(8)	0.048(9)	0.060(8)	0.010(7)	-0.009(7)	0.021(7)
C19'	0.054(8)	0.043(8)	0.052(8)	-0.006(6)	-0.001(6)	0.015(7)
C20'	0.049(7)	0.047(8)	0.042(6)	0.005(5)	-0.004(5)	0.022(7)
C21'	0.056(8)	0.056(9)	0.045(7)	0.004(6)	0.001(6)	0.022(7)
C22'	0.061(9)	0.048(9)	0.048(7)	-0.003(6)	-0.002(7)	0.019(8)
C23'	0.083(11)	0.052(9)	0.051(8)	0.010(7)	0.011(8)	0.029(9)
C24'	0.051(8)	0.053(9)	0.039(6)	-0.002(6)	-0.004(5)	0.017(7)
C25'	0.06(1)	0.054(10)	0.064(9)	0.005(8)	0.012(7)	0.016(8)
C26'	0.073(11)	0.064(11)	0.050(8)	-0.004(7)	-0.004(7)	0.031(9)
C27'	0.068(12)	0.060(13)	0.15(2)	0.032(14)	0.014(14)	0.020(11)
C28'	0.083(16)	0.16(3)	0.061(12)	-0.022(15)	0.009(11)	-0.012(17)
C29'	0.108(18)	0.098(18)	0.092(15)	0.007(13)	-0.042(14)	0.037(15)
C30'	0.063(12)	0.12(2)	0.104(17)	0.033(15)	0.027(11)	0.014(12)
B1'	0.058(9)	0.042(9)	0.045(8)	-0.001(6)	-0.007(7)	0.023(8)
Br2	0.0763(12)	0.0796(13)	0.0482(9)	-0.0019(8)	0.0049(8)	0.0056(10)
Cl2	0.067(3)	0.114(4)	0.056(2)	0.032(2)	0.0088(19)	0.012(3)
F2	0.054(5)	0.066(6)	0.065(5)	0.017(4)	-0.001(4)	0.013(5)
O3	0.053(7)	0.079(10)	0.065(8)	-0.006(7)	-0.001(7)	0.021(7)
O3*	0.051(10)	0.060(12)	0.063(12)	0.002(10)	-0.003(10)	0.022(10)
04	0.061(8)	0.061(9)	0.060(8)	-0.005(7)	-0.005(7)	0.018(7)
O4*	0.054(9)	0.059(11)	0.061(11)	-0.006(10)	-0.007(10)	0.022(9)
N2	0.063(8)	0.049(7)	0.041(6)	0.003(5)	0.009(5)	0.015(6)
C31	0.069(10)	0.042(8)	0.050(8)	0.015(6)	0.010(7)	0.013(7)

C32	0.071(10)	0.059(10)	0.037(7)	0.009(6)	0.002(7)	0.008(8)
C33	0.069(10)	0.059(11)	0.044(8)	0.004(7)	-0.005(7)	0.004(8)
C34	0.075(10)	0.046(9)	0.040(7)	0.009(6)	-0.007(7)	0.019(8)
C35	0.061(9)	0.055(10)	0.054(8)	0.009(7)	-0.003(7)	0.028(8)
C36	0.061(8)	0.047(8)	0.028(6)	0.002(5)	-0.005(5)	0.021(7)
C37	0.054(8)	0.043(8)	0.037(6)	-0.002(5)	-0.009(5)	0.018(7)
C38	0.065(10)	0.069(11)	0.048(8)	0.003(7)	-0.008(7)	0.029(9)
C39	0.069(10)	0.056(9)	0.045(7)	-0.012(6)	-0.008(7)	0.030(8)
C40	0.050(8)	0.048(8)	0.043(7)	0.001(6)	-0.003(6)	0.020(7)
C41	0.047(7)	0.047(8)	0.050(7)	0.019(6)	0.010(6)	0.019(6)
C42	0.069(9)	0.043(8)	0.036(6)	0.007(6)	0.014(6)	0.009(7)
C43	0.057(8)	0.049(9)	0.038(6)	0.001(6)	0.000(6)	0.016(7)
C44	0.059(8)	0.045(8)	0.045(7)	0.003(6)	0.001(6)	0.013(7)
C45	0.053(9)	0.06(1)	0.068(10)	0.032(8)	-0.003(7)	0.016(8)
C46	0.054(9)	0.079(12)	0.040(7)	0.003(7)	0.002(6)	0.026(8)
C47	0.087(13)	0.061(11)	0.051(9)	0.004(7)	0.007(8)	0.017(10)
C48	0.072(11)	0.065(11)	0.045(8)	0.007(7)	0.013(7)	0.019(9)
C49	0.072(10)	0.049(9)	0.046(7)	0.012(6)	0.002(7)	0.028(8)
C50	0.067(9)	0.055(9)	0.039(6)	0.001(6)	-0.005(6)	0.039(8)
C51	0.058(9)	0.053(9)	0.058(9)	0.007(7)	-0.009(7)	0.020(7)
C52	0.068(10)	0.055(9)	0.049(8)	0.006(6)	-0.010(7)	0.027(8)
C53	0.066(9)	0.049(9)	0.049(7)	0.002(6)	-0.012(7)	0.025(8)
C54	0.061(8)	0.041(8)	0.046(7)	0.003(6)	-0.010(6)	0.023(7)
C55	0.057(7)	0.068(9)	0.066(8)	-0.002(7)	-0.008(7)	0.017(7)
C55*	0.055(9)	0.063(10)	0.067(10)	0.003(9)	-0.006(9)	0.020(9)
C56	0.056(8)	0.060(9)	0.060(8)	0.004(7)	-0.009(7)	0.016(7)
C56*	0.059(9)	0.065(10)	0.067(10)	-0.005(9)	-0.006(9)	0.017(9)
C57	0.064(12)	0.060(13)	0.077(13)	-0.026(11)	-0.001(10)	0.023(11)
C57*	0.051(17)	0.066(19)	0.09(2)	0.007(18)	-0.007(17)	0.032(16)
C58	0.074(13)	0.084(15)	0.057(11)	0.013(11)	-0.017(10)	0.005(12)
C58*	0.074(17)	0.078(18)	0.069(16)	-0.003(16)	-0.009(16)	0.006(16)
C59	0.074(13)	0.065(13)	0.096(14)	0.036(11)	0.000(11)	0.021(11)
C59*	0.073(17)	0.076(17)	0.082(17)	0.003(16)	0.002(16)	0.003(16)
C60	0.054(11)	0.059(12)	0.074(12)	0.006(10)	-0.008(10)	0.025(10)
C60*	0.06(2)	0.09(2)	0.09(2)	-0.01(2)	-0.021(19)	0.01(2)
B2	0.077(12)	0.051(11)	0.040(8)	0.009(7)	-0.003(7)	0.032(10)
Br2'	0.0699(11)	0.0668(11)	0.068(1)	-0.0039(8)	-0.0153(8)	0.0319(10)
Cl2'	0.136(5)	0.134(5)	0.045(2)	0.019(2)	0.007(2)	0.091(4)
F2'	0.049(5)	0.088(8)	0.116(9)	0.030(7)	0.012(5)	0.032(5)
O3'	0.096(11)	0.069(9)	0.085(9)	-0.022(7)	-0.036(8)	0.040(8)
O4'	0.078(9)	0.072(10)	0.092(10)	-0.044(8)	0.018(8)	0.009(7)
N2'	0.057(7)	0.054(8)	0.036(6)	0.015(5)	-0.003(5)	0.016(6)
C31'	0.050(8)	0.063(10)	0.047(7)	0.033(7)	0.001(6)	0.020(7)

C32'	0.050(8)	0.048(9)	0.045(7)	0.010(6)	-0.001(6)	0.011(7)
C33'	0.073(11)	0.05(1)	0.074(11)	0.025(8)	0.003(9)	0.021(9)
C34'	0.069(11)	0.065(12)	0.075(11)	0.031(10)	0.006(9)	0.025(10)
C35'	0.044(8)	0.072(12)	0.061(9)	0.032(9)	0.000(7)	0.012(8)
C36'	0.056(9)	0.053(10)	0.052(8)	0.020(7)	-0.006(7)	0.021(8)
C37'	0.054(8)	0.053(9)	0.054(8)	0.018(7)	-0.003(6)	0.020(7)
C38'	0.054(9)	0.084(13)	0.066(10)	0.033(9)	-0.001(8)	0.022(9)
C39'	0.058(10)	0.068(11)	0.051(8)	-0.002(7)	-0.006(7)	0.018(9)
C40'	0.058(9)	0.049(9)	0.042(7)	0.010(6)	-0.003(6)	0.008(7)
C41'	0.054(9)	0.043(8)	0.052(8)	0.012(6)	-0.001(6)	0.013(7)
C42'	0.048(8)	0.045(9)	0.056(8)	0.001(7)	-0.012(6)	0.013(7)
C43'	0.062(9)	0.063(10)	0.045(7)	0.007(7)	-0.004(6)	0.035(8)
C44'	0.056(9)	0.064(11)	0.058(9)	-0.013(8)	-0.011(7)	0.019(8)
C45'	0.06(1)	0.095(15)	0.054(9)	-0.005(9)	-0.014(7)	0.041(10)
C46'	0.097(13)	0.095(14)	0.028(6)	-0.003(7)	0.004(7)	0.069(12)
C47'	0.074(11)	0.101(15)	0.054(9)	0.032(9)	0.021(8)	0.055(11)
C48'	0.053(8)	0.067(10)	0.046(7)	0.017(7)	0.009(6)	0.029(8)
C49'	0.061(9)	0.046(8)	0.049(7)	0.010(6)	0.011(6)	0.013(7)
C50'	0.065(9)	0.047(9)	0.054(8)	0.018(7)	0.009(7)	0.011(7)
C51'	0.089(13)	0.059(11)	0.051(8)	0.011(7)	0.009(8)	0.02(1)
C52'	0.098(14)	0.084(14)	0.055(9)	0.010(9)	0.008(9)	0.047(12)
C53'	0.100(15)	0.055(10)	0.058(9)	0.011(8)	0.018(9)	0.012(10)
C54'	0.056(9)	0.051(9)	0.044(7)	0.015(6)	0.008(6)	0.004(7)
C55'	0.085(12)	0.063(11)	0.049(8)	-0.002(7)	-0.005(8)	0.031(10)
C56'	0.095(14)	0.053(11)	0.062(10)	-0.008(8)	0.01(1)	0.021(10)
C57'	0.16(3)	0.12(2)	0.030(9)	-0.01(1)	-0.012(11)	-0.035(18)
C58'	0.080(14)	0.073(15)	0.14(2)	0.054(15)	0.014(14)	0.027(12)
C59'	0.076(13)	0.101(18)	0.070(12)	-0.006(11)	0.015(10)	0.010(12)
C60'	0.21(4)	0.071(17)	0.12(2)	-0.035(15)	-0.10(2)	0.037(19)
B2'	0.083(14)	0.043(10)	0.043(8)	0.006(7)	0.010(8)	0.009(9)

Br1-C2	1.888(19)	CI1-C16	1.73(2)	F1-C4	1.353(19)
O1-C26	1.48(2)	O1-B1	1.37(2)	O2-C25	1.49(2)
O2-B1	1.30(2)	N1-C1	1.38(2)	N1-C11	1.372(19)
N1-C12	1.44(2)	C1-C2	1.42(2)	C1-C6	1.46(2)
C2-C3	1.39(3)	C3-C4	1.34(3)	C4-C5	1.43(3)
C5-C6	1.41(2)	C6-C7	1.42(3)	C7-C8	1.51(3)
C7-C11	1.37(2)	C8-C9	1.54(3)	C9-C10	1.56(3)
C10-C11	1.51(2)	C10-C19	1.53(2)	C12-C13	1.50(2)
C13-C14	1.43(2)	C13-C18	1.39(2)	C14-C15	1.37(2)
C15-C16	1.36(3)	C16-C17	1.36(4)	C17-C18	1.43(3)
C19-C20	1.49(2)	C20-C21	1.58(2)	C20-C22	1.55(3)
C20-C23	1.51(2)	C20-C24	1.90(3)	C21-C24	1.55(3)
C22-C24	1.56(2)	C23-C24	1.55(2)	C24-B1	1.58(3)
C25-C26	1.50(3)	C25-C27	1.55(3)	C25-C28	1.48(3)
C26-C29	1.49(2)	C26-C30	1.57(3)	Br1'-C2'	1.916(16)
CI1'-C16'	1.756(14)	F1'-C4'	1.353(15)	O1'-C26'	1.45(2)
O1'-B1'	1.33(2)	O2'-C25'	1.45(2)	O2'-B1'	1.36(2)
N1'-C1'	1.400(17)	N1'-C11'	1.408(19)	N1'-C12'	1.439(17)
C1'-C2'	1.37(2)	C1'-C6'	1.454(18)	C2'-C3'	1.40(2)
C3'-C4'	1.41(2)	C4'-C5'	1.37(2)	C5'-C6'	1.38(2)
C6'-C7'	1.43(2)	C7'-C8'	1.54(2)	C7'-C11'	1.361(18)
C8'-C9'	1.54(2)	C9'-C10'	1.58(2)	C10'-C11'	1.50(2)
C10'-C19'	1.49(2)	C12'-C13'	1.499(17)	C13'-C14'	1.40(2)
C13'-C18'	1.40(2)	C14'-C15'	1.394(19)	C15'-C16'	1.39(2)
C16'-C17'	1.39(2)	C17'-C18'	1.39(2)	C19'-C20'	1.50(2)
C20'-C21'	1.547(19)	C20'-C22'	1.566(19)	C20'-C23'	1.54(2)
C20'-C24'	1.87(2)	C21'-C24'	1.53(2)	C22'-C24'	1.54(2)
C23'-C24'	1.58(2)	C24'-B1'	1.60(2)	C25'-C26'	1.56(3)
C25'-C27'	1.51(3)	C25'-C28'	1.50(3)	C26'-C29'	1.51(3)
C26'-C30'	1.49(3)	Br2-C32	1.912(16)	Cl2-C46	1.771(17)
F2-C34	1.37(2)	O3-C55	1.47(2)	O3-B2	1.33(2)
O3*-C55*	1.46(3)	O3*-B2	1.39(3)	O4-C56	1.45(2)
O4-B2	1.36(2)	O4*-C56*	1.47(4)	O4*-B2	1.36(3)
N2-C31	1.43(2)	N2-C41	1.36(2)	N2-C42	1.45(2)
C31-C32	1.38(2)	C31-C36	1.39(2)	C32-C33	1.34(3)
C33-C34	1.32(3)	C34-C35	1.40(2)	C35-C36	1.43(2)
C36-C37	1.473(19)	C37-C38	1.50(2)	C37-C41	1.35(2)
C38-C39	1.52(2)	C39-C40	1.58(2)	C40-C41	1.51(2)
C40-C49	1.49(2)	C42-C43	1.50(2)	C43-C44	1.35(2)
C43-C48	1.39(2)	C44-C45	1.42(2)	C45-C46	1.35(3)
C46-C47	1.37(3)	C47-C48	1.38(2)	C49-C50	1.52(2)

Table S12. Bond Distances in Compound 4ar, Å

C50-C51	1.54(2)	C50-C52	1.51(2)	C50-C53	1.57(2)
C50-C54	1.90(2)	C51-C54	1.55(2)	C52-C54	1.58(2)
C53-C54	1.553(19)	C54-B2	1.58(2)	C55-C56	1.539(17)
C55-C57	1.539(17)	C55-C58	1.534(18)	C55*-C56*	1.539(19)
C55*-C57*	1.536(19)	C55*-C58*	1.545(19)	C56-C59	1.535(17)
C56-C60	1.547(17)	C56*-C59*	1.549(19)	C56*-C60*	1.535(19)
Br2'-C32'	1.901(16)	Cl2'-C46'	1.741(16)	F2'-C34'	1.35(2)
O3'-C55'	1.45(2)	O3'-B2'	1.38(2)	O4'-C56'	1.46(2)
O4'-B2'	1.34(3)	N2'-C31'	1.38(2)	N2'-C41'	1.37(2)
N2'-C42'	1.475(19)	C31'-C32'	1.41(3)	C31'-C36'	1.42(2)
C32'-C33'	1.40(2)	C33'-C34'	1.31(3)	C34'-C35'	1.37(3)
C35'-C36'	1.42(2)	C36'-C37'	1.41(3)	C37'-C38'	1.46(3)
C37'-C41'	1.36(2)	C38'-C39'	1.52(2)	C39'-C40'	1.54(2)
C40'-C41'	1.50(2)	C40'-C49'	1.52(2)	C42'-C43'	1.51(2)
C43'-C44'	1.42(2)	C43'-C48'	1.37(3)	C44'-C45'	1.32(3)
C45'-C46'	1.40(3)	C46'-C47'	1.37(3)	C47'-C48'	1.43(2)
C49'-C50'	1.51(2)	C50'-C51'	1.55(3)	C50'-C52'	1.58(3)
C50'-C53'	1.59(2)	C50'-C54'	1.91(2)	C51'-C54'	1.54(2)
C52'-C54'	1.57(2)	C53'-C54'	1.59(3)	C54'-B2'	1.55(3)
C55'-C56'	1.58(3)	C55'-C57'	1.49(2)	C55'-C58'	1.52(3)
C56'-C59'	1.56(3)	C56'-C60'	1.47(4)		

Table S13. Bond Angles in Compound 4ar, °	Table S13.	Bond	Angles in	Compound 4ar, <sup>4</sup>	כ
---	------------	------	-----------	----------------------------	---

B1-O1-C26	105.7(14)	B1-O2-C25	108.6(15)	C1-N1-C12	128.4(14)
C11-N1-C1	107.2(13)	C11-N1-C12	124.4(14)	N1-C1-C2	134.8(15)
N1-C1-C6	108.2(13)	C2-C1-C6	117.0(15)	C1-C2-Br1	121.3(13)
C3-C2-Br1	117.8(14)	C3-C2-C1	120.9(18)	C4-C3-C2	120.4(19)
F1-C4-C5	116.0(17)	C3-C4-F1	120(2)	C3-C4-C5	124.1(17)
C6-C5-C4	115.6(16)	C5-C6-C1	121.9(16)	C5-C6-C7	132.7(16)
C7-C6-C1	105.4(14)	C6-C7-C8	140.7(18)	C11-C7-C6	107.4(15)
C11-C7-C8	111.7(17)	C7-C8-C9	100.3(15)	C8-C9-C10	109.7(14)
C11-C10-C9	99.2(15)	C11-C10-C19	111.6(12)	C19-C10-C9	117.8(16)
N1-C11-C10	134.5(15)	C7-C11-N1	111.8(15)	C7-C11-C10	113.7(14)
N1-C12-C13	115.0(12)	C14-C13-C12	122.3(14)	C18-C13-C12	119.3(15)
C18-C13-C14	118.4(15)	C15-C14-C13	118.5(17)	C16-C15-C14	122.9(19)
C15-C16-Cl1	121.3(19)	C17-C16-Cl1	117.6(19)	C17-C16-C15	121.0(18)
C16-C17-C18	118.5(18)	C13-C18-C17	120.6(18)	C20-C19-C10	111.7(13)
C19-C20-C21	129.6(17)	C19-C20-C22	124.3(13)	C19-C20-C23	129.0(16)
C19-C20-C24	176.9(14)	C21-C20-C24	52.1(10)	C22-C20-C21	85.3(13)
C22-C20-C24	52.6(10)	C23-C20-C21	85.9(12)	C23-C20-C22	88.6(15)
C23-C20-C24	52.5(10)	C24-C21-C20	74.9(12)	C20-C22-C24	75.5(12)
C20-C23-C24	77.1(13)	C21-C24-C20	53.1(10)	C21-C24-C22	85.6(15)
C21-C24-B1	128.3(13)	C22-C24-C20	51.9(11)	C22-C24-B1	125.2(16)
C23-C24-C20	50.5(10)	C23-C24-C21	85.2(15)	C23-C24-C22	86.6(13)
C23-C24-B1	131.0(16)	B1-C24-C20	177.1(14)	O2-C25-C26	101.3(14)
O2-C25-C27	105.2(17)	C26-C25-C27	109.7(17)	C28-C25-O2	109.8(15)
C28-C25-C26	119.0(19)	C28-C25-C27	110.8(17)	O1-C26-C25	102.6(16)
O1-C26-C29	107.8(15)	O1-C26-C30	106.7(16)	C25-C26-C30	111.6(17)
C29-C26-C25	119.3(15)	C29-C26-C30	108.0(17)	O1-B1-C24	121.6(15)
O2-B1-O1	113.2(18)	O2-B1-C24	125.2(16)	B1'-O1'-C26'	110.0(14)
B1'-O2'-C25'	108.4(16)	C1'-N1'-C11'	107.4(11)	C1'-N1'-C12'	128.5(13)
C11'-N1'-C12'	123.4(12)	N1'-C1'-C6'	109.0(12)	C2'-C1'-N1'	132.4(13)
C2'-C1'-C6'	118.2(13)	C1'-C2'-Br1'	124.1(12)	C1'-C2'-C3'	122.1(14)
C3'-C2'-Br1'	113.8(12)	C2'-C3'-C4'	116.8(14)	F1'-C4'-C3'	116.6(13)
F1'-C4'-C5'	118.9(14)	C5'-C4'-C3'	124.4(13)	C4'-C5'-C6'	117.2(13)
C5'-C6'-C1'	121.2(13)	C5'-C6'-C7'	134.8(13)	C7'-C6'-C1'	104.0(12)
C6'-C7'-C8'	139.3(13)	C11'-C7'-C6'	110.3(12)	C11'-C7'-C8'	110.0(13)
C7'-C8'-C9'	100.4(12)	C8'-C9'-C10'	109.1(12)	C11'-C10'-C9'	97.6(11)
C19'-C10'-C9'	115.3(12)	C19'-C10'-C11'	119.4(13)	N1'-C11'-C10'	134.6(12)
C7'-C11'-N1'	109.2(13)	C7'-C11'-C10'	115.7(13)	N1'-C12'-C13'	114.0(11)
C14'-C13'-C12'	117.6(13)	C18'-C13'-C12'	122.4(12)	C18'-C13'-C14'	120.0(13)
C15'-C14'-C13'	121.1(14)	C16'-C15'-C14'	117.5(13)	C15'-C16'-Cl1'	118.2(10)
C15'-C16'-C17'	122.4(13)	C17'-C16'-Cl1'	119.4(12)	C18'-C17'-C16'	119.8(15)
C17'-C18'-C13'	119.1(14)	C10'-C19'-C20'	115.1(13)	C19'-C20'-C21'	128.9(13)

C19'-C20'-C22'	122.4(13)	C19'-C20'-C23'	129.8(14)	C19'-C20'-C24'	174.6(14)
C21'-C20'-C22'	87.1(11)	C21'-C20'-C24'	52.2(8)	C22'-C20'-C24'	52.4(8)
C23'-C20'-C21'	86.8(12)	C23'-C20'-C22'	88.3(12)	C23'-C20'-C24'	54.1(9)
C24'-C21'-C20'	74.7(10)	C24'-C22'-C20'	74.0(11)	C20'-C23'-C24'	73.7(11)
C21'-C24'-C20'	53.0(8)	C21'-C24'-C22'	88.5(13)	C21'-C24'-C23'	85.9(12)
C21'-C24'-B1'	129.9(12)	C22'-C24'-C20'	53.6(9)	C22'-C24'-C23'	87.8(12)
C22'-C24'-B1'	124.3(13)	C23'-C24'-C20'	52.1(9)	C23'-C24'-B1'	127.0(14
B1'-C24'-C20'	177.0(11)	O2'-C25'-C26'	103.4(15)	O2'-C25'-C27'	106.1(17
O2'-C25'-C28'	106(2)	C27'-C25'-C26'	116.2(17)	C28'-C25'-C26'	115.8(17
C28'-C25'-C27'	108(2)	O1'-C26'-C25'	103.0(14)	O1'-C26'-C29'	105.9(17
O1'-C26'-C30'	108(2)	C29'-C26'-C25'	111.9(19)	C30'-C26'-C25'	114.6(17
C30'-C26'-C29'	112(2)	O1'-B1'-O2'	113.2(15)	O1'-B1'-C24'	122.4(14
O2'-B1'-C24'	124.3(15)	B2-O3-C55	105.7(16)	B2-O3*-C55*	111(3)
B2-O4-C56	104.0(16)	B2-O4*-C56*	113(3)	C31-N2-C42	123.8(14
C41-N2-C31	106.8(12)	C41-N2-C42	124.0(14)	C32-C31-N2	133.2(15
C32-C31-C36	117.7(17)	C36-C31-N2	108.5(14)	C31-C32-Br2	121.8(14
C33-C32-Br2	117.3(12)	C33-C32-C31	120.8(15)	C34-C33-C32	121.0(16
F2-C34-C35	115.9(14)	C33-C34-F2	119.5(14)	C33-C34-C35	124.5(18
C34-C35-C36	113.0(15)	C31-C36-C35	122.4(14)	C31-C36-C37	105.8(14
C35-C36-C37	131.8(13)	C36-C37-C38	139.9(15)	C41-C37-C36	106.5(13
C41-C37-C38	113.1(14)	C37-C38-C39	101.7(13)	C38-C39-C40	107.9(12
C41-C40-C39	99.7(12)	C49-C40-C39	116.2(12)	C49-C40-C41	119.8(13
N2-C41-C40	134.6(13)	C37-C41-N2	112.5(14)	C37-C41-C40	112.6(13
N2-C42-C43	116.1(14)	C44-C43-C42	123.2(15)	C44-C43-C48	118.9(15
C48-C43-C42	117.9(15)	C43-C44-C45	120.5(16)	C46-C45-C44	118.4(16
C45-C46-Cl2	119.0(14)	C45-C46-C47	122.5(16)	C47-C46-Cl2	118.5(13
C46-C47-C48	118.2(19)	C47-C48-C43	121.4(18)	C40-C49-C50	117.8(13
C49-C50-C51	129.8(15)	C49-C50-C53	126.1(12)	C49-C50-C54	177.7(13
C51-C50-C53	86.2(12)	C51-C50-C54	52.3(9)	C52-C50-C49	125.6(13
C52-C50-C51	87.8(11)	C52-C50-C53	87.7(12)	C52-C50-C54	53.9(9)
C53-C50-C54	52.2(8)	C50-C51-C54	75.7(12)	C50-C52-C54	75.6(11)
C54-C53-C50	74.7(10)	C51-C54-C50	51.9(9)	C51-C54-C52	85.0(13)
C51-C54-C53	86.6(12)	C51-C54-B2	131.1(13)	C52-C54-C50	50.6(8)
C53-C54-C50	53.1(9)	C53-C54-C52	86.0(11)	C53-C54-B2	128.3(13
B2-C54-C50	175.3(13)	B2-C54-C52	124.8(13)	O3-C55-C56	100.5(16
O3-C55-C57	107.4(19)	O3-C55-C58	109(2)	C57-C55-C56	114(2)
C58-C55-C56	113(2)	C58-C55-C57	112(2)	O3*-C55*-C56*	103(3)
O3*-C55*-C57*	109(4)	O3*-C55*-C58*	101(4)	C56*-C55*-C58*	115(5)
C57*-C55*-C56*	126(4)	C57*-C55*-C58*	100(5)	O4-C56-C55	103.2(16
O4-C56-C59	111(2)	O4-C56-C60	107.8(17)	C55-C56-C60	112.3(18
C59-C56-C55	113(2)	C59-C56-C60	110(2)	O4*-C56*-C55*	103(3)
	102(4)	O4*-C56*-C60*	108(4)	C55*-C56*-C59*	106(5)
C60*-C56*-C55*	132(5)	C60*-C56*-C59*	103(5)	03-B2-04	115 8(17
	102(0)	000 000 000	100(0)		. 10.0(17

03-B2-C54	123 6(16)	03*-B2-C54	126 1(19)	O4-B2-C54	120 5(14)
04*-B2-03*	108(2)	04*-B2-C54	126.1(10)	B2'-03'-C55'	109 7(17)
B2'-04'-C56'	110 8(16)	C31'-N2'-C42'	126.8(14)	C41'-N2'-C31'	107 7(14)
C41'-N2'-C42'	125 5(15)	N2'-C31'-C32'	133 0(15)	N2'-C31'-C36'	107.6(16)
C32'-C31'-C36'	119 4(15)	C31'-C32'-Br2'	123 7(12)	C33'-C32'-Br2'	119 0(13)
C33'-C32'-C31'	117 3(15)	C34'-C33'-C32'	123(2)	E2'-C34'-C35'	118 2(18)
C33'-C34'-F2'	119(2)	C33'-C34'-C35'	123(2)	C34'-C35'-C36'	118 3(17)
C35'-C36'-C31'	119 3(16)	C37'-C36'-C31'	1067(15)	C37'-C36'-C35'	134 0(16)
C36'-C37'-C38'	141 7(16)	C41'-C37'-C36'	107 4(15)	C41'-C37'-C38'	110 7(16)
C37'-C38'-C39'	103 1(14)	C38'-C39'-C40'	110.9(16)	C41'-C40'-C39'	98 5(14)
C41'-C40'-C49'	117 6(12)	C49'-C40'-C39'	113 4(14)	N2'-C41'-C40'	133 9(15)
C37'-C41'-N2'	110.6(12)	C37'-C41'-C40'	115 5(15)	N2'-C42'-C43'	112 6(13)
C44'-C43'-C42'	118 2(17)	C48'-C43'-C42'	123 4(14)	C48'-C43'-C44'	112.0(10) 118.4(15)
C45'-C44'-C43'	122 5(19)	C44'-C45'-C46'	118 4(16)	C45'-C46'-Cl2'	118 2(14)
C47'-C46'-Cl2'	118 9(17)	C47'-C46'-C45'	122 8(15)	C46'-C47'-C48'	117 0(19)
C43'-C48'-C47'	120 7(16)	$C_{40} = C_{40} = C_{40}$	122.0(13) 114 2(13)	C49'-C50'-C51'	130 2(16)
$C_{49}^{+}C_{50}^{+}C_{52}^{+}$	126.7(10) 126.2(14)	C49'-C50'-C53'	1265(14)	C49'-C50'-C54'	178 0(15)
C51'-C50'-C52'	86 9(15)	C51'-C50'-C53'	86 1(13)	C51'-C50'-C54'	51 7(10)
C52'-C50'-C53'	86 8(15)	C52'-C50'-C54'	52 3(0)	C53'-C50'-C54'	53 1(10)
C52-C50-C53	76 2(12)	C54' C52' C50'	52.3(3)	C54' C53' C50'	72.9(12)
C54-C51-C50	F1 0(10)	C54 - C52 - C50	73.0(13) 07 2(12)	C54 - C53 - C50	75.0(12)
C51-C54-C50	51.9(10)	051-054-052	07.3(13)	051-054-053	00.3(14)
C51-C54-B2	131.8(15)	052-054-050	52.7(10)	052-054-053	87.2(13)
C53'-C54'-C50'	53.1(10)	B2'-C54'-C50'	172.9(13)	B2'-C54'-C52'	120.1(15)
B2'-C54'-C53'	129.8(14)	O3'-C55'-C56'	103.7(15)	O3'-C55'-C57'	111(2)
O3'-C55'-C58'	107.7(18)	C57'-C55'-C56'	114.5(19)	C57'-C55'-C58'	107(2)
C58'-C55'-C56'	112.9(17)	O4'-C56'-C55'	103.4(17)	O4'-C56'-C59'	105.4(18)
O4'-C56'-C60'	109(2)	C59'-C56'-C55'	112.7(17)	C60'-C56'-C55'	119(2)
C60'-C56'-C59'	107(3)	O3'-B2'-C54'	122.1(19)	O4'-B2'-O3'	112.0(17)
O4'-B2'-C54'	125.9(16)				

This report has been created with Olex2<sup>38</sup>, compiled on 2020.11.12 svn.r5f609507 for OlexSys.

#### 10. References

- 1 Polites, V. C., Badir, S. O., Keess, S., Jolit, A. & Molander, G. A. Nickel-Catalyzed Decarboxylative Cross-Coupling of Bicyclo[1.1.1]pentyl Radicals Enabled by Electron Donor–Acceptor Complex Photoactivation. *Org. Lett.* **23**, 4828-4833, doi:10.1021/acs.orglett.1c01558 (2021).
- 2 Patel, N. R., Kelly, C. B., Jouffroy, M. & Molander, G. A. Engaging Alkenyl Halides with Alkylsilicates via Photoredox Dual Catalysis. *Org. Lett.* **18**, 764-767, doi:10.1021/acs.orglett.6b00024 (2016).
- Wercruysse, S., Cornelissen, L., Nahra, F., Collard, L. & Riant, O. Cul/Pd<sup>0</sup> Cooperative Dual Catalysis: Tunable Stereoselective Construction of Tetra-Substituted Alkenes. *Chem. Eur. J.* **20**, 1834-1838, doi:https://doi.org/10.1002/chem.201304284 (2014).
- 4 in Protective Groups in Organic Synthesis 494-653.
- 5 Cornella, J. *et al.* Practical Ni-Catalyzed Aryl–Alkyl Cross-Coupling of Secondary Redox-Active Esters. *J. Am. Chem. Soc.* **138**, 2174-2177, doi:10.1021/jacs.6b00250 (2016).
- 6 Hu, C. & Chen, Y. Chemoselective and fast decarboxylative allylation by photoredox catalysis under mild conditions. *Org. Chem. Front.* **2**, 1352-1355, doi:10.1039/C5QO00187K (2015).
- 7 Correia, J. T. M., Piva da Silva, G., André, E. & Paixão, M. W. Photoredox Decarboxylative Alkylation/(2+2+1) Cycloaddition of 1,7-Enynes: A Cascade Approach Towards Polycyclic Heterocycles Using N-(Acyloxy)phthalimides as Radical Source. *Adv. Synth. Catal.* **361**, 5558-5564, doi:https://doi.org/10.1002/adsc.201900657 (2019).
- 8 Toriyama, F. *et al.* Redox-Active Esters in Fe-Catalyzed C–C Coupling. *J. Am. Chem. Soc.* **138**, 11132-11135, doi:10.1021/jacs.6b07172 (2016).
- 9 Fawcett, A. *et al.* Photoinduced decarboxylative borylation of carboxylic acids. *Science* **357**, 283-286, doi:10.1126/science.aan3679 (2017).
- 10 Qin, T. *et al.* Nickel-Catalyzed Barton Decarboxylation and Giese Reactions: A Practical Take on Classic Transforms. *Angew. Chem. Int. Ed.* **56**, 260-265, doi:https://doi.org/10.1002/anie.201609662 (2017).
- 11 Hu, D., Wang, L. & Li, P. Decarboxylative Borylation of Aliphatic Esters under Visible-Light Photoredox Conditions. *Org. Lett.* **19**, 2770-2773, doi:10.1021/acs.orglett.7b01181 (2017).
- 12 Yu, L. *et al.* Zinc-Mediated Decarboxylative Alkylation of Gem-difluoroalkenes. *Org. Lett.* **20**, 4579-4583, doi:10.1021/acs.orglett.8b01866 (2018).
- 13 Yang, T. *et al.* Chemoselective Union of Olefins, Organohalides, and Redox-Active Esters Enables Regioselective Alkene Dialkylation. *J. Am. Chem. Soc.* **142**, 21410-21419, doi:10.1021/jacs.0c09922 (2020).
- 14 Liu, X.-G. *et al.* Decarboxylative Negishi Coupling of Redox-Active Aliphatic Esters by Cobalt Catalysis. *Angew. Chem. Int. Ed.* **57**, 13096-13100, doi:https://doi.org/10.1002/anie.201806799 (2018).
- 15 Schwarz, J. & König, B. Decarboxylative Alkynylation of Biomass-Derived Compounds by Metal-Free Visible Light Photocatalysis. *ChemPhotoChem* **1**, 237-242, doi:https://doi.org/10.1002/cptc.201700034 (2017).
- 16 Qin, T. *et al.* A general alkyl-alkyl cross-coupling enabled by redox-active esters and alkylzinc reagents. *Science* **352**, 801-805, doi:doi:10.1126/science.aaf6123 (2016).
- 17 Webb, E. W. *et al.* Nucleophilic (Radio)Fluorination of Redox-Active Esters via Radical-Polar Crossover Enabled by Photoredox Catalysis. *J. Am. Chem. Soc.* **142**, 9493-9500, doi:10.1021/jacs.0c03125 (2020).
- 18 Yin, H. *et al.* Stereoselective and Divergent Construction of β-Thiolated/Selenolated Amino Acids via Photoredox-Catalyzed Asymmetric Giese Reaction. *J. Am. Chem. Soc.* **142**, 14201-14209, doi:10.1021/jacs.0c04994 (2020).
- 19 Li, C. *et al.* Decarboxylative borylation. *Science* **356**, eaam7355, doi:doi:10.1126/science.aam7355 (2017).
- 20 Wang, J., Cary, B. P., Beyer, P. D., Gellman, S. H. & Weix, D. J. Ketones from Nickel-Catalyzed Decarboxylative, Non-Symmetric Cross-Electrophile Coupling of Carboxylic Acid Esters. *Angew. Chem. Int. Ed.* **58**, 12081-12085, doi:https://doi.org/10.1002/anie.201906000 (2019).
- 21 Pratsch, G., Lackner, G. L. & Overman, L. E. Constructing Quaternary Carbons from N-(Acyloxy)phthalimide Precursors of Tertiary Radicals Using Visible-Light Photocatalysis. *J. Org. Chem.* **80**, 6025-6036, doi:10.1021/acs.joc.5b00795 (2015).

- 22 Wang, D., Zhu, N., Chen, P., Lin, Z. & Liu, G. Enantioselective Decarboxylative Cyanation Employing Cooperative Photoredox Catalysis and Copper Catalysis. *J. Am. Chem. Soc.* **139**, 15632-15635, doi:10.1021/jacs.7b09802 (2017).
- 23 Tanaka, T., Yazaki, R. & Ohshima, T. Chemoselective Catalytic α-Oxidation of Carboxylic Acids: Iron/Alkali Metal Cooperative Redox Active Catalysis. J. Am. Chem. Soc. 142, 4517-4524, doi:10.1021/jacs.0c00727 (2020).
- 24 Gianatassio, R. *et al.* Strain-release amination. *Science* **351**, 241-246, doi:doi:10.1126/science.aad6252 (2016).
- 25 Zhao, J.-X. *et al.* 1,2-Difunctionalized bicyclo[1.1.1]pentanes: Long–sought-after mimetics for ortho/meta-substituted arenes. *Proceedings of the National Academy of Sciences* **118**, e2108881118, doi:10.1073/pnas.2108881118 (2021).
- 26 Kondo, M. *et al.* Silaboration of [1.1.1]Propellane: A Storable Feedstock for Bicyclo[1.1.1]pentane Derivatives. *Angew. Chem. Int. Ed.* **59**, 1970-1974, doi:https://doi.org/10.1002/anie.201909655 (2020).
- 27 Bagutski, V., Ros, A. & Aggarwal, V. K. Improved method for the conversion of pinacolboronic esters into trifluoroborate salts: facile synthesis of chiral secondary and tertiary trifluoroborates. *Tetrahedron* **65**, 9956-9960, doi:https://doi.org/10.1016/j.tet.2009.10.002 (2009).
- 28 Matsui, J. K., Primer, D. N. & Molander, G. A. Metal-free C–H alkylation of heteroarenes with alkyltrifluoroborates: a general protocol for 1°, 2° and 3° alkylation. *Chem. Sci.* **8**, 3512-3522, doi:10.1039/C7SC00283A (2017).
- 29 Campbell, M. W., Compton, J. S., Kelly, C. B. & Molander, G. A. Three-Component Olefin Dicarbofunctionalization Enabled by Nickel/Photoredox Dual Catalysis. *J. Am. Chem. Soc.* **141**, 20069-20078, doi:10.1021/jacs.9b08282 (2019).
- 30 Newcomb, M. in *Encyclopedia of Radicals in Chemistry, Biology and Materials* (2012).
- 31 Kim, J. H., Ruffoni, A., Al-Faiyz, Y. S. S., Sheikh, N. S. & Leonori, D. Divergent Strain-Release Amino-Functionalization of [1.1.1]Propellane with Electrophilic Nitrogen-Radicals. *Angew. Chem. Int. Ed.* **59**, 8225-8231, doi:https://doi.org/10.1002/anie.202000140 (2020).
- 32 Yang, Q. *et al.* Photocatalytic C–H activation and the subtle role of chlorine radical complexation in reactivity. *Science* **372**, 847-852, doi:10.1126/science.abd8408 (2021).
- 33 CrysAlisPro 1.171.41.107a: Rigaku Oxford Diffraction, Rigaku Corporation, Oxford, UK. (2020).
- 34 CrysAlisPro 1.171.41.107a: Rigaku Oxford Diffraction, Rigaku Corporation, Oxford, UK. (2020).
- 35 SCALE3 ABSPACK v1.0.7: an Oxford Diffraction program; Oxford Diffraction Ltd: Abingdon, UK, 2005.
- 36 SHELXT v2018/2: Sheldrick, G.M., Acta Cryst., A, 71, 3-8 (2015).
- 37 SHELXL-2018/3: Sheldrick, G.M., Acta Cryst., A, 71, 3-8 (2015).
- 38 Olex2: Dolomanov,O.V., Bourhis, L.J., Gildea, R.J., Howard, J.A.K., Puschmann, H., J. Appl. Cryst., 42, 339-341 (2009).

11. NMR Spectra of Synthesized Compounds

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of  $\mathbf{1a}$ 







## $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 1a



-10 f1 (ppm) зo ò 

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of  $\mathbf{1b}$ 



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 1b



 $^1\text{H}$  NMR (600 MHz, CDCl<sub>3</sub>) of 1c



134

## $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 1c





 $^1\text{H}$  NMR (600 MHz, CDCl<sub>3</sub>) of 1d







<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of 1e



# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 1e



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of  $\mathbf{1f}$ 



## $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of $\pmb{1f}$







# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 1g


$^1\text{H}$  NMR (600 MHz, CDCl<sub>3</sub>) of 1h



# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 1h



### <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of 1i



### $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 1i



210 200 170 160 110 100 f1 (ppm) -10 ò

### $^1\text{H}$ NMR (600 MHz, CDCl<sub>3</sub>) of S-1a



### $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1a







# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1b



### $^1\text{H}$ NMR (600 MHz, CDCl3) of S-1c



152

-0.

### $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1c





### <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1d**

### $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1d



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1e** 



# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1e



 $^1\text{H}$  NMR (600 MHz, CDCl<sub>3</sub>) of S-1f



# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1f



	- I - I			· · ·			· · ·		'		·			· · · ·		· · ·				· · · ·		· · ·	
210	200	190	180	170	160	150	140	130	120	110	100 f1 (ppm)	90 )	80	70	60	50	40	30	20	10	0	-10	)

 $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>) of S-1g



### $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1g







<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1h** 



# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1h







<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1i** 

# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1i



 										- · ·												
210	200	190	180	170	160	150	140	130	120	110	100	90	80	70	60	50	40	30	20	10	0	-10
							140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)															

#### $^{19}\mathsf{F}$ NMR (376 MHz, CDCl\_3) of S-1i

∠ -95.44 ∠ -96.08 √ -98.16





### <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of **S-1j**



### $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1j





### <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) of **S-1k**



### <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of **S-1**I





### <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1m**



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of S-1m







 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of S-1n



#### <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-10**



#### <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) of **S-10**




### $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1p



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1q** 



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of S-1q



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1r** 



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of S-1r



### <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1s**



### $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1s



210 200 f1 (ppm) 170 160 140 130 -10 

### <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1t**



### $^{13}\text{C}$ NMR (151 MHz, CDCl<sub>3</sub>) of S-1t





-110 f1 (ppm) -20 -30 -40 -50 -60 -70 -80 -90 -100 -120 -140 -150 -160 -170 -180 -130 -190 -200 <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1u** 





# <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) of **S-1u**



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1v** 



# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-1v







 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of S-1w



### <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1x**



### <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) of **S-1x**



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1y** 



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of S-1y



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1z** 

-510







# <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) of **S-1z**









### <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1aa**



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of S-1aa



#### <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1ab**



### $^{13}\text{C}$ NMR (151 MHz, CDCl<sub>3</sub>) of **S-1ab**





 $^{13}\text{C}$  NMR (151 MHz, CDCl<sub>3</sub>) of **S-1ac** 



# <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-1ad**



# $^{13}\text{C}$ NMR (151 MHz, CDCl<sub>3</sub>) of S-1ad





<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) of **S-1ae** 



# <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of **S-1af**



# $^{13}\text{C}$ NMR (151 MHz, CDCl<sub>3</sub>) of S-1af



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)



_															· · · ·			
-20	-30	-40	-50	-60	-70	-80	-90	-100	-110 f1 (ppm)	-120 )	-130	-140	-150	-160	-170	-180	-190	-200


 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>) of **S-1ag** 



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of  $\mathbf{4a}$ 



 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>) of 4a



 $^{11}\text{B}$  NMR (128 MHz, CDCl<sub>3</sub>) of 4a



 $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>) of 4b



 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>) of 4b









### <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **4c**



### $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 4c



# $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 4c







 $^{13}\text{C}$  NMR (101 MHz, CDCl\_3) of 4d



 $^{11}\text{B}$  NMR (128 MHz, CDCl<sub>3</sub>) of 4d



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of 4e



1.85 1.83 1.83 1.81 1.81 1.81 1.71	1.42 1.42 1.40 1.40 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.3
~~~~~//	Land and a second a s

1H NMR

Br



 $^{13}\text{C}$  NMR (151 MHz, CDCl<sub>3</sub>) of 4e





<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of **4f** 



 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>) of 4f





# 



 $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>) of 4g



 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>) of 4g





 $^{19}\mathsf{F}$  NMR (376 MHz, CDCl<sub>3</sub>) of 4g





 $^{11}\text{B}$  NMR (128 MHz, CDCl<sub>3</sub>) of 4g



งงงรีสารปล่องใหม่กลู่กับสำหรับเห็นไหม่ๆไข้สารเป็นขางขององๆไข้ไข่หลายหลังหลังหลังไปเป็นไหล่ไปแหล่อนไหล่ไข่เห็นหลายไม่ได้



### $^1\text{H}$ NMR (400 MHz, CDCl<sub>3</sub>) of 4h



### $^{13}\text{C}$ NMR (101 MHz, CDCl\_3) of 4h



 $^{11}\text{B}$  NMR (128 MHz, CDCl<sub>3</sub>) of 4h









#### 243

-0

 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>) of 4i



# $^{19}\mathsf{F}\ \mathsf{NMR}\ (376\ \mathsf{MHz},\ \mathsf{CDCl}_3)$ of 4i





 $^{11}\text{B}$  NMR (128 MHz, CDCl<sub>3</sub>) of 4i

\_\_\_\_29.92

H<sub>3</sub>C

.CH₃ ∠CH₃

CH



F

Ween A specific weeken werden werd





 $^{13}\text{C}$  NMR (101 MHz, CDCl\_3) of 4j



 $^{11}\text{B}$  NMR (128 MHz, CDCl<sub>3</sub>) of 4j





<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of 4k



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 4k


$^{11}\text{B}$  NMR (128 MHz, CDCl<sub>3</sub>) of 4k



90 80 70 60 50 40 30 20 י 0 (maa) f1 -10 -20 -30 -50 -60 -70 -80 10 -40 -90

بلاجب الشاهية أرعد فرائه

فارأيم اللابان ورزا

## <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **4**



## $^{13}\text{C}$ NMR (151 MHz, CDCl<sub>3</sub>) of 4I



# <sup>11</sup>B NMR (128 MHz, CDCl<sub>3</sub>) of **4**I



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of **4m** 



 $^{13}\text{C}$  NMR (101 MHz, CDCl\_3) of 4m





 $^{11}\text{B}$  NMR (128 MHz, CDCl\_3) of 4m







 $^1\text{H}$  NMR (600 MHz, CDCl<sub>3</sub>) of 4n









 $^{13}\text{C}$  NMR (151 MHz, CDCl<sub>3</sub>) of 4n







 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>) of 4o



<sup>11</sup>B NMR (128 MHz, CDCl<sub>3</sub>) of **40** 







## $^{13}\text{C}$ NMR (151 MHz, CDCl<sub>3</sub>) of 4p



# $^{11}\text{B}$ NMR (128 MHz, CDCl<sub>3</sub>) of 4p











<sup>13</sup> C NMR (151 MHz, CDCl <sub>3</sub> ) of <b>4q</b>				
				28.34 77.84 77.04 23.16 28.24 28.24 28.24
B				



13C NMR

## $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 4q





### <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of 4r



 $^{13}\text{C}$  NMR (151 MHz, CDCl<sub>3</sub>) of 4r—54.63 —47.54 ~33.16 ~32.34 ~26.62 ~24.92 ~24.92 ~22.18 13C NMR f1 (ppm) ò



## $^{11}\text{B}$ NMR (151 MHz, CDCl<sub>3</sub>) of 4r

11B NMR

0 B







 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 4s







13C NMR

## $^{11}\text{B}$ NMR (128 MHz, CDCl<sub>3</sub>) of 4s





 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>) of 4t



<sup>11</sup>B NMR (128 MHz, CDCl<sub>3</sub>) of **4t** 



10

ò

f1 (ppm)

30

-10

-30

-20

-40

-50

-60

-70

-80

90

80

70

60

50

40



-90



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 4u



## $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 4u









 $^{13}\text{C}$  NMR (101 MHz, CDCl\_3) of 4v







<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of 4w



1H NMR



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 4w


## $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 4w





<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of 4x



# $^{13}\text{C}$ NMR (101 MHz, CDCl<sub>3</sub>) of 4x



f1 (ppm) -10 ò





-20 -30 -70 -110 f1 (ppm) -120 -150 -190 -200 -40 -50 -60 -80 -90 -100 -170 -130 -140 -160 -180

 $^{11}\text{B}$  NMR (128 MHz, CDCl<sub>3</sub>) of 4x







## <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of ${f 4y}$



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 4y





<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of 4z



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 4z





<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of 4aa



## $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of **4aa**





<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **4ab** 



 $^{13}\text{C}$  NMR (151 MHz, CDCl<sub>3</sub>) of **4ab** 





<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of 4ac



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 4ac



## $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 4ac





 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 4ad



# $^{11}\text{B}$ NMR (128 MHz, CDCl3) of 4ad





 $^{13}\text{C}$  NMR (151 MHz, CDCl<sub>3</sub>) of **4ae** 



f1 (ppm) -10 Ó

 $^{11}\text{B}$  NMR (128 MHz, CDCl\_3) of 4ae







## $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 4af



## $^{11}\text{B}$ NMR (128 MHz, CDCl3) of 4af





## <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **4ag**



# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 4ag



# <sup>11</sup>B NMR (128 MHz, CDCl<sub>3</sub>) of **4ag**



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of **4ah** 



 $^{13}\text{C}$  NMR (151 MHz, CDCl<sub>3</sub>) of **4ah** 



 $^{11}\text{B}$  NMR (128 MHz, CDCl<sub>3</sub>) of **4ah** 





## <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **4ai**


$^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 4ai



# $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 4ai









# <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **4ak**



1H NMR













<sup>11</sup>B NMR (128 MHz, CDCl<sub>3</sub>) of **4ak** 



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **4al** 





# $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 4al



# <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of 4am



7.027.017.015.675.675.666.646.64

1H NMR





# $^{13}\text{C}$ NMR (151 MHz, CDCl<sub>3</sub>) of **4am**





337

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of **4an** 



 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>) of **4an** 





-20 -30 -70 -90 -100 -110 f1 (ppm) -120 -130 -150 -160 -170 -180 -190 -200 -40 -50 -60 -80 -140

 $^{11}\text{B}$  NMR (128 MHz, CDCl<sub>3</sub>) of **4an** 







 $^{13}\text{C}$  NMR (151 MHz, CDCl<sub>3</sub>) of **4ao** 



 $^{11}\text{B}$  NMR (128 MHz, CDCl3) of 4ao







<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) of **4ap** 







# <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **4aq**



 $^{11}\text{B}$  NMR (128 MHz, CDCl<sub>3</sub>) of 4aq











 $^{19}\mathsf{F}\ \mathsf{NMR}\ (376\ \mathsf{MHz},\ \mathsf{CDCI}_3)$  of 4ar





			· .	· ·		· .	· .											
-20	-30	-40	-50	-60	-70	-80	-90	-100	-110	-120	-130	-140	-150	-160	-170	-180	-190	-200
									f1 (ppm)	)								

 $^{11}\text{B}$  NMR (128 MHz, CDCl\_3) of 4ar









<sup>11</sup>B NMR (128 MHz, CDCl<sub>3</sub>) of **5a** 

10.06---



\_

90	80	70	60	50	40	30	20	10	0 f1 (ppm)	-10	-20	-30	-40	-50	-60	-70	-80	-90	_










<sup>11</sup>B NMR (128 MHz, CDCl<sub>3</sub>) of **5b** 

- 30.07







 $^{13}\text{C}$  NMR (101 MHz, CDCl\_3) of 5c



 $^{11}\text{B}$  NMR (128 MHz, CDCl\_3) of 5c





Whee we wind the product of the contraction of the production of the product of t













 $^{19}\mathsf{F}\ \mathsf{NMR}\ (376\ \mathsf{MHz},\ \mathsf{CDCl}_3)$  of 5e



-20 -30 -40 -50 -60 -70 -80 -90 -100 -110 f1 (ppm) -120 -130 -140 -150 -160 -170 -180 -190 -200  $^{11}\text{B}$  NMR (128 MHz, CDCl\_3) of 5e







## $^{13}\text{C}$ NMR (101 MHz, CDCl\_3) of 5f







-20 -30 -70 -110 f1 (ppm) -120 -200 -60 -80 -90 -100 -170 -190 -40 -50 -130 -140 -150 -160 -180

 $^{11}\text{B}$  NMR (128 MHz, CDCl<sub>3</sub>) of  $\mathbf{5f}$ 





nandunanunan



 $^{13}\text{C}$  NMR (101 MHz, CDCl\_3) of 5g



 $^{11}\text{B}$  NMR (128 MHz, CDCl\_3) of 5g



-10

0 f1 (ppm) -20

-30

-40

30

40

20

10

80

70

60

50

90

-90

-80

-70

-60

-50







 $^{11}\text{B}$  NMR (128 MHz, CDCl\_3) of 5h







 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>) of 5i



 $^{11}\text{B}$  NMR (128 MHz, CDCl\_3) of 5i









 $^{13}\text{C}$  NMR (101 MHz, CDCl\_3) of 5j



<sup>11</sup>B NMR (128 MHz, CDCl<sub>3</sub>) of **5**j







1H NMR



-1.26





f1 (ppm) ò

#### $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5k



N≡

0

المريح المريح والمريح المريح المريحية المريحية المريح المريحية المريحية المريحية المريحية والمريح ومريحة المريح المريح مريحة مريحة مريحة مريحة مريحة المريحة المريحة المريحة مريحة مريحة مريحة المريحة المريحة المريحة المريحة ا

en for the second s







#### $^{13}\text{C}$ NMR (151 MHz, CDCl<sub>3</sub>) of **51**





#### $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5I



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of 5m



### $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 5m


### $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5m



-80

-90

## $^1\text{H}$ NMR (600 MHz, CDCl<sub>3</sub>) of 5n



-1.26

1H NMR





## $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 5n



## $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5n



## $^1\text{H}$ NMR (400 MHz, CDCl<sub>3</sub>) of 5o

1H NMR

-1.23



## $^{13}\text{C}$ NMR (101 MHz, CDCl\_3) of 5o



## $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5o



## $^1\text{H}$ NMR (600 MHz, CDCl<sub>3</sub>) of 5p



## $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 5p



## $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5p



## $^1\text{H}$ NMR (600 MHz, CDCl<sub>3</sub>) of 5q



1H NMR

-2.16 -2.16





 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 5q



## $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5q



## <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of $\mathbf{5r}$





409

0.0











## $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5s



-в *,*0-

en en blev i fele se en mediden af trens i et hun a ska a kord ætid far de solgtione, nev mes jeldted angel, strate Anne med tree treens sonn ren i nevers sonn af en nev skaper og ter inden skaper i ster føren et en ander av av n sealar da bakala menang da bakang babang da bahang da bang dan bertak ang bahang da bahang baha



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **5t** 



1H NMR





## $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 5t



## $^{11}\text{B}$ NMR (128 MHz, CDCl<sub>3</sub>) of 5t



## $^1\text{H}$ NMR (600 MHz, CDCl\_3) of 5u



## $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 5u



## $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5u



11B NMR



, en adia para de va de bregle da pada en polo para de la mande de ada de de de a parte de la construcción de a recense de para de verse polo pada en polo para terra de verse para de ser se apresa de la construcción de se مراب المرابع ال



## $^1\text{H}$ NMR (600 MHz, CDCl\_3) of 5v



## $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 5v





## <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **5w**



1H NMR





 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 5w



19F NMR



			1															
-20	-30	-40	-50	-60	-70	-80	-90	-100	-110	-120	-130	-140	-150	-160	-170	-180	-190	-200
									f1 (ppm)									



 $^1\text{H}$  NMR (600 MHz, CDCl<sub>3</sub>) of 5x



## $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 5x



 $^{19}\mathsf{F}$  NMR (376 MHz, CDCl\_3) of 5x

19F NMR





# $^{11}\text{B}$ NMR (128 MHz, CDCl<sub>3</sub>) of 5x






# $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5y

11B NMR

a o too ka na maa ka gara dabay ka oo ka sa sa ahay ka ka ka dada daha da a ka a saba oo ka ahay ka ka ka sa s Mara pada waxa na ya ka majan ka maa ya ka ba ya da ba ya sa ka sa ka sa ka sa ka sa ka waxa ka ka waxaa ka ka w







# $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5z



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **5aa** 





# $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of **5aa**

11B NMR

0





# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 5ab



# $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5ab



70 50 30 10 -30 -50 60 40 20 0 f1 (ppm) -20 -60 -70 -10 -40 -90 90 80 -80

# <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **5ac**



# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of **5ac**



# $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5ac





# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of **5ad**



# $^{11}\text{B}$ NMR (128 MHz, CDCl\_3) of 5ad



# <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **5ae**







# <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **5af**



# $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of 5af









<sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>) of **6** 



\_\_\_\_

-	r (	· · · ·	I	1 1	· · ·	· · ·		1	· · ·		- 1		· · ·	· · · ·			· · · ·	<u> </u>	1	-
	-20	-30	-40	-50	-60	-70	-80	-90	-100	-110 f1 (ppm)	-120	-130	-140	-150	-160	-170	-180	-190	-200	

<sup>11</sup>B NMR (128 MHz, acetone- $d_6$ ) of **6** 







 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>) of 7





 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 8







 $^1\text{H}$  NMR (600 MHz, CDCl<sub>3</sub>) of 10








## $^{11}\text{B}$ NMR (128 MHz, CDCl<sub>3</sub>) of 11





-----



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 13







## 



<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) of **S-4a** 



## $^{13}\text{C}$ NMR (151 MHz, CDCl\_3) of S-4a







f1 (ppm) -10 ò

 $^{11}\text{B}$  NMR (128 MHz, CDCl3) of S-4a



 $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>) of 15



 $^{13}\text{C}$  NMR (151 MHz, CDCl\_3) of 15



 $^{11}\text{B}$  NMR (128 MHz, CDCl\_3) of 15

0.20



